Stefan S. Zeuzem

Stefan S. Zeuzem's AcademicInfluence.com Rankings

Stefan S. Zeuzem

Philosophy

#2684

World Rank

#4508

Historical Rank

Logic

#715

World Rank

#1230

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Stefan S. Zeuzem Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Stefan S. Zeuzem's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Sorafenib in advanced hepatocellular carcinoma. (2008) (5771)
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. (2004) (2954)
Telaprevir for previously untreated chronic hepatitis C virus infection. (2011) (2539)
Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. (2013) (2069)
Treatment of HCV infection by targeting microRNA. (2013) (1981)
Boceprevir for previously treated chronic HCV genotype 1 infection. (2011) (1711)
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. (2014) (1667)
Telaprevir for retreatment of HCV infection. (2011) (1630)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (2017) (1601)
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. (2012) (1468)
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. (2008) (1454)
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2011) (1454)
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. (1998) (1334)
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis (2009) (1203)
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial (2005) (1160)
Peginterferon alfa-2a in patients with chronic hepatitis C. (2000) (1120)
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. (2009) (1096)
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. (2018) (1034)
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. (2015) (947)
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) (1998) (929)
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. (2014) (904)
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) (881)
Sofosbuvir and ribavirin in HCV genotypes 2 and 3. (2014) (824)
EASL Clinical Practice Guidelines: management of hepatitis C virus infection. (2014) (783)
Telaprevir for previously treated chronic HCV infection. (2010) (769)
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015) (764)
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. (2010) (739)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. (2007) (656)
Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. (2009) (646)
Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. (2007) (622)
Effect of treatment with peginterferon or interferon alfa‐2b and ribavirin on steatosis in patients infected with hepatitis C (2003) (622)
Sustained Virologic Response and Clinical Outcomes in Patients with Chronic Hepatitis C and Advanced Fibrosis (2007) (618)
Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. (2014) (617)
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. (2009) (570)
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin. (2006) (564)
Resistance to direct antiviral agents in patients with hepatitis C virus infection. (2010) (552)
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. (2014) (518)
Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. (2006) (509)
Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER‐medicare database (2011) (503)
Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. (2004) (471)
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta‐analysis (2012) (470)
Clinical Course of acute‐on‐chronic liver failure syndrome and effects on prognosis (2015) (455)
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection (2017) (452)
Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. (2006) (428)
A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel (2011) (428)
Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C (2005) (425)
Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. (2005) (410)
Telaprevir and pegylated interferon–alpha‐2a inhibit wild‐type and resistant genotype 1 hepatitis C virus replication in patients (2007) (410)
Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients (2003) (387)
Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. (2009) (375)
Population-Attributable Fractions of Risk Factors for Hepatocellular Carcinoma in the United States (2013) (358)
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. (2010) (358)
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus–infected patients (2009) (338)
Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. (2007) (336)
SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. (2007) (332)
Retroperitoneal endoscopic debridement for infected peripancreatic necrosis (2000) (332)
Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection (2018) (324)
Telbivudine versus lamivudine in patients with chronic hepatitis B. (2007) (322)
GrazoprevirElbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection (2015) (321)
Antiviral strategies in hepatitis C virus infection. (2012) (311)
Prediction of treatment outcome in patients with chronic hepatitis C: Significance of baseline parameters and viral dynamics during therapy (2002) (311)
Expression of Interleukin‐12‐Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin‐23p19 and Interleukin‐27p28 in Crohn's Disease But Not in Ulcerative Colitis (2005) (304)
Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. (2017) (300)
Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. (2001) (297)
Once‐daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment‐naïve genotype 1 hepatitis C: The randomized PILLAR study (2013) (295)
High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial (2010) (294)
Heterogeneous Virologic Response Rates to Interferon-Based Therapy in Patients with Chronic Hepatitis C: Who Responds Less Well? (2004) (292)
Real-time elastography for the differentiation of benign and malignant thyroid nodules: a meta-analysis. (2010) (291)
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. (2014) (287)
From non-A, non-B hepatitis to hepatitis C virus cure. (2015) (287)
Peginterferon-2a and Ribavirin Combination Therapy in Chronic Hepatitis C (2004) (280)
Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. (2007) (276)
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus (2008) (270)
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. (2014) (268)
Antiviral activity of telaprevir (VX‐950) and peginterferon alfa‐2a in patients with hepatitis C (2007) (266)
Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo (1996) (265)
Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon (2003) (264)
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function (2009) (261)
Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma (1999) (257)
Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis (2015) (256)
Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: The HEP‐NET acute‐HCV‐II study (2006) (253)
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. (2014) (252)
The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. (2015) (251)
HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality (2009) (249)
Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. (2004) (249)
Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results (2007) (237)
Faldaprevir and deleobuvir for HCV genotype 1 infection. (2013) (234)
Effect of peginterferon alfa‐2a on liver histology in chronic hepatitis C: A meta‐analysis of individual patient data (2004) (234)
Expert opinion on the treatment of patients with chronic hepatitis C (2009) (232)
Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. (2006) (230)
IP‐10 predicts viral response and therapeutic outcome in difficult‐to‐treat patients with HCV genotype 1 infection (2006) (225)
Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. (2005) (222)
Late HDV RNA relapse after peginterferon alpha‐based therapy of chronic hepatitis delta (2014) (217)
Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling study. (2017) (216)
Response‐guided peginterferon therapy in hepatitis B e antigen‐positive chronic hepatitis B using serum hepatitis B surface antigen levels (2013) (216)
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. (2007) (216)
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. (1996) (212)
New therapies for hepatitis C virus infection. (2009) (210)
Factors that predict response of patients with hepatitis C virus infection to boceprevir. (2012) (209)
Functional analysis of hMLH1 variants and HNPCC-related mutations using a human expression system. (2002) (206)
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. (2016) (206)
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection. (2011) (206)
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives (2012) (204)
NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. (2017) (204)
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. (2009) (203)
Benefit of a clipping device in use in intestinal bleeding and intestinal leakage. (2011) (203)
Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa (1997) (198)
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C (2003) (197)
Serum miR-122 as a Biomarker of Necroinflammation in Patients With Chronic Hepatitis C Virus Infection (2011) (197)
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort (2016) (197)
Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. (2013) (191)
Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. (2012) (187)
The way forward in HCV treatment — finding the right path (2008) (187)
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. (2018) (185)
[Prophylaxis, diagnosis and therapy of hepatitis B virus infection - the German guideline]. (2011) (181)
Quantification of the initial decline of serum hepatitis c virus RNA and response to interferon alfa (1998) (179)
Hepatitis C virus dynamics in vivo: Effect of ribavirin and interferon alfa on viral turnover (1998) (176)
Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management. (2013) (176)
Albinterferon α-2b: a genetic fusion protein for the treatment of chronic hepatitis C (2007) (176)
Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy (2010) (174)
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. (2008) (173)
Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms (2011) (172)
Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. (2013) (172)
Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. (2012) (171)
Hepatitis C pharmacogenetics: State of the art in 2010 (2011) (168)
Differential Stability of Cell-Free Circulating microRNAs: Implications for Their Utilization as Biomarkers (2013) (165)
Pharmacokinetics of peginterferons. (2003) (164)
Peginterferon plus adefovir versus either drug alone for hepatitis delta. (2011) (163)
International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. (2005) (162)
New kinetic models for the hepatitis C virus (2005) (160)
Improvement of health-related quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. (2015) (157)
Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. (2008) (157)
Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. (2014) (156)
Regression of fibrosis and portal hypertension in HCV‐associated cirrhosis and sustained virologic response after interferon‐free antiviral therapy (2016) (151)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis. (2016) (151)
The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis (2013) (149)
Expression and Release of IL-18 Binding Protein in Response to IFN-γ1 (2001) (149)
Detection of residual hepatitis C virus RNA by transcription‐mediated amplification in patients with complete virologic response according to polymerase chain reaction–based assays (2000) (149)
The PREDICT study uncovers three clinical courses in acutely decompensated cirrhosis with distinct pathophysiology (120/120). (2020) (146)
Impact of COVID-19 on global HCV elimination efforts (2020) (141)
Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. (2011) (140)
Systemic and intrahepatic interferon‐gamma‐inducible protein 10 kDa predicts the first‐phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C (2010) (138)
A new standard of care for the treatment of chronic HCV infection (2011) (137)
Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study (2014) (135)
Treatment with ledipasvir and sofosbuvir improves patient‐reported outcomes: Results from the ION‐1, ‐2, and ‐3 clinical trials (2015) (135)
Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis (2010) (133)
Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD). (2002) (133)
Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histolog (1996) (132)
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. (2011) (131)
Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma (2011) (131)
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. (2019) (131)
Inhibition of RNAse A family enzymes prevents degradation and loss of silencing activity of siRNAs in serum. (2006) (129)
Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge (2013) (128)
The way forward in HCV treatment — finding the right path (2007) (127)
Structure and allosteric effects of low-molecular-weight activators on the protein kinase PDK1. (2009) (127)
Differences between Two Real-Time PCR-Based Hepatitis C Virus (HCV) Assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and One Signal Amplification Assay (Versant HCV RNA 3.0) for RNA Detection and Quantification (2008) (126)
Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. (2011) (126)
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. (2011) (126)
Predicted effects of treatment for HCV infection vary among European countries. (2012) (126)
Two-year Results from the Globe Trial in Patients with Hepatitis B: Greater Clinical and Antiviral Efficacy for Telbivudine (LdT) vs Lamivudine (2006) (126)
Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. (2018) (126)
The protease inhibitor, GS‐9256, and non‐nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C (2012) (125)
Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients (2013) (125)
Epac activation converts cAMP from a proliferative into a differentiation signal in PC12 cells. (2005) (123)
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals. (2017) (119)
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. (2014) (118)
Serum microRNA‐122 levels in different groups of patients with chronic hepatitis B virus infection (2012) (117)
Prevalence of hepatitis C virus antibodies and evaluation of hepatitis C virus genotypes in patients with lichen planus. (1997) (116)
Meta‐analysis: the outcome of anti‐viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis (2008) (115)
Acoustic Radiation Force Impulse-Imaging for the evaluation of the thyroid gland: a limited patient feasibility study. (2012) (115)
Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. (1998) (115)
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. (2011) (114)
Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. (2017) (114)
IL28B single nucleotide polymorphisms in the treatment of hepatitis C. (2011) (113)
Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. (2013) (113)
Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. (2012) (112)
Transarterial chemoembolization in the treatment of patients with unresectable cholangiocarcinoma: Results and prognostic factors governing treatment success (2012) (112)
Dynamics of hepatitis B virus infection in vivo. (1997) (112)
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. (2013) (111)
Review article: specifically targeted anti‐viral therapy for hepatitis C – a new era in therapy (2010) (110)
Acoustic Radiation Force Impulse Imaging for Differentiation of Thyroid Nodules (2012) (109)
A global view of hepatitis C: Physician knowledge, opinions, and perceived barriers to care (2013) (109)
Comparison of Conventional PCR with Real-Time PCR and Branched DNA-Based Assays for Hepatitis C Virus RNA Quantification and Clinical Significance for Genotypes 1 to 5 (2006) (109)
Noninvasive assessment of liver fibrosis in patients with Fontan circulation using transient elastography and biochemical fibrosis markers. (2008) (108)
Contrast‐Enhanced Ultrasound for the differentiation of benign and malignant focal liver lesions: a meta‐analysis (2013) (108)
Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. (2011) (107)
Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. (2016) (107)
Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. (2017) (106)
Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis (2010) (105)
Hepatitis C Virus Kinetics (1999) (105)
The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection. (2008) (104)
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. (2022) (103)
Perspectives and challenges of interferon-free therapy for chronic hepatitis C. (2013) (103)
A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis B. (2000) (102)
Emerging therapies for the treatment of hepatitis C (2013) (101)
Intraductal endoscopic radiofrequency ablation for the treatment of hilar non-resectable malignant bile duct obstruction. (2014) (100)
Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection. (2018) (100)
Occult hepatitis C: How convincing are the current data? (2009) (100)
Tumor regression by combination antisense therapy against Plk1 and Bcl-2 (2003) (99)
Chronic hepatitis C in patients with persistently normal alanine transaminase levels. (2006) (98)
PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. (2020) (98)
Allosteric activation of the protein kinase PDK1 with low molecular weight compounds (2006) (98)
Addressing Profiles of Systemic Inflammation Across the Different Clinical Phenotypes of Acutely Decompensated Cirrhosis (2019) (98)
Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. (2014) (97)
Dysregulation of global microRNA expression in splenic marginal zone lymphoma and influence of chronic hepatitis C virus infection (2012) (97)
Quantitative HBsAg and HDV‐RNA levels in chronic delta hepatitis (2010) (97)
Enlargement of perihepatic lymph nodes in relation to liver histology and viremia in patients with chronic hepatitis C (1997) (95)
Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials (2012) (95)
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices (2013) (95)
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. (2014) (94)
Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. (2014) (94)
Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. (2014) (94)
Cyclic AMP Induces Transactivation of the Receptors for Epidermal Growth Factor and Nerve Growth Factor, Thereby Modulating Activation of MAP Kinase, Akt, and Neurite Outgrowth in PC12 Cells* (2002) (94)
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis (2015) (93)
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies. (2017) (92)
Market uptake of new antiviral drugs for the treatment of hepatitis C. (2008) (91)
Deep Sequencing Reveals Mutagenic Effects of Ribavirin during Monotherapy of Hepatitis C Virus Genotype 1-Infected Patients (2013) (91)
Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms (2008) (89)
Assessment of Liver Fibrosis and Steatosis in PBC With FibroScan, MRI, MR-spectroscopy, and Serum Markers (2010) (88)
Randomized, double‐blind, placebo‐controlled trial of interferon Alfa2a with and without amantadine as initial treatment for chronic hepatitis C (2000) (88)
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. (2016) (88)
A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipovoxil (ADV) for treatment naïve patients with chronic hepatitis B (CHB): Week 52 analysis (2003) (88)
Assessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver disease. (2015) (86)
High Serum Levels of the Interleukin-33 Receptor Soluble ST2 as a Negative Prognostic Factor in Hepatocellular Carcinoma. (2013) (86)
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3 (2011) (85)
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. (2010) (85)
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16‐week abbreviated course of peginterferon alfa‐2a (40KD) plus ribavirin (2010) (84)
Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C (2008) (84)
Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis (2012) (83)
13C‐methacetin breath test as liver function test in patients with chronic hepatitis C virus infection (2005) (83)
Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection (2007) (83)
Mutagenic effect of ribavirin on hepatitis C nonstructural 5B quasispecies in vitro and during antiviral therapy. (2007) (82)
Capnographic monitoring of propofol-based sedation during colonoscopy (2013) (82)
Intravesicular acidification correlates with binding of ADP-ribosylation factor to microsomal membranes. (1992) (82)
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials (2015) (82)
Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis. (2013) (82)
Randomized, placebo‐controlled, double‐blind trial of Boswellia serrata in maintaining remission of Crohn's disease: Good safety profile but lack of efficacy (2011) (81)
IL28B Polymorphism Predicts Virologic Response in Patients With Hepatitis C Genotype 1 Treated With Boceprevir (Boc) Combination Therapy (2011) (81)
Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B). (2016) (80)
Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus (2008) (80)
Bethesda Guidelines: Relation to Microsatellite Instability and MLH1 Promoter Methylation in Patients with Colorectal Cancer (2001) (80)
The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection (2016) (79)
Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. (2000) (79)
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants (2010) (79)
5′-CpG island methylation of theLKB1/STK11 promoter and allelic loss at chromosome 19p13.3 in sporadic colorectal cancer (2000) (79)
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. (2006) (78)
Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen‐positive chronic hepatitis B (2012) (78)
12 IL28B POLYMORPHISM PREDICTS VIROLOGIC RESPONSE IN PATIENTS WITH HEPATITIS C GENOTYPE 1 TREATED WITH BOCEPREVIR (BOC) COMBINATION THERAPY (2011) (78)
Comparison of two quantitative hepatitis C virus reverse transcriptase PCR assays (1996) (78)
Pulmonary dysfunction in non-cirrhotic patients with chronic viral hepatitis. (2002) (78)
Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. (2015) (77)
Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy. (1999) (77)
Bacterial infection‐triggered acute‐on‐chronic liver failure is associated with increased mortality (2018) (77)
Antioxidative treatment prevents activation of death-receptor- and mitochondrion-dependent apoptosis in the hearts of diabetic rats (2004) (77)
HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). (2007) (76)
Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease. (2009) (76)
Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. (2013) (75)
Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. (2006) (75)
Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C. (2007) (75)
Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study (2016) (75)
Severe 25‐hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma – a prospective cohort study (2014) (75)
Telbivudine Globe Trial: Maximal Early HBV Suppression is Predictive of Optimal Two-year Efficacy in Nucleoside-treated Hepatitis B Patients (2006) (74)
The safety of pegylated interferon alpha‐2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation (2005) (74)
Cholecystokinin Stimulates Extracellular Signal-regulated Kinase through Activation of the Epidermal Growth Factor Receptor, Yes, and Protein Kinase C (2003) (74)
Soluble Serum CD81 Is Elevated in Patients with Chronic Hepatitis C and Correlates with Alanine Aminotransferase Serum Activity (2012) (73)
Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C (2010) (72)
Vitamin D receptor polymorphisms in differentiated thyroid carcinoma. (2009) (71)
Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. (2019) (71)
Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. (2002) (71)
Triple therapy with amantadine in treatment‐naive patients with chronic hepatitis C: A placebo‐controlled trial (2003) (70)
Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients (2015) (70)
Patterns of viral decline during PEG‐interferon alpha‐2b therapy in HBeAg‐positive chronic hepatitis B: Relation to treatment response (2006) (70)
Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. (1998) (69)
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. (2020) (69)
Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study (2011) (69)
Acoustic radiation force impulse imaging for non‐invasive assessment of liver fibrosis in chronic hepatitis B (2013) (68)
Diagnostic and prognostic significance of cell death and macrophage activation markers in patients with hepatocellular carcinoma. (2013) (68)
Serum MicroRNA-122 Predicts Survival in Patients with Liver Cirrhosis (2012) (68)
Sofosbuvir and Velpatasvir Combination Improves Patient‐reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis (2016) (68)
Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients (1997) (68)
Interobserver Agreement of Thyroid Imaging Reporting and Data System (TIRADS) and Strain Elastography for the Assessment of Thyroid Nodules (2013) (68)
Multiple plastic stents versus covered metal stent for treatment of anastomotic biliary strictures after liver transplantation: a prospective, randomized, multicenter trial. (2017) (68)
Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin/sofosbuvir treatment. (2016) (67)
Treatment of chronic hepatitis C patients with the NS3/4A protease inhibitor danoprevir (ITMN-191/RG7227) leads to robust reductions in viral RNA: a phase 1b multiple ascending dose study. (2011) (67)
An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn’s disease and experimental colitis in vivo (2004) (67)
Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. (2009) (67)
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha‐2a (2008) (67)
13 SIMILAR SVR RATES IN IL28B CC, CT OR TT PRIOR RELAPSER PARTIAL- OR NULL-RESPONDER PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/RIBAVIRIN: RETROSPECTIVE ANALYSIS OF THE REALIZE STUDY (2011) (66)
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease (2012) (66)
Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. (2009) (66)
Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response (2011) (66)
High Prevalence of Anti-HCV Antibodies in Two Metropolitan Emergency Departments in Germany: A Prospective Screening Analysis of 28,809 Patients (2012) (65)
Real-time elastography and contrast-enhanced ultrasound for the assessment of thyroid nodules. (2009) (65)
Non-invasive measurement of liver and pancreas fibrosis in patients with cystic fibrosis. (2013) (65)
101 SVR4 AND SVR12 WITH AN INTERFERON-FREE REGIMEN OF BI201335 AND BI207127, +/- RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE-1 HCV INFECTION: INTERIM RESULTS OF SOUND-C2 (2012) (65)
Hepatitis C Virus Nonstructural 5A Protein and Interferon Resistance: a New Model for Testing the Reliability of Mutational Analyses (2002) (65)
Review article: predicting response in hepatitis C virus therapy (2006) (65)
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors (2005) (65)
Clinical evaluation of a new polymerase chain reaction assay (Amplicor HCV) for detection of hepatitis C virus. (1994) (65)
Ribavirin: current role in the optimal clinical management of chronic hepatitis C. (2009) (64)
Current and future treatment options for HCV. (2009) (63)
Allosteric regulation of protein kinase PKCζ by the N‐terminal C1 domain and small compounds to the PIF‐pocket (2011) (63)
[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. (2012) (63)
Mutations in the MutSα interaction interface of MLH1 can abolish DNA mismatch repair (2006) (62)
Identification of 19 Novel Hepatitis C Virus Subtypes—Further Expanding HCV Classification (2019) (62)
A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C (2012) (62)
Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens. (2016) (62)
Individualized treatment strategy according to early viral kinetics in hepatitis C virus type 1–infected patients (2009) (61)
Durable Hepatitis B Surface Antigen Decline in Hepatitis B E Antigen-Positive Chronic Hepatitis B Patients Treated with Pegylated Interferon-α2B: Relation to Response and HBV Genotype (2012) (61)
Substrate-selective inhibition of protein kinase PDK1 by small compounds that bind to the PIF-pocket allosteric docking site. (2012) (61)
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. (2013) (60)
3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY (2013) (60)
PD‐L1 expression in extrahepatic cholangiocarcinoma (2017) (59)
58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION (2012) (59)
The anti‐lymphoma activity of antiviral therapy in HCV‐associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis (2016) (59)
Deterioration of health-related quality of life and fatigue in patients with chronic hepatitis C: Association with demographic factors, inflammatory activity, and degree of fibrosis. (2008) (59)
LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: INTERIM ANALYSIS OF THE EXTEND STUDY (2010) (59)
Transient mismatch repair gene transfection for functional analysis of genetic hMLH1 and hMSH2 variants (2002) (58)
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy. (2010) (58)
Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. (2015) (57)
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. (2016) (57)
Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. (2013) (57)
Risk factors for the transmission of hepatitis C. (1996) (57)
1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS (2012) (56)
Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids (2018) (56)
New therapeutic strategies in HCV: polymerase inhibitors (2013) (56)
Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. (2004) (56)
Prospective study of bone mineral density and metabolism in patients with chronic hepatitis C during pegylated interferon α and ribavirin therapy (2008) (56)
Low 25-Hydroxyvitamin D Levels Are Associated with Infections and Mortality in Patients with Cirrhosis (2015) (55)
Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C. (2011) (55)
Applying a system approach to forecast the total hepatitis C virus‐infected population size: model validation using US data (2011) (55)
Contrast-enhanced sonography of adrenal masses: differentiation of adenomas and nonadenomatous lesions. (2008) (54)
N‐terminus of hMLH1 confers interaction of hMutLα and hMutLβ with hMutSα (2003) (54)
Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity (2006) (54)
Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK1 Protein Kinase. (2016) (54)
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin (2012) (54)
Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapy (2005) (54)
Hepatocellular proliferation in patients with chronic hepatitis C and persistently normal or abnormal aminotransferase levels. (2000) (54)
1416 FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAÏVE PATIENTS: FINAL RESULTS FROM STARTVERSO1, A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III TRIAL (2013) (54)
104 BOCEPREVIR (B) COMBINATION THERAPY IN NULL RESPONDERS (NR): RESPONSE DEPENDENT ON INTERFERON RESPONSIVENESS (2008) (53)
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma. (2015) (53)
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. (2003) (53)
Serum acid sphingomyelinase is upregulated in chronic hepatitis C infection and non alcoholic fatty liver disease. (2014) (53)
ERCP in elderly patients: increased risk of sedation adverse events but low frequency of post-ERCP pancreatitis. (2015) (53)
Progress towards hepatitis C virus elimination in high‐income countries: An updated analysis (2021) (53)
Evaluation of an automated, highly sensitive, real-time PCR-based assay (COBAS Ampliprep/COBAS TaqMan) for quantification of HCV RNA. (2008) (53)
A phase I/II study of recombinant human interleukin‐12 in patients with chronic hepatitis C (1999) (52)
Impaired vitamin D activation and association with CYP24A1 haplotypes in differentiated thyroid carcinoma. (2012) (52)
Treatment of Amanita phalloides intoxication by fractionated plasma separation and adsorption (Prometheus®). (2012) (52)
Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma (2016) (52)
Serum Autotaxin Is a Parameter for the Severity of Liver Cirrhosis and Overall Survival in Patients with Liver Cirrhosis – A Prospective Cohort Study (2014) (52)
Assessment, by Transcription-Mediated Amplification, of Virologic Response in Patients with Chronic Hepatitis C Virus Treated with Peginterferon α-2a (2001) (52)
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C. (2006) (51)
O4 PROLONGED THERAPY OF HEPATITIS DELTA FOR 96 WEEKS WITH PEGYLATED-INTERFERON-α-2a PLUS TENOFOVIR OR PLACEBO DOES NOT PREVENT HDVRNA RELAPSE AFTER TREATMENT: THE HIDIT-2 STUDY (2014) (51)
Severity of HCV-Induced Liver Damage Alters Glucose Homeostasis in Noncirrhotic Patients with Chronic HCV Infection (2000) (51)
Improvement of platelets after SVR among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (51)
4 ONCE DAILY ALISPORIVIR (DEB025) PLUS PEGIFNALFA2A/RIBAVIRIN RESULTS IN SUPERIOR SUSTAINED VIROLOGIC RESPONSE (SVR24) IN CHRONIC HEPATITIS C GENOTYPE 1 TREATMENT NAIVE PATIENTS (2011) (51)
Clinical implications of hepatitis C viral kinetics. (1999) (51)
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. (2011) (51)
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life (2006) (50)
Mutations selected in the hepatitis C virus NS3 protease domain during sequential treatment with boceprevir with and without pegylated interferon alfa‐2b (2012) (50)
Photoallergic skin reaction to ribavirin (1999) (50)
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study. (2011) (50)
Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study (2012) (50)
Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C. (2014) (50)
P0773 : The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/- RBV (2015) (50)
Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response (2017) (49)
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients. (2018) (49)
1419 A RANDOMIZED TRIAL COMPARING RIBAVIRIN DOSE REDUCTION VERSUS ERYTHROPOIETIN FOR ANEMIA MANAGEMENT IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC HEPATITIS C RECEIVING BOCEPREVIR PLUS PEGINTERFERON/RIBAVIRIN (2012) (49)
An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa‐2b combination therapy for chronic hepatitis C (2009) (49)
Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. (2017) (49)
Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C (2005) (49)
Gut-liver axis (2000) (49)
1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 (2011) (48)
Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy. (2001) (48)
Involvement of the platelet‐derived growth factor receptor in angiotensin II‐induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells (2000) (48)
O8 SUCCESSFUL RETREATMENT WITH SOFOSBUVIR-CONTAINING REGIMENS FOR HCV GENOTYPE 2 OR 3 INFECTED PATIENTS WHO FAILED PRIOR SOFOSBUVIR PLUS RIBAVIRIN THERAPY (2014) (48)
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. (2003) (48)
Evaluation and comparison of different hepatitis C virus genotyping and serotyping assays. (1997) (48)
Sofosbuvir/velpatasvir in patients with hepatitis C virus genotypes 1‐6 and compensated cirrhosis or advanced fibrosis (2018) (48)
Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. (2004) (48)
8 EVOLUTION OF TREATMENT-EMERGENT RESISTANT VARIANTS IN TELAPREVIR PHASE 3 CLINICAL TRIALS (2011) (47)
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response (2000) (47)
Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. (2011) (47)
PROPEL: A randomized trial of mericitabine plus peginterferon alpha‐2a/ribavirin therapy in treatment‐naïve HCV genotype 1/4 patients (2013) (47)
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. (2017) (47)
Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: Results from the REALIZE trial (2012) (47)
Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope (2011) (47)
Comparison of transcription mediated amplification (TMA) and reverse transcription polymerase chain reaction (RT-PCR) for detection of hepatitis C virus RNA in liver tissue. (2005) (47)
484 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG GENOTYPE 1 PREVIOUS NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (46)
p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. (1996) (46)
Is there sufficient evidence to recommend antiviral therapy in hepatitis C? (2014) (46)
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. (2015) (46)
Amino Acid Variations in Hepatitis C Virus P7 and Sensitivity to Antiviral Combination Therapy with Amantadine in Chronic Hepatitis C (2005) (46)
58 TREATMENT OF CHRONIC HEPATITIS C WITH TELAPREVIR (TVR) IN COMBINATION WITH PEGINTERFERON-ALFA-2A WITH OR WITHOUT RIBAVIRIN: FURTHER INTERIM ANALYSIS RESULTS OF THE PROVE2 STUDY (2008) (45)
[8] SHOULD TREATMENT WITH PEGINTERFERON PLUS RIBAVIRIN BE INTENSIFIED IN PATIENTS WITH HCV GENOTYPE 2/3 WITHOUT A RAPID VIROLOGICAL RESPONSE? (2007) (45)
Virologic Escape during Danoprevir (ITMN-191/RG7227) Monotherapy Is Hepatitis C Virus Subtype Dependent and Associated with R155K Substitution (2011) (45)
Thymosin beta 4 expression and nuclear transport are regulated by hMLH1. (2007) (45)
A Common HLA-DPA1 Variant Is Associated with Hepatitis B Virus Infection but Fails to Distinguish Active from Inactive Caucasian Carriers (2012) (45)
Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis (2017) (44)
Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease (2004) (44)
Interferon lambda 4 genotypes and resistance‐associated variants in patients infected with hepatitis C virus genotypes 1 and 3 (2016) (44)
Transferrin-Coated Gadolinium Nanoparticles as MRI Contrast Agent (2013) (44)
Anemia Had No Effect on Efficacy Outcomes in Treatment-NaïVE Patients Who Received Telaprevir-Based Regimen in the Advance and Illuminate Phase 3 Studies (2011) (44)
Superiority of Interferon-Free Regimens for Chronic Hepatitis C (2017) (44)
RNAse A‐like enzymes in serum inhibit the anti‐neoplastic activity of siRNA targeting polo‐like kinase 1 (2007) (43)
Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. (2005) (43)
481 THE EFFICIENCY OF ACOUSTIC RADIATION FORCE IMPULSE-IMAGING FOR THE STAGING OF LIVER FIBROSIS: A META-ANALYSIS (2013) (43)
869b Simeprevir (TMC435) With Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-Based Therapy: Results From PROMISE, a Phase III Trial (2013) (43)
Microsatellite Instability Occurs Rarely in Patients with Cholangiocarcinoma: A Retrospective Study from a German Tertiary Care Hospital (2018) (43)
Rapid decrease of wild-type hepatitis C virus on telaprevir treatment (2008) (43)
Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. (2012) (43)
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. (2012) (43)
Receptor tyrosine kinases are signaling intermediates of G protein-coupled receptors. (2004) (43)
Differentiation between benign and malignant adrenal mass using contrast-enhanced ultrasound. (2010) (43)
Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. (2005) (43)
New developments in HCV therapy (2012) (43)
Long‐term effectiveness and cost‐effectiveness of antiviral treatment in hepatitis C (2010) (43)
Hepatocellular carcinoma recurrence after direct antiviral agent treatment: A European multicentre study. (2017) (42)
Viral dynamics in chronic hepatitis B patients during lamivudine therapy. (2002) (42)
Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. (2019) (42)
[Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]. (2007) (42)
P0772 : Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: Interim results of a multicenter compassionate use program (2015) (42)
Anti-HDV IgM as a Marker of Disease Activity in Hepatitis Delta (2014) (42)
CCK, carbachol, and bombesin activate distinct PLC-beta isoenzymes via Gq/11 in rat pancreatic acinar membranes. (1997) (42)
How to use virological tools for the optimal management of chronic hepatitis C (2011) (42)
[Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection - AWMF-Register-No.: 021/012]. (2018) (42)
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. (2012) (41)
The safety and efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 1b infection (2018) (41)
Contrast‐enhanced ultrasound in the diagnosis of malignant mesenchymal liver tumors (2010) (41)
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. (2016) (41)
Perihepatic lymph nodes as a marker of antiviral response in patients with chronic hepatitis C infection. (2000) (41)
Long‐term follow‐up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation (2013) (41)
The prognostic significance of bacterial DNA in patients with decompensated cirrhosis and suspected infection (2016) (41)
Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. (2010) (40)
Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. (2016) (40)
Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection. (2014) (40)
Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura. (2011) (39)
A de novo deletion of chromosome 5q causing familial adenomatous polyposis, dysmorphic features, and mild mental retardation (2001) (39)
The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection. (2009) (39)
Does noninvasive staging of fibrosis challenge liver biopsy as a gold standard in chronic hepatitis C? (2004) (39)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis (2015) (39)
Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. (2020) (39)
Serum microRNA‐122 kinetics in patients with chronic hepatitis C virus infection during antiviral therapy (2013) (38)
Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. (1997) (38)
Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C. (2002) (38)
Randomized, controlled trial with IFN-α combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C (2003) (38)
Human colon organoids reveal distinct physiologic and oncogenic Wnt responses (2019) (38)
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation. (2011) (38)
477 ANEMIA HAD NO EFFECT ON EFFICACY OUTCOMES IN TREATMENT-NAIVE PATIENTS WHO RECEIVED TELAPREVIR-BASED REGIMEN IN THE ADVANCE AND ILLUMINATE PHASE 3 STUDIES (2011) (38)
Evaluation of a reverse hybridization assay for genotyping of hepatitis C virus. (1995) (37)
Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study (2012) (37)
Phylogenetic analysis of hepatitis C virus isolates from hemodialysis patients. (1996) (37)
Structural and functional comparison of the non-structural protein 4B in flaviviridae. (2007) (37)
106 International, multicenter, randomized, controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peginterferon alfa-2A (40KD) (PEGASYS®) and ribavirin (copegus®) (2003) (37)
Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. (2000) (37)
Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. (1996) (37)
1044 TELAPREVIR IN HEPATITIS C GENOTYPE-1-INFECTED PATIENTS WITH PRIOR NON-RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE TO PEGINTERFERON- ALFA-2A/B AND RIBAVIRIN THERAPY: SVR RESULTS OF THE PROVE3 STUDY (2009) (37)
N-terminus of hMLH1 confers interaction of hMutLalpha and hMutLbeta with hMutSalpha. (2003) (36)
Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels (2004) (36)
5 REALIZE TRIAL FINAL RESULTS: TELAPREVIR-BASED REGIMEN FOR GENOTYPE 1 HEPATITIS C VIRUS INFECTION IN PATIENTS WITH PRIOR NULL RESPONSE, PARTIAL RESPONSE OR RELAPSE TO PEGINTERFERON/RIBAVIRIN (2011) (36)
No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct‐acting antivirals for hepatitis C in a large real‐world cohort (2017) (36)
Variations in serum sphingolipid levels associate with liver fibrosis progression and poor treatment outcome in hepatitis C virus but not hepatitis B virus infection (2015) (36)
Insulin secretion, adipocyte insulin binding and insulin sensitivity in thyrotoxicosis. (1985) (36)
Placebo‐controlled trial of 400 mg amantadine combined with peginterferon alfa‐2a and ribavirin for 48 weeks in chronic hepatitis C virus‐1 infection (2008) (36)
Reliable prediction of clinical outcome in patients with chronic HCV infection and compensated advanced hepatic fibrosis: a validated model using objective and readily available clinical parameters (2014) (36)
Interleukin-12 in the treatment of chronic hepatitis B and C. (2001) (36)
Risk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals (2018) (36)
Interferon alfa down‐regulates CD81 in patients with chronic hepatitis C (2001) (36)
52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B (2013) (35)
Antiviral Activity of ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, in Chronic Hepatitis C Patients (2011) (35)
A multicenter study on the role of direct retrograde cholangioscopy in patients with inconclusive endoscopic retrograde cholangiography (2013) (35)
Promoter Methylation of MLH1, PMS2, MSH2 and p16 Is a Phenomenon of Advanced-Stage HCCs (2014) (35)
Cost‐effective and safe ambulatory long‐term immunoprophylaxis with intramuscular instead of intravenous hepatitis B immunoglobulin to prevent reinfection after orthotopic liver transplantation (2003) (35)
Quantification of hepatitis C virus RNA by competitive reverse transcription and polymerase chain reaction using a modified hepatitis C virus RNA transcript. (1995) (35)
A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection (2008) (35)
Expression Defect Size among Unclassified MLH1 Variants Determines Pathogenicity in Lynch Syndrome Diagnosis (2013) (34)
Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy (2001) (34)
Peutz-Jeghers syndrome: molecular analysis of a three-generation kindred with a novel defect in the serine threonine kinase gene STK11 (1999) (34)
Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure, a multicenter randomized trial (GRAFT study). (2021) (34)
Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results (2013) (34)
hMutSα forms an ATP-dependent complex with hMutLα and hMutLβ on DNA (2002) (34)
Forewarned is forearmed. (2009) (34)
Characterization of putrescine transport across the intestinal epithelium: study using isolated brush border and basolateral membrane vesicles of the enterocyte (1995) (34)
Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors (2018) (34)
Polo-like kinase1, a new target for antisense tumor therapy. (2000) (34)
Peri-hepatic lymphadenopathy in primary biliary cirrhosis reflects progression of the disease. (1999) (33)
Regulation of the Interaction between Protein Kinase C-related Protein Kinase 2 (PRK2) and Its Upstream Kinase, 3-Phosphoinositide-dependent Protein Kinase 1 (PDK1)* (2009) (33)
Divergent preS Sequences in Virion-Associated Hepatitis B Virus Genomes and Subviral HBV Surface Antigen Particles From HBV e Antigen-Negative Patients (2018) (33)
Impaired health‐related quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels (2006) (33)
Serum Sphingolipid Variations Associate with Hepatic Decompensation and Survival in Patients with Cirrhosis (2015) (33)
Role of nucleoside transporters SLC28A2/3 and SLC29A1/2 genetics in ribavirin therapy: protection against anemia in patients with chronic hepatitis C (2011) (33)
3507 ORAL Sorafenib improves survival in a large multi-center, randomized, placebo-controlled phase III trial in patients with hepatocellular carcinoma (2007) (33)
Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus (2015) (33)
Association of serum interleukin-8 with virologic response to antiviral therapy in patients with chronic hepatitis C. (2004) (33)
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha‐2a/ribavirin in HCV genotypes 1 or 4 (2015) (33)
Sofosbuvir-Based Direct-Acting Antiviral Therapies for HCV in People Receiving Opioid Substitution Therapy: An Analysis of Phase 3 Studies (2018) (33)
2 TMC435 IN HCV GENOTYPE 1 PATIENTS WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON/RIBAVIRIN TREATMENT: FINAL SVR24 RESULTS OF THE ASPIRE TRIAL (2012) (32)
Clinical evaluation of a single reaction, diagnostic polymerase chain reaction assay for the detection of hepatitis C virus RNA. (1996) (32)
734 Peginterferon alpha-2a (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks in patients with HCV genotype 2 OR 3. Final results of the accelerate trial (2006) (32)
Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. (2020) (32)
Development of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity (2011) (32)
GNB3 C825T polymorphism and response to interferon-alfa/ribavirin treatment in patients with hepatitis C virus genotype 1 (HCV-1) infection. (2005) (32)
Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C (2009) (32)
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations (2015) (32)
Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial (2013) (31)
Randomized, placebo‐controlled, double‐blind trial with interferon‐α with and without amantadine sulphate in primary interferon‐α nonresponders with chronic hepatitis C (2001) (31)
Three years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015 - March 2018. (2019) (31)
Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study (2018) (31)
Biodegradable human serum albumin nanoparticles as contrast agents for the detection of hepatocellular carcinoma by magnetic resonance imaging. (2014) (31)
T-29 Predictors of virologic response with telaprevir-based combination treatment in HCV genotype 1-infected patients with prior peginterferon/ribavirin treatment failure: post-hoc analysis of the phase III REALIZE study (2012) (31)
Faldaprevir Plus Pegylated Interferon Alfa-2a and Ribavirin in Chronic HCV Genotype-1 Treatment-Naïve Patients: Final Results from STARTVerso1: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Trial: 487 (2013) (31)
Impact of HBV genotype and mutations on HBV DNA and qHBsAg levels in patients with HBeAg‐negative chronic HBV infection (2018) (31)
Pertussis toxin inhibits cholecystokinin- and epidermal growth factor-induced mitogen-activated protein kinase activation by disinhibition of the cAMP signaling pathway and inhibition of c-Raf-1. (2000) (31)
Limited Value of Fluorine-18-Fluorodeoxyglucose PET for the Differential Diagnosis of Focal Liver Lesions in Patients with Chronic Hepatitis C Virus Infection (1998) (31)
MUTYH gene expression and alternative splicing in controls and polyposis patients (2012) (31)
Viral Kinetics in Patients with Chronic Hepatitis C Treated with the Serine Protease Inhibitor Biln 2061 (2005) (31)
1162 RIBAVIRIN DOSE MODIFICATION IN TREATMENT-NAIVE AND PREVIOUSLY TREATED PATIENTS WHO RECEIVED TELAPREVIR COMBINATION TREATMENT: NO IMPACT ON SUSTAINED VIROLOGIC RESPONSE IN PHASE 3 STUDIES (2012) (30)
Daclatasvir plus Sofosbuvir, with or without Ribavirin, in Real-World Patients with HIV–HCV Coinfection and Advanced Liver Disease (2016) (30)
Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. (2009) (30)
Safety and efficacy of boceprevir/peginterferon/ribavirin for HCV G1 compensated cirrhotics: meta-analysis of 5 trials. (2014) (30)
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II) (2015) (30)
Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation (2010) (30)
Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. (2017) (30)
Intracellular accumulation of subviral HBsAg particles and diminished Nrf2 activation in HBV genotype G expressing cells lead to an increased ROI level. (2015) (30)
1376 THE ASPIRE TRIAL: TMC435 IN TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE-1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGIFN/RBV TREATMENT (2011) (29)
Intratumoral heterogeneity of intrahepatic cholangiocarcinoma (2017) (29)
A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation (2016) (29)
Management of Hepatitis C virus Genotype 2 or 3 Infection: Treatment Optimization on the Basis of Virological Response (2009) (29)
First description of immune complex vasculitis after COVID-19 vaccination with BNT162b2: a case report (2021) (29)
Retreatment of Patients who Failed Daa-Combination Therapies: Real-World Experience from a Large Hepatitis C Resistance Database (2016) (29)
Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. (2014) (29)
Thursday, 24 AprilParallel Session 1: HEPATITIS C THERAPY7 RAPID VIROLOGICAL RESPONSE IS A MORE IMPORTANT PREDICTOR OF SUSTAINED VIROLOGICAL RESPONSE (SVR) THAN GENOTYPE IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION (2008) (29)
Predictive value of mucosal TNF‐&agr; transcripts in steroid‐refractory Crohn's disease patients receiving intensive immunosuppressive therapy (2007) (29)
Increased cytokine transcripts in pouchitis reflect the degree of inflammation but not the underlying entity (2006) (29)
Molecular detection of thyroid cancer: an update (2004) (29)
Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. (1998) (29)
Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture (1999) (28)
Clinical significance of in vitro replication-enhancing mutations of the hepatitis C virus (HCV) replicon in patients with chronic HCV infection. (2005) (28)
The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far. (2022) (28)
Development of sofosbuvir for the treatment of hepatitis C virus infection (2015) (28)
Effects of prostaglandins and indomethacin on gastric emptying in the rat. (1994) (28)
The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection (2011) (28)
Single measurement of hemoglobin predicts outcome of HCC patients (2013) (28)
Interleukin-2 in CD8+ T cells correlates with Banff score during organ rejection in liver transplant recipients (2009) (27)
Point Shear Wave Elastography by Acoustic Radiation Force Impulse Quantification in Comparison to Transient Elastography for the Noninvasive Assessment of Liver Fibrosis in Chronic Hepatitis C: A Prospective International Multicenter Study (2015) (27)
Telaprevir for the treatment of hepatitis C (2012) (27)
Peginterferon α-2a (40kD) [Pegasys®] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon®-A] (2012) (27)
Evaluation of 2D- Shear Wave Elastography for Characterisation of Focal Liver Lesions. (2017) (27)
Pan-intestinal capsule endoscopy in patients with postoperative Crohn's disease: a pilot study (2017) (27)
Hypoxia Causes Downregulation of Dicer in Hepatocellular Carcinoma, Which Is Required for Upregulation of Hypoxia-Inducible Factor 1α and Epithelial–Mesenchymal Transition (2017) (27)
Mericitabine and ritonavir‐boosted danoprevir with or without ribavirin in treatment‐naive HCV genotype 1 patients: INFORM‐SVR study (2015) (27)
Evaluation of the safety and efficacy of once-weekly PEG/interferon alfa-2A (PEGASYS™) for chronic hepatitis C. A multinational, randomized study (2000) (27)
New Antiviral Therapies in the Management of HCV Infection (2012) (27)
Role of portal venous platelet activation in patients with decompensated cirrhosis and TIPS (2019) (27)
Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1 (2014) (27)
Prevalence and clinical and histological manifestation of hepatitis G/GBV-C infections in patients with elevated aminotransferases of unknown etiology. (1997) (26)
Protein kinase A mediates cAMP-induced tyrosine phosphorylation of the epidermal growth factor receptor. (2003) (26)
Optimal therapy in genotype 1 patients (2009) (26)
Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and telaprevir (VX 950) in human plasma by LC-MS/MS. (2009) (26)
Anti-Hdv Immunoglobulin M Testing in Hepatitis Delta Revisited: Correlations with Disease Activity and Response to Pegylated Interferon-α2A Treatment (2012) (26)
10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB (2012) (26)
Clinical relevance of HCV antiviral drug resistance. (2012) (26)
Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. (2012) (26)
Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C (2014) (26)
The Periprocedural Management of Anticoagulation and Platelet Aggregation Inhibitors in Endoscopic Interventions. (2016) (26)
Dynamics of hepatitis C virus infection. (2002) (26)
Interferon-based therapy for chronic hepatitis C: current and future perspectives (2008) (25)
Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion (2020) (25)
[S3 guideline hepatitis C addendum]. (2015) (25)
Activation of a cryptic splice site of PTEN and loss of heterozygosity in benign skin lesions in Cowden disease. (2001) (25)
Early Viral Kinetics of Telbivudine and Entecavir: Results of a 12-Week Randomized Exploratory Study with Patients with HBeAg-Positive Chronic Hepatitis B (2009) (25)
Concordance between sustained virologic response week 12 (SVR12) and SVR24 in genotype 1 hepatitis C virus patients receiving interferon‐free treatment in the SOUND‐C2 study (2013) (25)
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-&agr;-2a and ribavirin (2010) (25)
740 HBSAG KINETICS IN PATIENTS WITH CHRONIC HEPATITIS B (CHB) TREATED WITH TENOFOVIR DISOPROXIL FUMARATE (TDF) FOR UP TO 4 YEARS (2011) (25)
Detection of hepatocellular carcinoma in transgenic mice by Gd-DTPA- and rhodamine 123-conjugated human serum albumin nanoparticles in T1 magnetic resonance imaging. (2015) (25)
T-27 Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study (2012) (25)
Trends and the course of liver cirrhosis and its complications in Germany: Nationwide population-based study (2005 to 2018) (2021) (25)
Applicability of Hepatitis C Virus RNA Viral Load Thresholds for 8-Week Treatments in Patients With Chronic Hepatitis C Virus Genotype 1 Infection. (2016) (25)
6 SUBANALYSES OF THE TELAPREVIR LEAD-IN ARM IN THE REALIZE STUDY: RESPONSE AT WEEK 4 IS NOT A SUBSTITUTE FOR PRIOR NULL RESPONSE CATEGORIZATION (2011) (25)
Regulation of Protein Kinase C-related Protein Kinase 2 (PRK2) by an Intermolecular PRK2-PRK2 Interaction Mediated by Its N-terminal Domain* (2012) (24)
OPTIMIZE trial: Non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients (2013) (24)
737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2a (2006) (24)
Screening for IL28B gene variants identifies predictors of hepatitis C therapy success (2010) (24)
Triple therapy with telaprevir: results in hepatitis C virus‐genotype 1 infected relapsers and non‐responders (2012) (24)
IL‐22 and IL‐22‐Binding Protein Are Associated With Development of and Mortality From Acute‐on‐Chronic Liver Failure (2019) (24)
Patient‐Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir (2017) (24)
Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification (2018) (24)
Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeficiency Virus RNA Load (2006) (24)
The case for simplifying and using absolute targets for viral hepatitis elimination goals (2020) (24)
Prevalence of colorectal cancer and its precursor lesions in symptomatic and asymptomatic patients undergoing total colonoscopy: results of a large prospective, multicenter, controlled endoscopy study (2013) (24)
CLINICAL ADVANCES IN LIVER, PANCREAS, AND BILIARY TRACT Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus (2010) (24)
Risk factors predictive of anemia development during telaprevir plus peginterferon/ribavirin therapy in treatment-experienced patients. (2014) (24)
Current standards in the treatment of chronic hepatitis C. (2012) (24)
The complex interrelationships between chronic lung and liver disease: a review (2010) (24)
Quantification of fecal carbohydrates by near-infrared reflectance analysis. (1996) (23)
EGF Stimulates Polyamine Uptake in Caco-2 Cells (1995) (23)
ACE2, the Receptor that Enables Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators (2020) (23)
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. (2006) (23)
Treatment Options in Hepatitis C. (2017) (23)
Subcellular distribution and function of Rab3A-D in pancreatic acinar AR42J cells. (2001) (23)
C-Terminal Fluorescent Labeling Impairs Functionality of DNA Mismatch Repair Proteins (2012) (23)
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. (2013) (23)
Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double‐blinded multicentre trial (2014) (23)
Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid‐Reducing Agents in Patients With Chronic HCV Infection (2019) (22)
Intraductal biopsies in indeterminate biliary stricture: Evaluation of histopathological criteria in fluoroscopy- vs. cholangioscopy guided technique. (2016) (22)
Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies (2014) (22)
Endoscopic transhiatal drainage of a mediastinal pancreatic pseudocyst. (2006) (22)
Effect of thrombocytopenia on treatment tolerability and outcome in patients with chronic HCV infection and advanced hepatic fibrosis. (2014) (22)
Serum Tests for Diagnosis and Follow-Up of Hepatocellular Carcinoma after Treatment (1998) (22)
P1345 : A randomized, open-label study to evaluate efficacy and safety of ombitasvir/paritaprevir/ritonavir co-administered with ribavirin in adults with genotype 4 chronic hepatitis C infection and cirrhosis (2015) (22)
Indication for ‘Over the Scope’ (OTS)-Clip vs. Covered Self-Expanding Metal Stent (cSEMS) Is Unequal in Upper Gastrointestinal Leakage: Results from a Retrospective Head-to-Head Comparison (2015) (22)
Do differences in pegylation of interferon alfa matter? (2010) (22)
[Analysis of hepatic echo patterns in chronic hepatitis C]. (1999) (22)
Novel hepatitis C drugs in current trials. (2008) (22)
Two-dimensional shear wave elastography predicts survival in advanced chronic liver disease (2021) (22)
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. (2012) (22)
Interferon‐free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND‐C3, a Phase 2b study (2015) (22)
Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers (2012) (22)
Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure (2017) (21)
85 ANTIVIRAL ACTIVITY AND SAFETY OF ITMN-191 IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) (2009) (21)
Quinolone- and multidrug-resistance predict failure of antibiotic prophylaxis of spontaneous bacterial peritonitis. (2020) (21)
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. (2011) (21)
The number needed to treat to prevent mortality and cirrhosis‐related complications among patients with cirrhosis and HCV genotype 1 infection (2014) (21)
Mutations in the putative HCV‐E2 CD81 binding regions and correlation with cell surface CD81 expression (2004) (21)
Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response (2010) (21)
The kinetics of hepatitis C virus infection. (2001) (21)
Viral kinetics in patients with lamivudine-resistant hepatitis B during adefovir-lamivudine combination therapy. (2005) (21)
Polymorphisms of HLA‐DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B (2014) (21)
Retreatment with Interferon-Alpha and Ribavirin in Primary Interferon-Alpha Non-Responders with Chronic Hepatitis C (2000) (21)
The macrophage activation marker CD163 is associated with IL28B genotype and hepatic inflammation in chronic hepatitis C virus infected patients (2016) (21)
Activation of Adenylyl Cyclase Causes Stimulation of Adenosine Receptors (2018) (21)
881 HIGH SVR RATES (SVR4) FOR 12-WEEK TOTAL TELAPREVIR COMBINATION THERAPY IN IL28B CC TREATMENT-NAÏVES AND PRIOR RELAPSERS WITH G1 CHRONIC HEPATITIS C: CONCISE INTERIM ANALYSIS (2013) (21)
FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. (2011) (21)
An Interstitial Deletion at 3p21.3 Results in the Genetic Fusion of MLH1 and ITGA9 in a Lynch Syndrome Family (2009) (21)
Probiotic Lactobacillus casei Shirota improves kidney function, inflammation and bowel movements in hospitalized patients with acute gastroenteritis – A prospective study (2015) (20)
[Ultrasound lymph node imaging in the abdomen and retroperitoneum of healthy probands]. (1998) (20)
78 The HCV NS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1 PEG-IFNα-2b non-responders: Antiviral activity and HCV variant analysis (2006) (20)
EGF stimulates polyamine uptake in Caco-2 cells. (1995) (20)
Mutations within the CD81-binding sites and hypervariable region 2 of the envelope 2 protein: correlation with treatment response in hepatitis C virus-infected patients. (2003) (20)
Absence of the interstitial cell of Cajal network in mitochondrial neurogastrointestinal encephalomyopathy (2009) (20)
[4] 72 WEEK DATA OF THE HIDIT-1 TRIAL: A MULTICENTER RANDOMISED STUDY COMPARING PEGINTERFERON α-2a PLUS ADEFOVIR VS. PEGINTERFERON α-2a PLUS PLACEBO VS. ADEFOVIR IN CHRONIC DELTA HEPATITIS (2007) (20)
4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR (2010) (20)
Hepatitis C virus: kinetics and quasispecies evolution during anti-viral therapy. (2000) (20)
Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection (2014) (20)
Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. (2013) (20)
Subanalyses of the Telaprevir Lead-in ARM in the Realize Study: Response at Week 4 is Not a Substitute for Prior Null Response Categorization (2011) (20)
Simeprevir with peginterferon/ribavirin for treatment of chronic hepatitis C virus genotype 1 infection: pooled safety analysis from Phase IIb and III studies (2015) (20)
The economics of treating chronic hepatitis C patients with peginterferon α‐2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase * (2006) (20)
Selective targeting of tumor associated macrophages in different tumor models (2018) (20)
Analysis of the human MutLα·MutSα complex (2006) (20)
A prospective, multicentre study in acute non‐cirrhotic, non‐malignant portal vein thrombosis: comparison of medical and interventional treatment (2020) (20)
Current therapy for hepatitis C (2007) (20)
Fulminant hepatitis A in a patient with severe hyperthyroidism: rapid recovery from hepatic coma after plasmapheresis and total thyroidectomy. (2000) (20)
Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low‐to‐moderate genetic barrier nucleoside analogs (2013) (20)
Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma (2013) (20)
BAX and caspase-5 frameshift mutations and spontaneous apoptosis in colorectal cancer with microsatellite instability (2004) (20)
Heterosexual transmission of GB virus-C/hepatitis G virus infection. (1997) (20)
Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs (2020) (20)
12 Wild-type HCV NS3 protease re-emerges during follow-up after 14 days of dosing with VX-950 in patients with genotype 1 HCV (2006) (20)
12 DETECTION OF RESISTANT VARIANTS IN THE HEPATITIS C VIRUS NS3 PROTEASE GENE BY CLONAL SEQUENCING AT LONG-TERM FOLLOW-UP IN PATIENTS TREATED WITH BOCEPREVIR (2009) (19)
DNA mismatch repair and Lynch syndrome (2006) (19)
Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin. (2007) (19)
The role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses (2017) (19)
65 CLONAL ANALYSIS OF MUTATIONS SELECTED IN THE HCV NS3 PROTEASE DOMAIN OF GENOTYPE 1 NON-RESPONDERS TREATED WITH BOCEPREVIR (SCH503034) (2008) (19)
Cystic adrenal lymphangioma: incidental diagnosis on abdominal sonography. (2000) (19)
Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa‐2a/ribavirin (2012) (19)
STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. (2015) (19)
Colonization with multidrug-resistant organisms is associated with in increased mortality in liver transplant candidates (2021) (19)
Pretreatment serum microRNA-122 is not predictive for treatment response in chronic hepatitis C virus infection. (2012) (19)
Tyrphostins inhibit secretagogue-induced 1,4,5-IP3 production and amylase release in pancreatic acini. (1994) (19)
Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry (2018) (19)
Liver transplantation for chronic hepatitis C virus infection in the United States 2002–2014: An analysis of the UNOS/OPTN registry (2017) (19)
Hepatitis B e antigen levels and response to peginterferon: influence of precore and basal core promoter mutants. (2013) (19)
Severity of coronary artery disease is associated with non-alcoholic fatty liver dis-ease: A single-blinded prospective mono-center study (2017) (19)
Use of Antiplatelet Agents Is Inversely Associated With Liver Fibrosis in Patients With Cardiovascular Disease (2018) (19)
Compliance and tolerability of subcutaneous hepatitis B immunoglobulin self-administration in liver transplant patients: a prospective, observational, multicenter study. (2013) (18)
Peptidomimetic escape mechanisms arise via genetic diversity in the ligand-binding site of the hepatitis C virus NS3/4A serine protease. (2012) (18)
[Standard treatment of acute and chronic hepatitis C]. (2004) (18)
Differential expression of Rab3 isoforms during differentiation of pancreatic acinar cell line AR42J. (1997) (18)
250 24 weeks of monotherapy with pegylated interferon alfa-2B in patients with acute hepatitis C (2003) (18)
The kinetics of hepatitis C virus (2006) (18)
SEMS vs cSEMS in duodenal and small bowel obstruction: high risk of migration in the covered stent group. (2013) (18)
911 PROLONGED EFFICACY AND SAFETY OF 3 YEARS OF CONTINUOUS TELBIVUDINE TREATMENT IN POOLED DATA FROM GLOBE AND 015 STUDIES IN CHRONIC HEPATITIS B PATIENTS (2009) (18)
Cytoskeletal scaffolding proteins interact with Lynch‐Syndrome associated mismatch repair protein MLH1 (2010) (18)
Validity of N-terminal propeptide of the brain natriuretic peptide in predicting left ventricular diastolic dysfunction diagnosed by tissue Doppler imaging in patients with chronic liver disease (2008) (18)
Downregulation of SPTAN1 is related to MLH1 deficiency and metastasis in colorectal cancer (2019) (18)
Reproducibility and limitations of transient elastography (2009) (18)
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (2020) (18)
Patatin‐like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events (2018) (18)
Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment‐Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis (2018) (18)
1041 EFFICACY AND SAFETY OF ALBINTERFERON ALFA-2B IN COMBINATION WITH RIBAVIRIN IN TREATMENT- NAIVE, CHRONIC HEPATITIS C GENOTYPE 1 (CHC G1) PATIENTS (2009) (18)
Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin (2011) (17)
Vitamin D Levels Vary during Antiviral Treatment but Are Unable to Predict Treatment Outcome in HCV Genotype 1 Infected Patients (2014) (17)
Tivantinib in hepatocellular carcinoma (2013) (17)
Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound. (2014) (17)
Correlation of amino acid variations within nonstructural 4B protein with initial viral kinetics during interferon‐alpha‐based therapy in HCV‐1b‐infected patients (2007) (17)
Impact of ribavirin priming on viral kinetics and treatment response in chronic hepatitis C genotype 1 infection (2014) (17)
Real‐world experience with daclatasvir plus sofosbuvir ± ribavirin for post‐liver transplant HCV recurrence and severe liver disease (2017) (17)
Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently ‘normal’ alanine aminotransferase levels treated with peginterferon α‐2a (40KD) plus ribavirin (2007) (17)
Serum sphingolipids predict de novo hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virologic response (2019) (17)
hMutSalpha forms an ATP-dependent complex with hMutLalpha and hMutLbeta on DNA. (2002) (17)
DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin (2002) (17)
Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. (2003) (17)
Will interferon-free regimens prevail? (2012) (17)
Characterization of the nuclear import of human MutLalpha. (2005) (17)
[Prediction of perioperative mortality in patients with advanced liver disease and abdominal surgery by the use of different scoring systems and tests]. (2008) (17)
Hepatitis C Virus: A European Perspective. (2015) (17)
[4 years of direct-acting antivirals (DAAs) in the German Hepatitis C-Registry (DHC-R)]. (2019) (17)
PEG-IFN Alpha but Not Ribavirin Alters NK Cell Phenotype and Function in Patients with Chronic Hepatitis C (2014) (17)
Malignant fibrous histiocytoma is a rare Lynch syndrome-associated tumor in two German families (2011) (17)
Telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in chronic hepatitis C patients. (2008) (16)
MUTYH hotspot mutations in unselected colonoscopy patients (2011) (16)
1420 THE EFFICACY AND SAFETY OF THE INTERFERON-FREE COMBINATION OF BI201335 AND BI207127 IN GENOTYPE 1 HCV PATIENTS WITH CIRRHOSIS - INTERIM ANALYSIS FROM SOUND-C2 (2012) (16)
Efficacy of Norfloxacin Prophylaxis to Prevent Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-Analysis (2020) (16)
Camptothecin and its analog SN‐38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE (2017) (16)
Dynamic Evolution of Therapy for Chronic Hepatitis C: How will Novel Agents be Incorporated into the Standard of Care? (2008) (16)
Duodenal angiolipoma -- endoscopic diagnosis and therapy. (2004) (16)
Efficacy of amantadine on quality of life in patients with chronic hepatitis C treated with interferon-&agr; and ribavirin: results from a randomized, placebo-controlled, double-blind trial (2007) (16)
425 FOUR-WEEK TREATMENT WITH GS-9256 AND TEGOBUVIR (GS-9190), ± RBV ± PEG, RESULTS IN ENHANCED VIRAL SUPPRESSION ON FOLLOW-UP PEG/RBV THERAPY, IN GENOTYPI 1A/1B HCV PATIENTS (2011) (16)
1404 DIAGNOSIS, PREVALENCE, AND PROGNOSIS OF ACUTE-ON- CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE EASL-CHRONIC LIVER FAILURE (CLIF) CONSORTIUM CANONIC STUDY (2012) (16)
S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study (2022) (16)
Nodular regenerative hyperplasia of the liver: a rare differential diagnosis of cholestasis with response to ursodeoxycholic acid. (2003) (16)
Structural and functional analysis of a novel mutation of CYP21B in a heterozygote carrier of 21-hydroxylase deficiency (2005) (16)
Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1. (2016) (16)
Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial (2020) (16)
9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN (2011) (16)
Eosinophilic cholangitis is a potentially underdiagnosed etiology in indeterminate biliary stricture (2017) (16)
2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION (2010) (16)
964 INCIDENCE OF VIROLOGIC ESCAPE OBSERVED DURING ITMN-191 (R7227) MONOTHERAPY IS GENOTYPE DEPENDENT, ASSOCIATED WITH A SPECIFIC NS3 SUBSTITUTION, AND SUPPRESSED UPON COMBINATION WITH PEGINTERFERON ALFA-2A/RIBAVIRIN (2009) (16)
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin (2013) (16)
High- and Small-Molecular-Weight GTP-Binding Proteins in Zymogen Granule Membranes of Rat Pancreatic Acinar Cells (1992) (16)
What is (cost) effective in patients with chronic hepatitis C virus infection? (2001) (16)
Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. (2000) (16)
Phosphorylation‐dependent signaling controls degradation of DNA mismatch repair protein PMS2 (2017) (16)
Persistence of HCV in Acutely-Infected Patients Depletes C24-Ceramide and Upregulates Sphingosine and Sphinganine Serum Levels (2016) (16)
European Ravs Database: Frequency and Characteristics of Ravs in Treatment-Naïve and DAA-Experienced Patients (2016) (16)
Epidermal growth factor activates phospholipase C-gamma 1 via G(i)1-2 proteins in isolated pancreatic acinar membranes. (1997) (15)
Efficacy and Safety of Sorafenib in Advanced Hepatocellular Carcinoma Under Daily Practice Conditions (2010) (15)
[Mediastinal lymphadenopathy: an extrahepatic manifestation of chronic hepatitis C?]. (2000) (15)
Epidermal growth factor regulates adenylate cyclase activity via Gs and Gi1-2 proteins in pancreatic acinar membranes. (1996) (15)
Dimerization of the hepatitis C virus nonstructural protein 4B depends on the integrity of an aminoterminal basic leucine zipper (2010) (15)
α-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C (1995) (15)
Interferon‐free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study (2016) (15)
Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue (2014) (15)
Association of HCV-related mixed cryoglobulinemia with specific mutational pattern of the HCV E2 protein and CD81 expression on peripheral B lymphocytes. (2004) (15)
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions. (2009) (15)
The hepatitis C virus NS5A protein and response to interferon α: mutational analyses in patients with chronic HCV genotype 3a infection from India (2007) (15)
EGF inhibits secretagogue-induced cAMP production and amylase secretion by Gi proteins in pancreatic acini. (1995) (15)
Impact of direct-acting antiviral therapy on the need for liver transplantation related to hepatitis C in Germany. (2018) (15)
Vesicle-associated microRNAs are released from blood cells on incubation of blood samples. (2016) (15)
Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment (2017) (15)
HLA class I allele associations with HCV genetic variants in patients with chronic HCV genotypes 1a or 1b infection. (2010) (15)
Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. (1999) (15)
Permanent loss of anti-HBc after reactivation of hepatitis B virus infection in an anti-HBs and anti-HBc-positive patient after allogeneic stem cell transplantation. (2007) (15)
Epidermal growth factor inhibits bombesin-induced activation of phospholipase C-beta1 in rat pancreatic acinar cells. (1997) (15)
G07 : The phase 3 C-EDGE treatment-naïve (TN) study of a 12-week oral regimen of grazoprevir (GZR, MK-5172)/ elbasvir (EBR, MK-8742) in patients with chronic HCV genotype (GT) 1, 4, or 6 infection (2015) (15)
Nucleos(t)ide analogue treatment reduces apoptotic activity in patients with chronic hepatitis B. (2011) (14)
Residual low HDV viraemia is associated HDV RNA relapse after PEG‐IFNa‐based antiviral treatment of hepatitis delta: Results from the HIDIT‐II study (2020) (14)
Circulating hypoxia marker carbonic anhydrase IX (CA9) in patients with hepatocellular carcinoma and patients with cirrhosis (2018) (14)
Beat-to-beat variation of heart rate in diabetic patients with autonomic neuropathy and in completely cardiac denervated patients following orthotopic heart transplantation. (1991) (14)
Evaluation of rapid microsatellite analysis of paraffin-embedded specimens in screening for hereditary nonpolyposis colorectal cancer. (1999) (14)
Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (14)
HBsAg kinetics of decay and baseline characteristics of HBeAg-positive patients with chronic hepatitis B following 3 years of tenofovir disoproxil fumarate (TDF) treatment (2010) (14)
Inflammatory markers neopterin and alanine aminotransferase in HCV patients treated with HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa-2a (2008) (14)
An Allosteric Inhibitor Scaffold Targeting the PIF-Pocket of Atypical Protein Kinase C Isoforms. (2017) (14)
A CRM1‐dependent nuclear export pathway is involved in the regulation of MutLα subcellular localization (2011) (14)
Cognition in hepatitis C patients treated with pegylated interferon (2009) (14)
[Treatment of liver metastases of colorectal carcinoma: overview of hyperthermal ablation methods]. (2013) (14)
Rectal colonization by resistant bacteria increases the risk of infection by the colonizing strain in critically ill patients with cirrhosis. (2022) (14)
Managing hepatitis C in patients with the complications of cirrhosis (2018) (14)
Six weeks of sofosbuvir/ledipasvir (SOF/LDV) are sufficient to treat acute hepatitis C virus genotype 1 monoinfection: The HepNet Acute HCV IV Study (2016) (14)
Cytokeratin 18‐based cell death markers indicate severity of liver disease and prognosis of cirrhotic patients (2016) (14)
Very low probability of significant liver inflammation in chronic hepatitis B patients with low ALT levels in the absence of liver fibrosis (2020) (14)
The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease (2017) (14)
Impact of Ribavirin on HCV Replicon RNA Decline during Treatment with Interferon-α and the Protease Inhibitors Boceprevir or Telaprevir (2011) (14)
Evaluation of the MLH1 I219V alteration in DNA mismatch repair activity and ulcerative colitis (2008) (14)
Safety and efficacy of the fixed-dose combination regimen of MK-3682/grazoprevir/ruzasvir in cirrhotic or non-cirrhotic patients with chronic HCV GT1 infection who previously failed a direct-acting antiviral regimen (C-SURGE) (2017) (14)
[Viral hepatitis C]. (1995) (14)
Evolution of Hepatitis C Virus Quasispecies during Repeated Treatment with the NS3/4A Protease Inhibitor Telaprevir (2015) (14)
Dynamics of CD81 expression on lymphocyte subsets during interferon‐α‐based antiviral treatment of patients with chronic hepatitis C (2006) (14)
Decade in review—HCV: Hepatitis C therapy—a fast and competitive race (2014) (14)
Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B (2007) (13)
Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes (2019) (13)
Dysregulated Adaptive Immunity Is an Early Event in Liver Cirrhosis Preceding Acute-on-Chronic Liver Failure (2021) (13)
Hepatitis C Clearance by Direct-Acting Antivirals Impacts Glucose and Lipid Homeostasis (2020) (13)
A randomized, double-blind, multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naive advanced or metastatic biliary tract cancer: First safety and efficacy data. (2011) (13)
1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY (2012) (13)
T-26 Impact of anemia and ribavirin dose reduction on SVR to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure in the Phase III REALIZE study (2012) (13)
Poor Prognosis of Advanced Cholangiocarcinoma: Real-World Data from a Tertiary Referral Center (2019) (13)
[Sonographic detection of perihepatic lymph nodes: technique and clinical value]. (1999) (13)
Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy. (2011) (13)
The Epidemiology of Acute Liver Failure. (2020) (13)
Retreatment with pegylated interferon-alpha2b plus ribavirin in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin (2003) (13)
The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care (2020) (13)
Interferon-alpha improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease. (1999) (13)
Role of CD15 expression in dysplastic and neoplastic tissue of the bile duct – a potential novel tool for differential diagnosis of indeterminate biliary stricture (2016) (13)
The capsule endoscopy “suspected blood indicator” (SBI) for detection of active small bowel bleeding: no active bleeding in case of negative SBI (2014) (13)
Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. (2003) (12)
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening of Patient-Reported Outcomes. (2019) (12)
Inhibition of the Equilibrative Nucleoside Transporter 1 and Activation of A2A Adenosine Receptors by 8-(4-Chlorophenylthio)-modified cAMP Analogs and Their Hydrolytic Products* (2009) (12)
Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study (2018) (12)
Impact of COVID-19 on global hepatitis C elimination efforts (2020) (12)
Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis (2013) (12)
Macrophage activation is a prognostic parameter for variceal bleeding and overall survival in patients with liver cirrhosis (2013) (12)
1430 SAFETY AND EFFICACY OF BOCEPREVIR/PEGINTERFERON/ RIBAVIRIN (BOC/P/R) COMBINATION THERAPY FOR CHRONIC HCV G1 PATIENTS WITH COMPENSATED CIRRHOSIS: A META-ANALYSIS OF FIVE PHASE 3 CLINICAL TRIALS (2013) (12)
Rejection quantity in kidney transplant recipients is associated with increasing intracellular interleukin-2 in CD8+ T-cells. (2014) (12)
Future treatment options for HCV: double, triple, what is the optimal combination? (2008) (12)
Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis (2016) (12)
Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122 (2018) (12)
Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α18 (2016) (12)
P476 SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE) (2014) (12)
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections. (2019) (12)
Colonisation with multidrug-resistant bacteria is associated with increased mortality in patients with cirrhosis (2015) (12)
Identifying Indications for Percutaneous (PTC) vs. Endoscopic Ultrasound (EUS)- Guided „Rendezvous“ Procedure in Biliary Obstruction and Incomplete Endoscopic Retrograde Cholangiography (ERC) (2014) (12)
The impact of antihyperlipidemic drugs on the viral load of patients with chronic hepatitis C infection: a meta‐analysis (2014) (12)
Association of a 19- and a 21-kDa GTP-binding protein to pancreatic microsomal vesicles is regulated by the intravesicular pH established by a vacuolar-type H+-ATPase (1992) (12)
Self-Expandable Metal Stent for Malignant Colonic Obstruction: Outcome in Proximal vs. Left Sided Tumor Localization (2013) (11)
943f TMC435 in HCV Genotype 1 Patients Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Final SVR24 Results of The ASPIRE Trial (2012) (11)
162 Role of Interferon Response During RE-Treatment of Null Responders with Boceprevir Combination Therapy: Results of Phase II Trial (2008) (11)
Efficacy and Safety of Faldaprevir, Deleobuvir, and Ribavirin in Treatment-Naive Patients with Chronic Hepatitis C Virus Infection and Advanced Liver Fibrosis or Cirrhosis (2014) (11)
Drug Treatment for Chronic Hepatitis C Infection and Cancer Risk. (2017) (11)
Hepatitis C virus variants resistant to macrocyclic NS3-4A inhibitors subvert IFN-β induction by efficient MAVS cleavage. (2015) (11)
[Sonographic detection of lymph nodes in the hepatoduodenal ligament]. (1997) (11)
Sarcopenia as a prognostic factor for survival in patients with locally advanced gastroesophageal adenocarcinoma (2019) (11)
Combination of Sorafenib and Transarterial Chemoembolization in Selected Patients with Advanced-Stage Hepatocellular Carcinoma: A Retrospective Cohort Study at Three German Liver Centers (2021) (11)
Dynamics of Apoptotic Activity during Antiviral Treatment of Patients with Chronic Hepatitis C (2007) (11)
Identification of germline mutations in hereditary nonpolyposis colorectal cancer using base excision sequence scanning analysis. (1999) (11)
Expertenempfehlungen zur Triple-Therapie der HCV-Infektion mit Boceprevir und Telaprevir (2012) (11)
GS-02-Efficacy of GKT831 in patients with primary biliary cholangitis and inadequate response to ursodeoxycholic acid: Interim efficacy results of a phase 2 clinical trial (2019) (11)
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-alfa-2a and ribavirin (2010) (11)
Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. (1997) (11)
[Small bowel diverticula - unknown disease]. (2009) (11)
Prospective follow‐up of patients with GBV‐C/HGV infection: Specific mutational patterns, clinical outcome, and genetic diversity (2000) (11)
Interaction of caffeine-, IP3- and vanadate-sensitive Ca2+ pools in acinar cells of the exocrine pancreas (2005) (11)
Corrigendum to “Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3” [J Hepatol 40 (2004) 939–999] (2005) (11)
Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. (2009) (11)
Proton MR Spectroscopy of Neurometabolites in Hepatic Encephalopathy During L-Ornithine-L-Aspartate Treatment–Results of a Pilot Study (2002) (10)
Resistance‐associated substitutions in patients with chronic hepatitis C virus genotype 4 infection (2020) (10)
Identification and in silico characterization of a novel compound heterozygosity associated with hereditary aceruloplasminemia (2007) (10)
Evaluation of MLH1 variants of unclear significance (2018) (10)
Sequencing of intraductal biopsies is feasible and potentially impacts clinical management of patients with indeterminate biliary stricture and cholangiocarcinoma (2018) (10)
Use of prothrombin complex concentrates in patients with decompensated liver cirrhosis is associated with thromboembolic events. (2019) (10)
Differential Kinetics of Coagulation Factors and Natural Anticoagulants in Patients with Liver Cirrhosis: Potential Clinical Implications (2016) (10)
FOXE1 association with differentiated thyroid cancer and its progression. (2014) (10)
Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis. (2022) (10)
Noninvasive screening identifies patients at risk for spontaneous bacterial peritonitis caused by multidrug-resistant organisms (2018) (10)
Fluorometric High-Performance Liquid Chromatography of Free Fatty Acids Using Panacyl Bromide (1993) (10)
Treatment of chronic hepatitis C: Anticipated impact of resistance in patients treated with protease inhibitors (2009) (10)
[Transient elastography (FibroScan) for the non-invasive assessment of liver fibrosis: current status and perspectives]. (2007) (10)
364 An Integrated Safety, Efficacy, and Virology Analysis of >500 Patients With Compensated Cirrhosis Treated With Ledipasvir/Sofosbuvir With or Without Ribavirin (2015) (10)
ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC). (2010) (10)
Peginterferon add‐on results in more HBsAg decline compared to monotherapy in HBeAg‐positive chronic hepatitis B patients (2016) (10)
Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib. (2015) (10)
Analysis of the human MutLalpha.MutSalpha complex. (2006) (10)
Triple therapy with amantadine sulphate plus ribavirin and interferon-alpha in previously untreated patients with chronic hepatitis C: results of a double-blind, placebo-controlled trial (2002) (10)
The Role of Macrophage-Inducible C-Type Lectin in Different Stages of Chronic Liver Disease (2020) (10)
Long-term follow-up of endoscopic therapy in stenosis of the bilio-biliary anastomosis associated with orthotopic liver transplantation. (2013) (10)
Loss of MLH1 sensitizes colon cancer cells to DNA‐PKcs inhibitor KU60648 (2017) (10)
Prediction of nonSVR to therapy with pegylated interferon‐α2a and ribavirin in chronic hepatitis C genotype 1 patients after 4, 8 and 12 weeks of treatment (2010) (10)
594 Ribavirin Dose Modification in Treatment-NaïVE and Previously Treated Patients Who Received Telaprevir Combination Treatment: No Impact on Sustained Virologic Response in Phase 3 Studies (2012) (10)
On-Treatment HCV RNA in Patients with Varying Degrees of Fibrosis and Cirrhosis in the SOLAR-1 Trial (2016) (10)
MicroRNA Profiling of Laser-Microdissected Hepatocellular Carcinoma Reveals an Oncogenic Phenotype of the Tumor Capsule123 (2014) (10)
Quantification of hepatitis C virus RNA by RT-PCR in comparison to the branched DNA method. (1998) (9)
Pre- and Post-Transplant Antiviral Therapy (HBV, HCV) (2016) (9)
Predicting treatment outcome following 24 weeks peginterferon α‐2a/ribavirin therapy in patients infected with HCV genotype 1: Utility of HCV‐RNA at day 0, day 22, day 29, and week 6 (2007) (9)
A synthetic peptide of the effector domain of rab3A stimulates inositol 1,4,5-trisphosphate production in digitonin-permeabilized pancreatic acini. (1993) (9)
Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin: Analyses of Pre-Defined Subpopulations in the Phase 3 Advance Trial (2011) (9)
Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study (2022) (9)
Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment (2011) (9)
Improved prediction of mortality by combinations of inflammatory markers and standard clinical scores in patients with acute‐on‐chronic liver failure and acute decompensation (2020) (9)
interferon-free Treatment with Faldaprevir, Deleobuvir (bi 207127) and Ribavirin in Sound-c3: 95% Svr12 in Hcv-gt1b : 1102 (2013) (9)
Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer. (2008) (9)
51 Optimal virologic and clinical efficacy at one year is associated with maximal early HBV suppression in nucleoside-treated hepatitis B patients (2006) (9)
Dynamics of hepatitis C virus quasispecies turnover during interferon-alpha treatment. (2000) (9)
[779] ANTIVIRAL RESPONSE AT WEEK 12 FOLLOWING COMPLETION OF TREATMENT WITH ALBINTERFERON a-2b PLUS RIBAVIRIN IN GENOTYPE 1, IFN-NAIVE, CHRONIC HEPATITIS C PATIENTS (2007) (9)
No Impact of Rass on the High Efficacy of SOF/VEL/VOX for 12 Weeks in Daa-Experienced Patients: An Integrated Resistance Analysis of the Polaris-1 and Polaris-4 Studies (2017) (9)
Antiviral effect of human recombinant interleukin‐12 in patients infected with hepatitis C virus (2000) (9)
Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection (2016) (9)
Clinical relevance of the 2'-5'-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. (2009) (9)
Functional testing strategy for coding genetic variants of unclear significance in MLH1 in Lynch syndrome diagnosis. (2015) (9)
Key role of renal biopsy in management of progressive chronic kidney disease in liver graft recipients (2018) (9)
54 COMPLETELY INDIVIDUALIZED TREATMENT DURATIONS (24, 30, 36, 42, 48, 60 OR 72 WEEKS) WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN IN HCV GENOTYPE 1-INFECTED PATIENTS (INDIV-2 STUDY) (2010) (9)
Stimulation of inositol 1,4,5-trisphosphate production by peptides corresponding to the effector domain of different Rab3 isoforms and cross-linking of an effector domain peptide target. (1995) (9)
DNA mismatch repair activity of MutLα is regulated by CK2‐dependent phosphorylation of MLH1 (S477) (2018) (9)
In vitro activity of biosynthetic human diarginylinsulin (1990) (9)
Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus. (2000) (8)
[Expert recommendations: Hepatitis C and transplantation]. (2016) (8)
Elevated plasma levels of N-terminal pro-brain natriuretic peptide in patients with chronic hepatitis C during interferon-based antiviral therapy. (2006) (8)
Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study (2022) (8)
Omega-3 and -6 fatty acid plasma levels are not associated with liver cirrhosis-associated systemic inflammation (2019) (8)
Intestinal failure-associated liver disease in patients with short bowel syndrome: Evaluation by transient elastography. (2019) (8)
[Are there gender-related differences in the therapeutic management of patients suffering from inflammatory bowel disease? Subgroup analysis of a prospective multicentre online-based trial]. (2009) (8)
and weight-based ribavirin in patients with genotype (2011) (8)
Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy. (2008) (8)
T-24 Retreatment with telaprevir/Peg-IFN/RBV after a short exposure to telaprevir in Phase I studies: interim results from a Phase IIIb rollover trial (C219) (2012) (8)
Differential modulation of hepatitis C virus replication and innate immune pathways by synthetic calcitriol-analogs (2018) (8)
Early viral kinetics do not predict treatment outcome with sofosbuvir+ribavirin for 12 or 24 weeks in HCV genotype 2/3 patients in the valence trial (2014) (8)
Renal function during treatment with adefovir plus peginterferon alfa‐2a vs either drug alone in hepatitis B/D co‐infection (2012) (8)
Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. (1995) (8)
Induction therapy in chronic hepatitis C: déjà-vu with pegylated interferons? (2004) (8)
Integrated safety analysis of Sofosbuvir-based HCV treatment regimens from phase 3 studies (2014) (8)
P0840 : Safety and effectiveness of sofosbuvir-based regimens for the treatment of hepatitis C genotype 3 and 4 infections: Interim analysis of a prospective, observational study (2015) (8)
Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis (2015) (8)
Risk factors for early and late procedure‐related adverse events in percutaneous endoscopic gastrostomy: A single center, retrospective study (2018) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Review article: HCV ? STAT-C era of therapy (2010) (8)
Effect of a Rab3A effector domain-related peptide, CCK, and EGF in permeabilized pancreatic acini. (1994) (8)
Hepatitis C in 2011: A new standard of care and the race towards IFN-free therapy (2012) (8)
606 Impaired quality of life in patients with chronic hepatitis C and persistently normal aminotransferase levels (2003) (8)
Randomized trial of albinterferon alfa‐2b every 4 weeks for chronic hepatitis C virus genotype 2/3 (2012) (8)
Predictors associated with treatment initiation and switch in a real‐world chronic hepatitis B population from five European countries (2014) (8)
Randomized, controlled trial with interferon-alpha (IFN-alpha) combined with ribavirin with and without amantadine sulfate in primary IFN-alpha nonresponsive patients with chronic hepatitis C (2001) (8)
1202 CHARACTERISATION OF HCV VARIANTS IN NON-SVR PATIENTS IN THE REALIZE STUDY SUGGESTS THAT TELAPREVIR EXHIBITS A CONSISTENT RESISTANCE PROFILE IRRESPECTIVE OF A LEAD-IN (2011) (8)
Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer. (2002) (8)
First‐phase parameters in hepatitis C viral kinetics (2002) (8)
Somatic hypermutation and mRNA expression levels of the BCL‐6 gene in patients with hepatitis C virus‐associated lymphoproliferative diseases * (2007) (8)
Anemia and Systemic Inflammation Rather than Arterial Circulatory Dysfunction Predict Decompensation of Liver Cirrhosis (2020) (8)
O66 SOFOSBUVIR-BASED REGIMENS ARE ASSOCIATED WITH HIGH SVR RATES ACROSS GENOTYPES AND AMONG PATIENTS WITH MULTIPLE NEGATIVE PREDICTIVE FACTORS (2014) (8)
946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS (2009) (7)
High Efficacy of an 8-Week 3-Drug Regimen of Grazoprevir/MK-8408/MK-3682 in HCV Genotype 1, 2 and 3-Infected Patients: SVR24 Data from the Phase 2 C-Crest 1 and 2 Studies (2016) (7)
479 Significance of HDV-RNA and HBsAg levels in delta hepatitis: First data of the Hep-Net/international HDV intervention trial (2006) (7)
Epidermal growth factor inhibits hormone- and fibroblast growth factor-induced activation of phospholipase C in rat pancreatic acini (1995) (7)
To bead or not to bead: is transarterial chemoembolization with Doxorubicin-eluting beads a new standard of care in hepatocellular carcinoma? (2010) (7)
317 International multicenter, randomized, controlled study comparing standard versus dynamically individualized treatment in patients with chronic hepatitis C (DITTO-HCV) project) (2003) (7)
Low Serum Levels of (Dihydro-)Ceramides Reflect Liver Graft Dysfunction in a Real-World Cohort of Patients Post Liver Transplantation (2018) (7)
Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium–Diethylenetriaminepentaacetic Acid–Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging (2012) (7)
Individual invitation letters lead to significant increase in attendance for screening colonoscopies: Results of a pilot study in Northern Hesse, Germany (2018) (7)
Prevalence and Clinical Importance of Hepatitis C Virus Genotype 2 K/1B Chimeras (2016) (7)
Liver Transplantation in Acute-on-Chronic Liver Failure: Considerations for a Systematic Approach to Decision Making (2018) (7)
[58] SUSTAINED OFF-TREATMENT HBeAg RESPONSE IN TELBIVUDINE AND LAMIVUDINE TREATED HBeAg-POSITIVE PATIENTS FROM THE GLOBE STUDY (2007) (7)
Acute-on-chronic liver failure (ACLF) precipitated by severe alcoholic hepatitis: another collateral damage of the COVID-19 pandemic? (2021) (7)
[Endoscopic-retrograde cholangiopancreatography in patients with surgical modification of anatomy]. (2010) (7)
Detection of microsatellite instability from archival, hematoxylin-eosin-stained colorectal cancer specimen. (2002) (7)
Pegylated interferon monotherapy for chronic hepatitis C. (2004) (7)
Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI ≤ 1 in a Single-Arm, Open-Label, Multicenter Study (2019) (7)
P1312 SOFOSBUVIR AND DACLATASVIR FOR RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: POTENT ANTIVIRAL ACTIVITY BUT LACK OF CLINICAL BENEFIT IF TREATMENT IS GIVEN TOO LATE (2014) (7)
Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C. (2005) (7)
Daclatasvir plus Sofosbuvir with or without Ribavirin for the Treatment of Chronic HCV Infection in Patients with Decompensated Cirrhosis: Results of a European Multicentre Compassionate Use Program (2016) (7)
Effect of epidermal growth factor on cholecystokinin-induced amylase release and inositol 1,4,5-trisphosphate production in pancreatic acinar cells. (1993) (7)
Synthetic Rab3A effector domain peptide stimulates inositol 1,4,5-trisphosphate production in various permeabilized cells. (1994) (7)
Chronic Hepatitis B Treatment Initiation and Modification Patterns in Five European Countries: A 2-Year Longitudinal, Non-Interventional Study (2014) (7)
All oral fixed-dose combination Sofosbuvir/Ledipasvir with or without Ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ION-1 study (2014) (7)
[The guidelines program of the DGVS]. (2013) (7)
Influence of antibiotic-regimens on intensive-care unit-mortality and liver-cirrhosis as risk factor. (2016) (7)
Daclatasvir plus Sofosbuvir with or without Ribavirin in patients infected with HCV genotype 3: Interim results of a multicenter compassionate use program in Europe (2015) (7)
Updated epidemiology of hepatitis C virus infections and implications for hepatitis C virus elimination in Germany (2022) (7)
Feasibility and reproducibility of liver and pancreatic stiffness in patients with alcohol-related liver disease. (2019) (7)
RNA-binding activity of hepatitis C virus NS4B: a novel target for small molecule inhibitors. (2009) (7)
Anti-p53 autoantibodies in hepatitis C virus-infected patients. (1997) (7)
Ribavirin Concentration Determines Treatment success of First-Generation DAA-Based Chronic HCV Therapy (2016) (7)
Dynamics of hepatitis C virus quasispecies turnover during interferon‐α treatment (2003) (7)
798 EFFICACY OF TELAPREVIR DOSED TWICE DAILY VERSUS EVERY 8 HOURS BY IL28B GENOTYPE: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2013) (7)
GARNET: High SVR Rates Following Eight-Week Treatment with Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir for Patients with HCV Genotype 1b Infection: 888 (2016) (7)
P1119 EARLY VIRAL KINETICS DO NOT PREDICT TREATMENT OUTCOME WITH SOFOSBUVIR + RIBAVIRIN FOR 12 OR 24 WEEKS IN HCV GENOTYPE 2/3 PATIENTS IN THE VALENCE TRIAL (2014) (7)
647 Sofosbuvir-Based Regimens Are Associated With High SVR Rates Across Genotypes and Among Patients With Multiple Negative Predictive Factors (2014) (7)
Glecaprevir/pibrentasvir for 8 weeks in patients with compensated cirrhosis: Safety and effectiveness data from the German Hepatitis C‐Registry (2021) (7)
Interleukin-18 is increased only in a minority of patients with active Crohn’s disease (2007) (7)
OP03 Telaprevir-based therapy in G1 HCV-infected patients with prior null response, partial response or relapse to peginterferon/ribavirin: REALIZE trial final results (2011) (7)
122 HCV BURDEN IN EUROPE: IMPACT OF NATIONAL TREATMENT PRACTICES ON FUTURE HCV-RELATED MORBIDITY AND MORTALITY THROUGH A MODELING APPROACH (2010) (6)
689 LACK OF INFLUENCE OF BASELINE GENOTYPE ON ANTIVIRAL RESPONSE IN SUBJECTS WITH CHRONIC HEPATITIS B INFECTION RECEIVING TENOFOVIR DF 300 MG QD FOR 1 YEAR (2008) (6)
Sorafenib Treatment and Modulation of the Sphingolipid Pathway Affect Proliferation and Viability of Hepatocellular Carcinoma In Vitro (2020) (6)
M1913 Lack of Influence of Baseline Genotype On Antiviral Response in Subjects with Chronic Hepatitis B Infection Receiving Tenofovir Df 300 Mg Qd for 1 Year (2008) (6)
Interferon-α improves glucose tolerance in diabetic and non-diabetic patients with HCV-induced liver disease (2009) (6)
PREDICTION OF RESPONSE TO PEGINTERFERON-ALFA IN HBEAG POSITIVE CHRONIC HEPATITIS B: A MODEL BASED ON 721 PATIENTS (2008) (6)
Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B (2014) (6)
Modulation of TH-1/TH-2 serum cytokine profiles and TNF-receptor response in patients with chronic hepatitis C during interleukin-12 (IL-12) treatment (2000) (6)
792 48 WEEKS OF PEGINTERFERON alfa-2a/RIBAVIRIN IMPROVES SVR24 AND DECREASES RELAPSE ACROSS HCV GENOTYPE 2/3 PATIENT SUBGROUPS NOT ACHIEVING A RAPID VIROLOGICAL RESPONSE: N-CORE STUDY (2013) (6)
Interferon-free treatment choice according to baseline RASs leads to high SVR rates in HCV genotype 1 infected patients. (2018) (6)
Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R) (2016) (6)
Risk of infections during interferon‐based treatment in patients with chronic hepatitis C virus infection and advanced hepatic fibrosis (2015) (6)
Extended treatment with pegylated interferon alfa/ribavirin in patients with genotype 2/3 chronic hepatitis C who do not achieve a rapid virological response: final analysis of the randomised N-CORE trial (2014) (6)
Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study (2015) (6)
778 PHASE IIB STUDY OF BALAPIRAVIR (RG1626; NUCLEOSIDE ANALOGUE INHIBITOR OF HCV POLYMERASE) PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN FOR CHC GENOTYPE 1: FINAL RESULTS (2010) (6)
Capnography monitoring of non‐anesthesiologist provided sedation during percutaneous endoscopic gastrostomy placement: A prospective, controlled, randomized trial (2020) (6)
Modulation of replication efficacy of the hepatitis C virus replicon Con1 by site‐directed mutagenesis of an NS4B aminoterminal basic leucine zipper (2012) (6)
Mixing and matching drugs: what makes sense? (2011) (6)
Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response. (2021) (6)
AFP ratio predicts HCC recurrence after liver transplantation (2020) (6)
Risk Factors and Outcomes Associated with the Carriage of Tigecycline- and Vancomycin-resistant Enterococcus faecium. (2020) (6)
503 Early prediction of sustained virological response (SVR) during treatment with peginterferon alfa-2A (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with chronic hepatitis C (CHC) and persistently normal alanine aminotransferase (ALT) levels (2004) (6)
Assessment of hemostatic profile in patients with mild to advanced liver cirrhosis (2020) (6)
Evaluation of 2 D-Shear Wave Elastography for Characterisation of Focal Liver Lesions (2017) (6)
Predictive Value of Computed Tomography Scans and Clinical Findings for the Need of Endoscopic Necrosectomy in Walled-off Necrosis From Pancreatitis (2017) (6)
[Current recommendations for the treatment of chronic hepatitis C]. (2014) (6)
Hepatitis B Surface Antigen Levels Can Be Used to Rule Out Cirrhosis in Hepatitis B e Antigen-Positive Chronic Hepatitis B: Results From the SONIC-B Study (2020) (6)
Conversion From Sirolimus to Everolimus in Long‐Term Liver Graft Recipients (2017) (6)
1132 HIGH CONCORDANCE BETWEEN SVR12 AND SVR24 IN PATIENTS RECEIVING TELAPREVIR PLUS PEGINTERFERON AND RIBAVIRIN IN THREE PHASE III CLINICAL TRIALS: ADVANCE, ILLUMINATE AND REALIZE (2012) (6)
Albumin administration in the prevention of hepatorenal syndrome (HRS) and death in patients with advanced cirrhosis and non-SBP infections (2018) (6)
539 2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS (2012) (6)
Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection (2019) (6)
Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection (2018) (6)
Chronic liver disease negatively affects outcome in hospitalised patients with community-acquired pneumonia (2020) (6)
Primary actinomycosis of the liver mimicking malignancy. (2009) (6)
On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study (2016) (6)
[88] VIRAL KINETICS DURING 14-DAY TREATMENT WITH DEBIO-025 DEMONSTRATE EFFICIENT BLOCKING OF VIRAL REPLICATION IN DIFFERENT HCV GENOTYPES WITHOUT SIGNS OF EMERGING VIRAL RESISTANCE (2007) (6)
OC-17 HCV burden in Europe: Impact of national treatment practices on future HCV-related morbidity and mortality through a modeling approach (2011) (6)
Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors (2020) (6)
JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 (2019) (6)
Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays. (2017) (6)
Effects of agonists on p21ras and ras-related proteins in rat pancreatic acinar cells. (1992) (6)
Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and sustained virologic response (SVR): 3 years follow‐up of a prospective longitudinal study (2021) (5)
733 Interim (week 12) phase 2b virological efficacy and safety results of albumin interferon Alpha-2b combined with ribavirin in genotype 1 chronic hepatitis C infection (2006) (5)
A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial (2014) (5)
Clinical trial: individualized treatment duration for hepatitis C virus genotype 1 with peginterferon‐alpha 2a plus ribavirin (2008) (5)
[Postexposure prevention after occupational exposure to HBV, HCV and HIV]. (2003) (5)
511 Evaluation of a new, highly sensitive, real time PCR based assay for quantification of HCV RNA (2004) (5)
Investigation of NS3 Protease Resistance-Associated Variants and Phenotypes for the Prediction of Treatment Response to HCV Triple Therapy (2016) (5)
67 Hepatitis C viral kinetics in chronically infected patients treated with the serine protease inhibitor BILN 2061 (2004) (5)
Preparation of basolateral membrane vesicles from rat enterocytes: influence of different gradient media. (1994) (5)
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection (2015) (5)
559 Individualized treatment strategy with peginterferon alpha-2b (PEG-IFN a) plus ribavirin according to early viral kinetics in hepatitis C virus (HCV) type 1 infected patients (2006) (5)
Corrigendum to “SHORT STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS”[J Hepatol 42 (2005) 615–624] (2005) (5)
Favourable and disappointing lessons from viral kinetics. (2002) (5)
Hepatocellular Carcinoma and Smoking: Oblivion or Contempt? (2013) (5)
High sustained virologic response rates in hepatitis C virus genotype 3 patients with and without cirrhosis treated with daclatasvir/sofosbuvir or velpatasvir/sofosbuvir ± ribavirin according to baseline resistance analysis (2017) (5)
Predictors of Sustained Virologic Response Among Genotype 1 Previous Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin (2011) (5)
Development of ulcerative colitis after heart transplantation during immunosuppressive therapy. (2005) (5)
No beneficial effect of all-trans retinoic acid in previous non-responder patients with chronic hepatitis C: the ATRACTION study, a phase II randomised trial. (2013) (5)
Global timing of hepatitis C virus elimination in high-income countries: an updated analysis (2020) (5)
Serum Sphingosine‐1‐Phosphate Is Decreased in Patients With Acute‐on‐Chronic Liver Failure and Predicts Early Mortality (2020) (5)
Analysis of MUTYH alternative transcript expression, promoter function, and the effect of human genetic variants (2019) (5)
Assessment of initial hexose uptake in adipocytes using the physiological substrate D-glucose. Particular relevance to human adipocytes. (1985) (5)
P0900 : Consideration of viral resistance for optimization of direct antiviral therapy of chronic hepatitis C (2015) (5)
Daclatasvir plus Sofosbuvir with or without Ribavirin for Treatment of Chronic HCV Infection in Patients with Advanced Liver Disease: Results of a European Compassionate use Program (2016) (5)
771 DECLINE OF DETECTABLE RESISTANCE MUTATIONS WITHIN THE HCV NS3 PROTEASE QUASISPECIES DURING LONG-TERM FOLLOW-UP AFTER TREATMENT WITH TELAPREVIR (2010) (5)
[Integrated management of patients with chronic inflammatory bowel disease in the Rhine-Main Region: results of the first integrated health-care project IBD in Germany]. (2013) (5)
Acoustic Radiation Force Impulse-Imaging for Non-Invasive Assessment of Liver Fibrosis: A Pooled Meta-Analysis (2011) (5)
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register). (2019) (5)
Genetic variants of innate immunity receptors are associated with mortality in cirrhotic patients with bacterial infection (2020) (5)
O115 PEGINTERFERON LAMBDA FOR THE TREATMENT OF CHRONIC HEPATITIS B (CHB): A PHASE 2B COMPARISON WITH PEGINTERFERON ALFA IN PATIENTS WITH HBeAg-POSITIVE DISEASE (2014) (5)
Reply to: "Response to DAA therapy in the NHS England Early Access Programme for rare HCV subtypes from low and middle income countries". (2017) (5)
Variation in Bile Microbiome by the Etiology of Cholestatic Liver Disease (2020) (4)
Hepatitis C: New therapeutic strategies needed for advanced disease (2009) (4)
898 TREATMENT WITH TELAPREVIR/PEG-IFN/RBV AFTER 14-DAY TELAPREVIR EXPOSURE IN PHASE I STUDIES: RESULTS FROM THE PHASE IIIB C219 ROLLOVER STUDY (2013) (4)
Simeprevir and daclatasvir for 12 or 24 weeks in treatment‐naïve patients with hepatitis C virus genotype 1b and advanced liver disease (2017) (4)
Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239 (2016) (4)
Impact of NS 5 A Sequences of Hepatitis C Virus Genotype 1 a on Early Viral Kinetics during Treatment with Peginterferon-a 2 a plus Ribavirin (2007) (4)
956 – Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hcv Genotype 1-6: Results of the Hcv-Target Study (2019) (4)
Interleukin-22 in acute-on-chronic liver failure: A matter of ineffective levels, receptor dysregulation or defective signalling? (2020) (4)
[GB virus-C/hepatitis G virus--discovery, epidemiology, diagnosis and clinical relevance]. (1998) (4)
Impressive Gains in Patient-Reported Outcomes are Observed in Chronic Hepatitis C Patients with or without Cirrhosis who are Treated with Sofosbuvir and Velpatasvir: Results from Astral-1, -2, -3 and-4 (2016) (4)
[Mutated serine-threonine kinase gene (STK11) is the cause of Peutz-Jeghers syndrome]. (1998) (4)
Lack of birth defects after paternal exposure to lamivudine. (2002) (4)
P1332 : The astral studies: evaluation of SOF/GS-5816 single tablet regimen for the treatment of genotype 1–6 HCV infection (2015) (4)
901 ADDING SIMEPREVIR (TMC435) TO PEGYLATED INTERFERON/ RIBAVIRIN DOES NOT INCREASE PATIENT REPORTED FATIGUE IN TREATMENT-EXPERIENCED PATIENTS WITH CHRONIC HCV INFECTION: RESULTS FROM THE ASPIRE TRIAL (2013) (4)
Intrahepatic mRNA levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C (2013) (4)
Rapid microsatellite analysis of paraffin embedded tumour specimens from patients with hereditary non-polyposis colorectal cancer. (1998) (4)
[625] NOVEL MODE OF VIRAL DECLINE DURING TELAPREVIR (VX-950) AND PEG-IFN COMBINATION TREATMENT PREDICTED BY A NEW COMBINED INTRACELLULAR AND CELLULAR HEPATITIS C VIRAL DYNAMICS MODEL (2007) (4)
848 VIRAL KINETICS DURING TREATMENT WITH A CONTROLLED-RELEASE RECOMBINANT INTERFERON ALFA 2B IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2008) (4)
No Distal Migration in Unfixed Versus Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease (2015) (4)
CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C (2011) (4)
Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R) (2017) (4)
Virodynamic Predictors of Response to Pegylated Interferon and Lamivudine Combination Treatment of Hepatitis B e Antigen-Positive Chronic Hepatitis B (2008) (4)
miRNA-26b Downregulation in Peripheral Blood Mononuclear Cells of Patients with Hepatitis C Associated Lymphomas is Restored by Successful Interferon-Free Antiviral Therapy (2019) (4)
Severe infection with multidrug-resistant Salmonella choleraesuis in a young patient with primary sclerosing cholangitis (2017) (4)
Therapie der hepatitis C-virus- infektion (2005) (4)
HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a (2011) (4)
932 FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED LIVER FIBROSIS (2012) (4)
Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard inferferon alfa-2a (2001) (4)
144 REDUCED DOSE AND DURATION OF PEGINTERFERON ALFA-2B + WEIGHT-BASED RIBAVIRIN IN EUROPEAN AND ASIAN GENOTYPE 2 AND 3 CHRONIC HEPATITIS C PATIENTS (REDD 2/3 TRIAL) (2009) (4)
Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆ (2003) (4)
Hepatic sarcoidosis: Clinical characteristics and outcome (2021) (4)
Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy (2016) (4)
1186 ITPA GENE VARIANTS PREDICT HEMOLYTIC RIBAVIRIN INDUCED ANAEMIA IN PATIENTS TREATED WITH THE INTERFERON-FREE REGIMEN OF FALDAPREVIR, BI 207127 AND RIBAVIRIN IN SOUND-C2 (2013) (4)
296 Importance of ribavirin dosage on virological response rates in patients chronically infected with hepatitis C virus and treated with interferon-based combination therapy (2003) (4)
Acute-on Chronic Liver Failure (ACLF): A distinct clinical syndrome (2012) (4)
911 EFFECTIVE TREATMENT OF AMANITA PHALLOIDES INTOXICATION BY FRACTIONED PLASMA SEPARATION AND ADSORPTION (PROMETHEUS) (2011) (4)
STARTVerso 1 : A randomized trial of faldaprevir plus pegylated interferon / ribavirin for chronic HCV genotype-1 infection q (2015) (4)
Efficacy and safety of direct‐acting antivirals for hepatitis C in the elderly: A systematic review and meta‐analysis (2019) (4)
Telaprevir-Based Regimen in Genotype 1 Hepatitis C Virus-Infected Patients With Prior Null Response, Partial Response or Relapse to Peginterferon/Ribavirin: REALIZE Trial Final Results (2011) (4)
Sofosbuvir/GS-5816 Fixed Dose Combination for 12 Weeks Compared to Sofosbuvir with Ribavirin for 24 Weeks in Genotype 3 HCV Infected Patients: The Randomized Controlled Phase 3 ASTRAL-3 Study (2015) (4)
617 E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: Results of a 15-month, placebo-controlled trial (2006) (4)
Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome (2006) (4)
P0873 : Ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin (RBV) has minimal impact on health-related quality of life (HRQOL) compared with placebo during 12-week treatment in treatment-naïve adults with chronic Hepatitis C (CHC) (2015) (4)
Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma (2021) (4)
Treatment with Telaprevir/PEG-IFN/RBV after 14-day Telaprevir exposure in phase I studies: Results from the phase IIIB C219 rollover study (2013) (4)
Gradual increase in platelets following sustained virological response among patients with HCV-induced advanced hepatic fibrosis (2013) (4)
Ultrasound evaluation of perihepatic lymph nodes during antiviral therapy with the protease inhibitor telaprevir (VX-950) in patients with chronic hepatitis C infection. (2007) (4)
IL28B gene variants and glucose metabolism in Type 2 Diabetes. (2016) (4)
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R) (2020) (4)
Operative Risk in Patients with Liver and Gastrointestinal Diseases (2007) (4)
705 CONTRAST-ENHANCED ULTRASOUND FOR THE DIFFERENTIATION OF BENIGN AND MALIGNANT FOCAL LIVER LESIONS: A META-ANALYSIS AND SYSTEMATIC REVIEW (2012) (4)
Genetic Background for Development of Resistance Mutations within the HCV Ns3 Protease–Helicase in Direct Acting Antiviral Naive Patients (2014) (4)
Neutrophil phenotype and function in partial hepatectomy in man (2010) (4)
451 TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN: ANALYSES OF PRE-DEFINED SUBPOPULATIONS IN THE PHASE 3 ADVANCE TRIAL (2011) (4)
[Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by private practice gastroenterologists]. (2006) (4)
[Pegylated interferon plus ribavirin in chronic hepatitis C. More than half of patients show a lasting response]. (2002) (4)
Synthetic peptides containing a BXBXXXB(B) motif activate phospholipase C-beta1. (1997) (4)
Hepatitis C viral kinetic models (2003) (4)
[Chronic hepatitis C : Standard treatment and remaining challenges]. (2018) (4)
Clinical Practice Guidelines : Management of hepatitis C virus infection European Association for the Study of the Liver ⇑ (2013) (3)
[Interferon-alpha and ribavirin: advances in the therapy of chronic hepatitis C]. (2008) (3)
P0872 : Early viral kinetics do not differ in patients with varying degrees of fibrosis and cirrhosis in the solar 1 trial (2015) (3)
Viral hepatitis Elimination: Towards a hepatitis free world. (2022) (3)
506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS (2013) (3)
Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients (2011) (3)
[Long-term follow-up and therapeutic control of a hepatic metastatic acinar cell carcinoma of the pancreas using FDG PET]. (1998) (3)
160 Prove2 Study: Treatment of Chronic Hepatitis C with Telaprevir (TVR)in Combination with Peginterferon-Alfa-2a with or Without Ribavirin, Interim Analysis Results (2008) (3)
Sustained Virological Response Improves Overall Survival in Chronic Hepatitis C Patients with Advanced Fibrosis (2011) (3)
Evaluation of the Integrated Pulmonary Index® during non-anesthesiologist sedation for percutaneous endoscopic gastrostomy (2020) (3)
Bile microbiome varies by etiology of cholestatic liver disease. (2020) (3)
Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates (2018) (3)
Efficacy and safety of elbasvir/grazoprevir for 12 weeks in people with hepatitis C virus infection aged 35 years or younger compared with older people: a retrospective integrated analysis (2020) (3)
Endoscopic findings in patients with eosinophilic esophagitis (2015) (3)
P1206 ITPA GENE VARIANTS AND ANEMIA DURING TELAPREVIR/PEGINTERFERON/RIBAVIRIN COMBINATION THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2014) (3)
Baseline and On-Treatment Predictors for Outcome of Chronic Hepatitis B Treatment (2010) (3)
Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis (2022) (3)
Real‐world medical costs of antiviral therapy among patients with chronic HCV infection and advanced hepatic fibrosis (2016) (3)
P508 VALIDATION OF THE CLIF-CONSORTIUM (CLIF-C) SCORE TO PREDICT MORTALITY OF PATIENTS WITH ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) IN AN EXTERNAL COHORT AND FOR SEQUENTIAL MEASUREMENTS (2014) (3)
499 The impact of sustained virological response (SVR) on health-related quality of life (HRQL) in patients with chronic hepatitis C (CHC) and persistently normal ALT levels (PNALT) treated with peginterferon alfa-2A (PEGASYS®) and ribavirin (COPEGUS®) (2004) (3)
Sequential Therapy of Transarterial Chemoembolisation and Sorafenib in Intermediate Stage Hepatocellular Carcinoma (2010) (3)
Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL) (2005) (3)
Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir with ribavirin in adults with genotype 1 or genotype 4 chronic hepatitis C virus infection and child-pugh B decompensated cirrhosis (2017) (3)
568 Natural history of patients with chronic hepatitis C and persistently normal alanine aminotransferase levels: data from the multinational PEGASYS study (NR 16071) (2003) (3)
Establishing an indwelling peritoneal catheter as a standard procedure for hospitalized patients with ascites: Retrospective data on feasibility, effectiveness and safety (2019) (3)
Epidermal growth factor inhibits amylase secretion and activation of phospholipase C in response to calcium-mobilizing secretagogues in rat pancreatic acini. (1994) (3)
Near-Neighbor Interactions in the NS3-4A Protease of HCV Impact Replicative Fitness of Drug-Resistant Viral Variants. (2019) (3)
Distribution and development of the postnatal murine Vδ1 T‐cell receptor repertoire (2010) (3)
Prolonged retention of prophylactic pancreatic stents is not associated with increased complications. (2019) (3)
Assessment of D-glucose uptake in isolated human adipocytes. Comparison of two validated and standardized methods. (1989) (3)
The American Association For the Study of Liver Diseases: new perspectives in the treatment of hepatitis C. (2006) (3)
Tax1BP1 limits hepatic inflammation and reduces experimental hepatocarcinogenesis (2020) (3)
Reply to “Vitamin D deficiency and HCV chronic infection: What comes first?” (2011) (3)
Comparison of Envelope 2 CD81 binding regions in PBMC‐derived versus serum‐derived hepatitis C virus isolates: higher conservation of CD81 region 2 in PBMC isolates (2011) (3)
Multi-center proficiency tests for Lab-MELD score diagnostics to improve the quality and safety for patients awaiting liver transplantation (2014) (3)
The KRAS p.G13D mutation in patients with metastatic colorectal cancer: a cheat in the orchestra of predictive biomarkers? (2011) (3)
Interobserver agreement of Thyroid Imaging Reporting and Data System (TIRADS) and realtime elastography for the assessment of thyroid nodules (2013) (3)
IDDF2018-ABS-0113 The safety and tolerability of sof/vel/vox for 8 or 12 weeks in >1,000 patients treated in the polaris-1, polaris-2, polaris-3, and polaris-4 studies: an integrated analysis (2017) (3)
[Characterization and economic impact of medical patients presenting at the emergency department of an university hospital]. (2013) (3)
[Hereditary non-polyposis colon carcinoma. Syndrome of the cancer family--a neglected disease]. (2008) (3)
P1118 NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS (2014) (3)
Resistance patterns in patients with chronic hepatitis C genotype 4 infection and treatment outcome (2017) (3)
Ip-10 Is Associated With Il28b Variation And Predicts The First Phase Decline Of Hcv Rna And Outcome Of Therapy In Chronic Hepatitis C (2010) (3)
P0896 : Long-term follow-up analysis of RAVs in HCV NS3, NS5A, and NS5B in daa therapy failure patients (2015) (3)
A possible role of miRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation (2016) (3)
Performance of Three Common Hepatitis C Virus (HCV) Genotyping Assays for Identification of HCV Genotype 2/1 Chimeras (2019) (3)
TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment. (2002) (3)
Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation (2015) (3)
A transient early HBV‐DNA increase during PEG‐IFNα therapy of hepatitis D indicates loss of infected cells and is associated with HDV‐RNA and HBsAg reduction (2020) (3)
Molecular Surveillance of Carbapenem-Resistant Gram-Negative Bacteria in Liver Transplant Candidates (2021) (3)
Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade (2023) (3)
Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity (2021) (3)
No Effect Of Resistance-Associated Substitutions In Patients With Rare HCV Subtypes Following Treatment With Sofosbuvir-Containing Regimens (2017) (3)
A proposal for an algorithm enhancing transparency and achieving harmonization for patient selection in rescue allocation for liver allografts in Germany (2013) (3)
Antiviral Targets in HCV (2012) (3)
In vivo evidence that human atrial natriuretic factor-(99–126) (hANF) stimulates parasympathetic activity in man (2007) (3)
Addition of pegylated interferon alfa-2a to an ongoing nucleos(t) ide treatment accelerates decrease of HBs-antigen levels in patients with chronic hepatitis B: Results from the PADD-ON study (2018) (3)
[Current Guidelines for treatment of hepatitis C. The eradication of HCV as a goal]. (2011) (3)
Letter: impact of HBV genotypes and PC/BCP mutations on serum HBsAg levels in Chinese HBeAg negative patients—Authors′ reply (2018) (3)
Differential binding of sulphated insulin to adipocytes and hepatocytes (1984) (3)
905 ADHERENCE WITH TELAPREVIR BID vs. q8h DOSING IN TREATMENT-NAÏVE HCV-INFECTED PATIENTS: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2013) (3)
THU-181-Safety and efficacy of glecaprevir/pibrentasvir for the treatment of HCV genotype 1-6: Results of the HCV-TARGET study (2019) (3)
642 INDIVIDUALIZED TREATMENT DURATION WITH PEGINTERFERON-ALFA-2B AND RIBAVIRIN FOR 24, 30 OR 36 WEEKS IN HCV GENOTYPE1-INFECTED PATIENTS WITH UNDETECTABLE HCV-RNA EARLY DURING THERAPY (INDIV-2 STUDY) (2009) (3)
Diagnostic Yield and Outcomes of Computed Tomography of the Head in Critically Ill Nontrauma Patients (2019) (3)
The Epidemiology of Acute Liver Failure of a Population-Based Study Including 25 Million State-Insured Individuals (2020) (3)
O163 TURQUOISE-II: SVR12 RATES OF 92–96% IN 380 HEPATITIS C VIRUS GENOTYPE 1-INFECTED ADULTS WITH COMPENSATED CIRRHOSIS TREATED WITH ABT-450/R/ABT-267 AND ABT-333 PLUS RIBAVIRIN (3D+RBV) (2014) (3)
Expression and secretion of the pro‑inflammatory cytokine IL‑8 is increased in colorectal cancer cells following the knockdown of non‑erythroid spectrin αII. (2020) (3)
821Daclatasvir and Asunaprevir Plus Peginterferon Alfa-2a and Ribavirin in Patients With HCV Genotype 1 or 4 Infection: Phase 3 HALLMARK-QUAD Results (2014) (3)
Hepatitis C care cascade in the country of Georgia after 2 years of starting national hepatitis C elimination program (2018) (3)
504 IMPROVEMENT OF INTERFERON-BASED THERAPY SUBSTANTIALLY REDUCED THE NUMBER NEEDED TO TREAT TO PREVENT HCC AMONG HCV GENOTYPE 1 INFECTED CIRRHOTICS (2013) (3)
Real-World Medical Costs of Antiviral Therapy Among Patients With Chronic Hcv Infection and Advanced Hepatic Fibrosis. (2015) (3)
Alox12/15 Deficiency Exacerbates, While Lipoxin A4 Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis (2020) (3)
[Clinical aspects of liver cirrhoses and its complications and diagnostic problems]. (2001) (2)
455 HCV VIRAL KINETICS DURING RIBAVIRIN MONOTHERAPY: RESULTS OF A RANDOMIZED PARTIALLY DOUBLE BLIND PLACEBO CONTROLLED CLINICAL TRIAL (2011) (2)
Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study) (2009) (2)
Real-world effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection within national hepatitis C elimination program in the country of Georgia (2017) (2)
Pulmonary impairment independently determines mortality in critically ill patients with acute‐on‐chronic liver failure (2022) (2)
Iron deficiency anaemia and cataracts in a patient with haemochromatosis (2013) (2)
Therapeutic vaccinationin chronic hepatitis B: qualitative and quantitative analysis of the virusspecific immune response (2001) (2)
Impact of disease severity on outcome of antiviral therapy in treatment‐naïve patients with chronic hepatitis C (2007) (2)
1414 THE CLIF-CONSORTIUM SCORE PREDICTS MORTALITY MORE ACCURATELY THAN THE MELD AND MELD-SODIUM SCORES IN PATIENTS HOSPITALIZED WITH DECOMPENSATED CIRRHOSIS WITH AND WITHOUT ACUTE-ON-CHRONIC-LIVER FAILURE (ACLF). (2013) (2)
Therapie der Hepatitis B und C - Standards 2004 (2004) (2)
Fast Interpretation of Thromboelastometry and Aggregometry in Patients Suffering from Chronic Liver Disease. (2019) (2)
Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy. (2013) (2)
Increased renal responsiveness to human atrial natriuretic peptide in patients with active acromegaly (1988) (2)
Randomized, controlled trial with interferon-alpha plus ribavirin with and without amantadine sulphate in patients with chronic hepatitis C relapsing after previous successful antiviral treatment (2002) (2)
SPTAN1 Expression Predicts Treatment and Survival Outcomes in Colorectal Cancer (2021) (2)
283 HCV PROTEASE INHIBITOR RESTORES INSULIN SENSITIVITY IN GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS (2010) (2)
P0895 : Comparison of three sequencing methods commonly used in hepatitis C virus resistance analysis: population-based vs. clonal vs. ultra deep sequencing (2015) (2)
Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis (2022) (2)
THU-051-Establishment of a new animal model for the acute-on-chronic liver failure (2019) (2)
[Is liver fibrosis a reversible event? Effect of pegylated interferon and ribavirin in patients with chronic hepatitis C]. (2003) (2)
Efficacy and Tolerability of Simeprevir and Daclatasvir for 12 or 24 Weeks in HCV Genotype 1b-Infected Treatment-Naïve Patients with Advanced Fibrosis or Compensated Cirrhosis (2016) (2)
Dynamics of hepatitis C virus quasispecies turnover during interferon alfa treatment (2003) (2)
[Postexposure prophylaxis after occupational exposure to HBV, HCV and HIV]. (2004) (2)
O13 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE 1 INFECTION IN EUROPEAN PATIENTS WHO RELAPSED AFTER PREVIOUS INTERFERON-BASED THERAPY: THE PROMISE TRIAL (2014) (2)
Treatment of acute hepatitis B with lamivudine vs. placebo: A prospective randomized multicenter trial (2013) (2)
[Diagnostic imaging in liver cirrhosis]. (2001) (2)
Thyroid dysfunction and virus genotype can predict response to immunotherapy with interferon-2α in chronic hepatitis C (1998) (2)
Application of Contrast-Enhanced Ultrasound to Detect Hepatic Hydrothorax in Patients with Liver Cirrhosis (2020) (2)
MELD-Lactate Predicts Poor Outcome in Variceal Bleeding in Cirrhosis (2022) (2)
O213: Daclatasvir vs telaprevir in combination with peginterferon alfa/ribavirin in treatment‐naive patients with HCV genotype 1: phase 3 COMMAND‐3 results (2014) (2)
Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance‐associated substitutions (2020) (2)
Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry (2022) (2)
Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors (2018) (2)
Viral Hepatitis and Its Complications (2016) (2)
[123] SUSTAINED VIROLOGICAL RESPONSE RATES WITH PEGINTERFERON a-2a (40 kD) (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) IN RANDOMISED CONTROLLED CLINICAL TRIALS ARE REPLICATED IN THE CLINICAL PRACTICE SETTING (2007) (2)
Meta-analysis of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis (2013) (2)
[592] NEOPTERIN AND ALT AS MARKERS OF INFLAMMATION IN CHRONIC HEPATITIS C PATIENTS DURING ADMINISTRATION OF THE HCV NS3-4A PROTEASE INHIBITOR TELAPREVIR (VX-950) IN COMBINATION WITH PEGINTERFERON ALFA 2a (2007) (2)
A randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohns disease: Good safety profile but lack of efficacy (2010) (2)
IDDF2018-ABS-0114 SOF/VEL/VOX results in high SVR12 rates when administered for 12 weeks in DAA-experienced patients or for 8 weeks in daa-naive patients: an integrated analysis of the polaris-1, polaris-2, polaris-3 and polaris-4 studies (2017) (2)
Erratum to “The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure” [J Hepatol 2015;62:831–840] (2015) (2)
Subcellular distribution of small GTP‐binding proteins in the intestinal cell line Caco‐2 (1995) (2)
Effectiveness and Safety of DAA Combination Therapies for Treatment of HCV in Elderly Patients (>70 Yrs): Results from the German Hepatitis C-Registry (2016) (2)
Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis (2019) (2)
Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience (2022) (2)
Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C. (2010) (2)
Safety of transient elastography in patients with implanted cardiac rhythm devices. (2017) (2)
Response prediction in chronic hepatitis C by assessment of IP-10 and IL 28 B-related single nucleotide polymorphisms LAGGING (2017) (2)
["Liver enzymes"--interpretation of laboratory values]. (2010) (2)
[Future of antiviral therapy for chronic hepatitis C. Direct antiviral acting medications]. (2011) (2)
Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy (2021) (2)
Randomized, controlled trial with interferon-α (IFN-α) combined with ribavirin with and without amantadinsulfat in primary IFN-α non-responders with chronic hepatitis C (2001) (2)
Investigation of the Wilson gene ATP7B transcriptional start site and the effect of core promoter alterations (2021) (2)
High Serum Levels of the Interleukin-33 Receptor Soluble ST 2 as a Negative Prognostic Factor in Hepatocellular Carcinoma 1 (2014) (2)
529 Real-time elastography for non-invasive assessment of liver fibrosis in chronic viral hepatitis (2006) (2)
Early occurrence of hepatocellular carcinoma in patients with and without cirrhosis after HCV treatment with direct-acting antivirals. (2018) (2)
PS-179-Analysis of long-term persistence of HCV resistance-associated substitutions within NS, NS5A and NS5B in genotype 1 and 3 after DAA treatment failure (2019) (2)
Diagnostic and prognostic significance of cell death markers in patients with cirrhosis and acute decompensation (2022) (2)
Electronic images of the month. Use of computed tomography with reformatted imaging to identify ingested drug packets. (2010) (2)
Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: The german telaprevir early access program (2013) (2)
The portal vein as a distinct immunological compartment - A comprehensive immune phenotyping study. (2018) (2)
NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis (2016) (2)
P1121 EARLY STOPPING RULES FOR FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS: EXPLORATORY STUDY OF POOLED DATA FROM PHASE III TRIALS (2014) (2)
Real world effectiveness of Ledipasvir/Sofosbuvir based regimens in hepatitis C virus genotype 1,2 and 3 infection within national hepatitis C elimination program in the country of Georgia (2018) (2)
1050 TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY (2009) (2)
Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected patients with low HBV viremia (2007) (2)
[Treatment of Hepatitis C: State of the Art 2018]. (2018) (2)
Simeprevir (TMC435) with Peginterferon/Ribavirin for treatment of chronic HCV genotype 1 infection in european patients who relapsed after previous interferon-based therapy: the promise trial (2014) (2)
Protein tyrosine phosphorylation in pancreatic acini: differential effects of VIP and CCK. (1997) (2)
P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES (2014) (2)
Effects of guanine nucleotides on bombesin-stimulated signal transduction in rat pancreatic acinar cells (1993) (2)
Not uncommon: HBV genotype G co‐infections among healthy European HBV carriers with genotype A and E infection (2021) (2)
Commentary: vitamin D deficiency and liver cancer – cause, effect or myth? Authors’ reply (2014) (2)
FOXO3a Polymorphism rs4946936 and its interaction with vitamin D in differentiated thyroid cancer (2014) (2)
[Severe acute cholestatic viral hepatitis E in a non-pregnant woman]. (2008) (2)
Evolution and function of the HCV NS3 protease in patients with acute hepatitis C and HIV coinfection. (2015) (2)
Diacylglycerol acyltransferase-1: a critical host factor for hepatitis C virus assembly and potential new drug target. (2011) (2)
Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis: an exploratory study (2020) (2)
O1 SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1 (2014) (2)
1022 METABOLIC SYNDROME INCREASES THE RISK OF PRIMARY LIVER CANCER IN THE UNITED STATES (2011) (2)
Occludin a new HCV entry factor: is the list of essential hepatitis C virus receptors complete? (2009) (2)
Late-breaking abstracts (2007) (2)
P0877 : HCVRNA levels assessed at early stages of sofosbuvir/ribavirin dual therapy identify relapse patients (2015) (2)
P1045 ESTIMATING THE PROBABILITY OF RESPONSE TO PEG-INTERFERON THERAPY IN HBeAg-POSITIVE CHRONIC HEPATITIS B: THE EPIC-B STUDY (2014) (2)
Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers (2020) (2)
The way forward in HCV treatment — finding the right path (2008) (2)
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (1)
[614] HOST AND VIRAL BASELINE CHARACTERISTICS IN HEPATITIS C NAIVE AND NON-RESPONDER PATIENTS: COMPARISON OF THREE LARGE RANDOMISED MULTINATIONAL TRIALS (2007) (1)
Final SVR24 Data From the Phase 3 C-Edge Treatment-Naïve Study of Elbasvir (EBR)/Grazoprevir (GZR) in Patients with Chronic HCV Genotype 1, 4 or 6 Infection (2016) (1)
Impact of Liver Fibrosis on Survival of Patients with Intrahepatic Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy (2022) (1)
Peginterferon Lambda, a New Potential Therapeutic Option for the Treatment of Chronic Hepatitis B: A Phase 2B Comparison with Peginterferon Alfa in Patients with HBeAg-Positive Disease (2012) (1)
P0669 : Consolidation therapy with entecavir can prevent post-treatment HBsAg rebound in HBeAg-positive chronic hepatitis B patients treated with peginterferon alpha (2015) (1)
P1209 FACTORS INFLUENCING RENAL FUNCTION IN PATIENTS RECEIVING TELAPREVIR TWICE DAILY OR EVERY 8 HOURS: RESULTS FROM THE PHASE III OPTIMIZE STUDY (2014) (1)
291 - Long-Term Follow-Up of Patients with Chronic HCV and F2 or F3 Fibrosis after Achieving SVR with Daa-Based Therapy: Results from the Gilead SVR Registry (2018) (1)
News in Hepatitis C: Report from the 39th Annual Meeting of the European Association for the Study of the Liver (2005) (1)
711 SERUM CYTOKINE LEVELS DURING PEG-IFNA-2a +/− ADEFOVIR TREATMENT OF DELTA HEPATITIS: RESULTS FROM THE HEP-NET/INTERNATIONAL HIDIT-1 STUDY (2008) (1)
1165 CLINICAL UTILITY OF THE ARCHITECT HCV AG ASSAY FOR EARLY TREATMENT RESPONSE MONITORING IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION (2012) (1)
Influence of interferon-alpha on CD81-expression in HCV-positive patients (2000) (1)
[Hypertransaminasaemia and impaired liver function in a patient with oligosymptomatic celiac disease]. (2001) (1)
FRI-175-Frequency, severity and impact of Peg-IFNa-associated flares in HDV infection: Results from the HIDIT-II study (2019) (1)
From the Editor's Desk…. (2021) (1)
Percutaneous endoscopic necrosectomy using an automated rotor resection device in severe necrotizing pancreatitis (2021) (1)
Improved Platelet Count and Smaller Spleen Size Long After Sustained Virological Response in Chronic Hepatitis C Patients With Advance Fibrosis (2011) (1)
Correlation of hepatitis B virus genomic variants with HBsAg Titers and HBV-DNA levels in a large European study cohort of patients with chronic hepatitis B (2017) (1)
New Rat Model of Advanced Non-Alcoholic-Steatohepatitis-Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (1)
62 Safety and Success of Direct Retrograde Cholangioscopy (DRC) by Use of an Ultra-Slim Endoscope - Results of a Multicenter Study (2013) (1)
Hepatitis B viral dynamics during four weeks of lamivudine: 150 mg versus 600 mg (1998) (1)
Controlled trial with pegylated interferon-alpha2b plus ribavirin retreatment in patients with chronic hepatitis C not responding to a previous antiviral treatment with standard interferons combined with ribavirin (2003) (1)
931 PREDICTION OF LONG-TERM SURVIVAL IN CHRONIC HEPATITIS C PATIENTS WITH ADVANCED FIBROSIS USING STANDARD LABORATORY TESTS (2012) (1)
The presence of liver cirrhosis is a strong negative predictor of survival for patients admitted to the intensive care unit – Cirrhosis in intensive care patients (2021) (1)
1092 EFFECTS OF PRE-TREATMENT WITH BEZAFIBRATE FOLLOWED BY STANDARD OF CARE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION AND ELEVATED GGT LEVELS (2012) (1)
[Post-exposure prevention after occupational exposure to HBV, HCV and HIV]. (2004) (1)
1104 ANALYSIS OF VIRAL FACTORS, CLINICAL PARAMETERS AND IL28B ASSOCIATED WITH OUTCOME OF PATIENTS WITH ACUTE HEPATITIS C AND HIV COINFECTION (2012) (1)
Towards Individualized Antiviral Therapy of Patients Infected with Hepatitis C Virus Genotypes 2 and 3 (2006) (1)
Tu2039 TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype 1-Infected Adults with Compensated Cirrhosis Treated with ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV) (2014) (1)
Growth differentiation factor (GDF) -15– a novel biomarker to assess the extent of liver fibrosis in patients with chronic liver disease? (2009) (1)
1240 ANALYSIS OF COMPLEX MUTATION PATTERNS IN THE HCV QUASISPECIES OF PATIENTS TREATED WITH TELAPREVIR OR BOCEPREVIR (2011) (1)
Dual-energy CT based material decomposition to differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma. (2022) (1)
Telaprevir in Combination with Peginterferon and Ribavirin In Genotype 1 HCV Treatment-Naïve Patients, Prior Relapsers and Prior Non-Responders: Pooled Analysis Of PROVE1, PROVE2, PROVE3 and Study 107: 274 (2010) (1)
Fidaxomicin-the next step? A new narrow-spectrum macrocyclic antibiotic for the management of clostridium difficile infection. (2011) (1)
A Possible Role of miRNAs as Predicitve Markers for the Recurrence of Hepatocellular Carcinoma After Liver Transplantation.: Abstract# A382 (2014) (1)
Final safety and efficacy results from a 106 real‐world patients registry with an ascites‐mobilizing pump (2022) (1)
Add on Interferon-Alpha-2a for the treatment of hbeag negative Hepatitis B patients receiving effective nucleos (t)ide therapy: interim results of the prospective multicentre padd-on trial (2016) (1)
Differentiation of thyroid nodules using Acoustic Radiation Force Impulse Imaging (2012) (1)
Reply to: 'Evidence recommending antiviral therapy in hepatitis C'. (2014) (1)
P0194 : Severe 25-hydroxyvitamin D deficiency is associated with infections and mortality in cirrhosis (2015) (1)
[Difficult-to-treat patients with chronic hepatitis C]. (2006) (1)
Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2019 (2020) (1)
Long-term follow up of patients with chronic HCV and F2 or F3 fibrosis after achieving SVR with DAA-based therapy: results from the Gilead SVR registry (2018) (1)
Tu1018 Sofosbuvir-Based Regimens for Patients With Hepatitis C Virus Genotype 3 Infection: Summary Results From the VALENCE, LONESTAR-2, and ELECTRON-2 Studies (2015) (1)
P545 SEVERE 25-HYDROXYVITAMIN D DEFICIENCY IDENTIFIES HCC PATIENTS WITH A POOR PROGNOSIS (2014) (1)
T-01 OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8 hours in treatment-naïve, genotype 1 HCV infected patients (2013) (1)
Cytoskeletal scaffolding proteins interact with Lynch‐Syndrome associated mismatch repair protein MLH1 (2010) (1)
Assessment of liver fibrosis with Supersonic Shear Wave elastography (Aixplorer™) in comparison to the transient elastography (Fibroscan®) and Acoustic Radiation Force Impulse (ARFI)-Imaging in patients with chronic liver disease (2013) (1)
Efficacy of Treatment Using Direct Acting Antiviral Drugs (DAAS) in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma – Real Life Data (2016) (1)
[Magnetic resonance cholangiopancreatography (MRCP) from a radiological and gastroenterological perspective]. (2009) (1)
Early monotherapy with pegylated interferon alfa–2b for acute hepatitis C infection: Final Results of the German HEP-NET Acute HCV II Study (2005) (1)
191 Relationship between early viral kinetics and immune reactivity in chronic hepatitis C (Genotype 1) patients treated with peginterferon-alfa 2A and ribavirin (2003) (1)
Impact of colonization with multidrug-resistant organisms on antibiotic prophylaxis in patients with cirrhosis and variceal bleeding (2022) (1)
[Germline mutations of the MSH6 gene in patients with an atypical hereditary nonpolyposis colorectal carcinoma (HNPCC)]. (2000) (1)
[Prevention and therapy of reactivation of hepatitis B in immunosuppressed patients]. (2009) (1)
919 ANEMIA AND ITS MANAGEMENT IN PATIENTS TREATED WITH TELAPREVIR TWICE DAILY VERSUS EVERY 8 HOURS IN THE PHASE III OPTIMIZE STUDY (2013) (1)
579 Effectiveness of antiviral therapy in patients with chronic hepatitis C treated by gastroenterologists in private practice (2006) (1)
A183 SOFOSBUVIR-BASED ALL-ORAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 3 INFECTION: INTEGRATED ANALYSIS OF FIVE CLINICAL STUDIES (2018) (1)
Response predictors and results of a long-term treatment with lamivudine in patients with chronic hepatitis B. (2003) (1)
[Pathogenetic germ-line mutation in patients with hereditary nonpolyposis colorectal carcinoma (HNPCC)]. (1999) (1)
P0528 : Transient elastography is safe in patients with pacemakers and implantable cardioverter-defibrillators (2015) (1)
418 UTILITY OF HISTORICAL DATA COMPARED TO LEAD-IN RESPONSE IN PREDICTING SUSTAINED VIROLOGIC RESPONSE IN NON-RESPONDERS AND RELAPSERS TO PEGINTERFERON/RIBAVIRIN WHEN RE-TREATED WITH BOCEPREVIR+PEGINTERFERON ALFA-2B/RIBAVIRIN (P/R) (2011) (1)
812e The Use of Sofosbuvir and Velpatasvir is Associated With High Efficacy and Improvement in Patient-Reported Outcomes in Patients with Genotype 1, 2, 4, 5 and 6 Chronic Hepatitis C: Results from the ASTRAL-1 Clinical Trial (2016) (1)
[Treatment of hepatitis B and C -- current standards]. (2004) (1)
O10 Granulocyte-Colony Stimulating Factor (G-CSF) to treat acute-on-chronic liver failure; results of the first multicenter randomized trial (GRAFT study) (2021) (1)
876 SOLUBLE SERUM CD81 IS ELEVATED IN PATIENTS WITH CHRONIC HEPATITIS C AND CORRELATES WITH ALANINE AMINOTRANSFERASE SERUM ACTIVITY (2012) (1)
330 ACOUSTIC RADIATION FORCE IMPULSE-IMAGING FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS: A POOLED META-ANALYSIS (2011) (1)
[Treatment of hepatitis C]. (2013) (1)
[Diagnosis of autonomic diabetic neuropathies of the gastrointestinal tract]. (1992) (1)
Neprilysin-dependent neuropeptide Y cleavage in the liver promotes fibrosis by blocking NPY-receptor 1 (2021) (1)
Expression of MUC16/CA125 Is Associated with Impaired Survival in Patients with Surgically Resected Cholangiocarcinoma (2022) (1)
Overview of commercial HBV assays systems. (2004) (1)
P1011 ACOUSTIC RADIATION FORCE IMPULSE-IMAGING IN COMPARISON TO TRANSIENT ELASTOGRAPHY FOR NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS C: A PROSPECTIVE INTERNATIONAL MULTICENTER STUDY (2014) (1)
P1312 : Alfapump system versus transjugular intrahepatic portosystemic shunt and paracentesis in the treatment of ascites. A multicentre randomised controlled study (AGUA-trial) (2015) (1)
Sofosbuvir/Velpatasvir (SOF/VEL) with or without Voxilaprevir (VOX) is Associated with Excellent Efficacy and Significant Improvements of Patient-Reported Outcomes (PROS) During Treatment and After Achieving Sustained Virologic Response (SVR) (2017) (1)
P0818 : Analysis of NS3 protease resistance-associated variants and phenotypes for the prediction of treatment response to HCV triple therapy (2015) (1)
Hepatitis C virus non-structural (NS)5A protein and interferon resistance: challenge of simple mutational analyses by a new bio-mathematical model (2002) (1)
271 EXTENDED TREATMENT OF TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1-INFECTION AND SLOW RESPONSE TO PEGYLATED INTERFERON-ALFA AND RIBAVIRIN: A META-ANALYSIS (2010) (1)
745 eGFR IMPROVEMENT IN CHRONIC HEPATITIS B PATIENTS WITH TELBIVUDINE TREATMENT IS INDEPENDENT OF ANTIVIRAL ACTIVITY (2013) (1)
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure. (2022) (1)
On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1–6 HCV Infection Treated with Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the Astral-1, Astral-2, and Astral-3 Studies (2016) (1)
STATEMENT OF THE FIRST EUROPEAN CONSENSUS CONFERENCE ON THE TREATMENT OF CHRONIC HEPATITIS B AND C IN HIV CO-INFECTED PATIENTS * (2005) (1)
1227 AN ANALYSIS OF RESPONSE RATES BY FIBROSIS STAGE IN PATIENTS TREATED WITH FALDAPREVIR, BI 207127 AND RIBAVIRIN IN THE SOUND-C2 STUDY (2013) (1)
Interferon (IFN)– g –Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN- a 2a and Ribavirin for Chronic Hepatitis C Virus Infection (2006) (1)
Reply to Real-time elastography in the assessment of liver fibrosis. (2008) (1)
Alternative AKT2 splicing produces protein lacking the hydrophobic motif regulatory region (2020) (1)
Hepatopulmonary syndrome (HPS) in chronic viral hepatitis (1998) (1)
Characteristics of HBeAg-positive patients chronically infectedwith hepatitis b virus (HBV) who achieved hbsag loss/seroconversion following tenofovir disoproxil fumarate (TDF) treatment (2009) (1)
Mutations in the MutSa interaction interface of MLH1 can abolish DNA mismatch repair (2006) (1)
Adding trastuzumab to standard chemotherapy in HER2-positive esophagogastric adenocarcinoma: a further step toward personalized medicine. (2011) (1)
Overcoming the roadblocks in hepatitis C virus infection. (2014) (1)
SAT-269-The sustained deleterious impact of viremia on patient reported outcomes in patients with chronic hepatitis C who don’t achieve sustained virologic response (2019) (1)
Low Platelet Count Predicts Reduced Survival in Potentially Resectable Hepatocellular Carcinoma (2022) (1)
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression. (2021) (1)
494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project) (2004) (1)
[539] ULTRASOUND EVALUATION OF PERIHEPATIC LYMPH NODES DURING ANTIVIRAL THERAPY WITH THE PROTEASE INHIBITOR TELAPREVIR (VX-950) IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2007) (1)
Hepatitis B patients under oral nucleos(t)ide treatment with intermittent kidney function assessment (The BONIKA-study) – a multicenter, prospective, observational trial (NCT-Nr. 02267473) (2017) (1)
P1199 RE-TREATMENT WITH TELAPREVIR-BASED TRIPLE THERAPY AFTER TELAPREVIR EXPOSURE IN PHASE 1 STUDIES: DEEP SEQUENCE ANALYSIS FOR PERSISTENCE OF RESISTANT VARIANTS (2014) (1)
Point Shear‐Wave Elastography Using Acoustic Radiation Force Impulse Imaging for the Prediction of Liver‐Related Events in Patients With Chronic Viral Hepatitis (2020) (1)
Investigation of Viral Escape Mutations within HCV P7 during Treatment with Amantadine in Patients with Chronic Hepatitis C (2013) (1)
P0766 : Epidemiology of viral resistance in genotype 1 infected patients at approval of IFN-free DAA combination therapy of chronic hepatitis C in Germany (2015) (1)
High efficacy is accompanied with substantial gains in patient reported outcomes in cirrhotic patients with chronic hepatitis C treated with sofosbuvir (SOF), velpatasvir with or without voxilaprevir (VOX): data from POLARIS 1, 2, 3 and 4 (2017) (1)
[Combination therapy for chronic viral hepatitis C]. (2003) (1)
52 DESCRIPTION OF AN AUTOMATED LOW-FLOW ASCITES (ALFA) PUMP SYSTEM FOR THE TREATMENT OF REFRACTORY ASCITES IN PATIENTS WITH CIRRHOSIS. PRELIMINARY REPORT (2012) (1)
[98] EFFECTOR/MEMORY SUBSETS AND FUNCTIONALITY OF CD4/CD8+ T-CELLS DURING POTENT ANTIVIRAL THERAPY IN CHRONIC HEPATITIS B (CHB) (2007) (1)
The non-selective Rho-kinase inhibitors Y-27632 and Y-33075 decrease contraction but increase migration in murine and human hepatic stellate cells (2023) (1)
1203 CLONAL SEQUENCING OF HCV NS3 PROTEASE AND HELICASE T CELL EPITOPES IN PATIENTS IMMUNIZED WITH THE THERAPEUTIC HCV VACCINE IC41 (2011) (1)
Real world effectiveness of ledipasvir/sofosbuvir (LDV/SOF) for 8 weeks in patients coinfected with HCV and HIV-1 (2017) (1)
[Indications and possibilities for using an insulin injection device in the treatment of type II diabetes mellitus with intermediate insulin]. (1988) (1)
Non-invasive assessment of liver fibrosis with Acoustic Radiation Force Imaging and Transient Elastography in chronic viral hepatitis (2013) (1)
Detection of mutations necessary for HCV replication in the in vitro replicon system in patients with chronic hepatitis C (2003) (1)
163 EVALUATION STUDY FOR THE INFLUENCE OF DIAGNOSTIC METHODS FOR BILIRUBIN, CREATININE AND PROTHROMBIN (INR) FOR LABORATORY MELD SCORE CALCULATIONS (2013) (1)
[Boceprevir-benefit assessment by the Institute for Quality and Efficiency in Health Care (IQWiG) in accordance with Â§ 35a SGB V (dosage evaluation)]. (2012) (1)
Effects of pre-treatment with bezafibrate followed by standard of care in treatment-naive patients with chronic hepatitis C genotype 1 infection and elevated GGT levels (2012) (1)
[Cystic polyposis of the stomach]. (2008) (1)
[Joint opinion of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Daclatasvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (1)
New Rat Model of Cholestatic Liver Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (1)
Acute-on-Chronic Liver Failure (2018) (1)
[648] CHARACTERISATION OF HCV GENOTYPE 2/3 PATIENTS WITHOUT A RAPID VIROLOGICAL RESPONSE (RVR): OPTIMISING TREATMENT BY PREDICTING SLOWER RESPONDERS TO PEGINTERFERON a-2a (PEGASYS®) PLUS RIBAVIRIN (COPEGUS®) (2007) (1)
Ribavirin plus either peginterferon α-2a or peginterferon α-2b for patients with chronic HCV infection? (2008) (1)
A fractured duodenal self-expanding metal stent in a patient with pancreatic cancer (2014) (1)
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy (2019) (1)
601 Anti-viral activity of VX-950 resolves expression of an HCV-associated gene signature (2006) (1)
Novel protease and polymerase inhibiting agents to treat chronic hepatitis C infection (2008) (1)
Efficacy of Boceprevir / Peginterferon / Ribavirin for HCV G 1 Compensated Cirrhotics : Meta-Analysis of 5 Trials (2014) (1)
Real world effectiveness of 8 vs 12 weeks of ledipasvir/sofosbuvir (LDV/SOF) in blacks with HCV: A comparative analysis of clinical trials with real world cohorts. (2017) (1)
[The state of health care and health care paths in inflammatory bowel disease (Crohn's disease and ulcerative colitis)]. (2009) (1)
Short article: Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study (2016) (1)
Treatment of hepatocellular carcinoma with sorafenib - preclinical rational and results of a phase II trial (2007) (0)
Stool and sputum microbiome during quinolone prophylaxis of spontaneous bacterial peritonitis (2020) (0)
[Blood oncogene detection in patients with colorectal carcinoma]. (1998) (0)
From the Editor's Desk... (2022) (0)
Management of HCV genotype 1 non-responders/relapsers: a European perspective. (2010) (0)
[Chronic hepatitis C: improved cure rates with new approved medications]. (2012) (0)
Human PDK1 Kinase Domain in Complex with an HM-Peptide Bound to the PIF-Pocket (2016) (0)
6.2 Phlebothrombose (2013) (0)
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Simeprevir-benefit assessment according to § 35a SGB V the Federal Joint Committee]. (2014) (0)
Reply (2003) (0)
Update on viral kinetics and hcv antiviral therapy (2004) (0)
Effect of ribavirin on the frequency of RNase L cleavage sites within the hepatitis C viral genome (2010) (0)
P0185 : Acute-on-Chronic Liver Failure not associated with bacterial infections. Characteristics, prognosis and importance of systemic inflammatory response (2015) (0)
The Mortality of Acute-on-Chronic Liver Failure by APASL vs. EASL-CLIF definition: A Multicenter, Retro- spective Cohort Study in Korea (KACLiF Study) (2014) (0)
Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure (2022) (0)
Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa‐2a in hepatitis C null responders (2015) (0)
4.3 Leitsymptom (2013) (0)
Su1600 Indication of Over-the-Scope (OTS)-Clip vs. Self-Expanding Metal Stent (CSEMS) for Upper Gastrointestinal Leakage: Results of a Large Multicentre Study (2014) (0)
Comparison of short‐course antibiotic therapy of 6 or less days with a longer treatment in patients with cholangitis after liver transplantation (2022) (0)
Biological effects of sulphated insulin in adipocytes and hepatocytes (1985) (0)
[New procedures for submission of comments strengthens the professional societies]. (2012) (0)
EDP-239, A Novel HCV NS5A Inhibitor, Demonstrates Potent Antiviral Activity After a Single Dose Treatment of Genotype 1 HCV Patients. (2015) (0)
153 TELAPREVIR BLOOD LEVELS ARE UNALTERED IN PATIENTS WITH CICLOSPORIN AND TACROLIMUS BASED IMMUNOSUPPRESSION AFTER ORTHOTOPIC LIVER TRANSPLANTATION (2013) (0)
Not uncommon: HBV genotype g co-infection in HBeAg-negative chronic HBV infected patients (2020) (0)
398 HCV-associated mixed cryoglobulinemia: Importance of mutations within the HCV E2 region and CD81 expression on peripheral B lymphocytes (2004) (0)
494 REAL-WORLD DATA ON TREATMENT MODIFICATION FROM A LONG-TERM OBSERVATIONAL STUDY OF CHRONIC HEPATITIS B PATIENTS FROM 5 EUROPEAN COUNTRIES (2012) (0)
Reduced efficacy of norfloxacin prophylaxis to prevent spontaneous bacterial peritonitis over time: a systematic review and meta-analysis (2020) (0)
From the Editor's Desk… (2020) (0)
Computed Tomography Radiomics to Differentiate Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma. (2023) (0)
From the Editor's Desk... (2022) (0)
Adrenal myelolipomas in CAH: is there role for ultrasound screening of the adrenal glands? (2012) (0)
496 GENOTYPIC RESISTANCE REDUCED TO VERY LOW LEVELS IN CHRONIC HEPATITIS B (CHB) PATIENTS TREATED OVER 2-YEARS WITH TELBIVUDINE (LDT) WHEN CONSIDERING BASELINE CHARACTERISTICS AND ROADMAP (2012) (0)
3.3 Lymphadenopathie (2013) (0)
PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING—A SYSTEMATIC REVIEW (2008) (0)
PREVENTION OF ISCHEMIC TYPE BILIARY LESIONS BY ARTERIAL FIRST REPERFUSION IN ORTHOTOPIC LIVER TRANSPLANTATION: 2799 (2010) (0)
1349 VIROLOGIC RELAPSE IS HIGHLY CORRELATED WITH RESPONSE AT WEEK 4 AND 12 BUT NOT WITH IL28B GENOTYPE IN HCV GENOTYPE 1-INFECTED PATIENTS TREATED WITH PEG-INTERFERON/RIBAVIRIN (2011) (0)
Impact of antibiotic prophylaxis of spontaneous bacterial peritonitis on colonization and infections with multidrug-resistant bacteria (2018) (0)
[Therapy of autonomic diabetic neuropathy of the gastrointestinal tract]. (1992) (0)
Assessing practical identifiability in hepatitis C viral kinetic modeling (2008) (0)
348 HOMODIMERIZATION OF THE HEPATITIS C VIRUS NON-STRUCTURAL 4B PROTEIN REQUIRES AN INTACT BASIC LEUCINE ZIPPER (2009) (0)
Sofosbuvir-based all-oral regimens for patients with chronic hepatitis C genotype 2 infection: integrated analysis of eleven clinical studies (2017) (0)
1157 NUCLEOSIDE TRANSPORTER SLC28A2/3 AND SLC29A1/2 GENETICS: PROTECTION AGAINST ANAEMIA IN CHRONIC HEPATITIS C PATIENTS RECEIVING RIBAVIRIN (2011) (0)
443 VITAMIN D DEFICIENCY IS FREQUENT IN CHRONIC HEPATITIS C AND AFFECTS THE OUTCOME OF INTERFERON-ALFA BASED THERAPY (2011) (0)
489 A COMMON HLA-DPA1 VARIANT IS ASSOCIATED WITH HEPATITIS B VIRUS INFECTION BUT FAILS TO DISTINGUISH ACTIVE FROM INACTIVE CAUCASIAN CARRIERS (2012) (0)
Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia (2022) (0)
Inside Front Cover (2019) (0)
P732 PREDICTIVE VALUE OF THE INTERFERON-LAMBDA 4 GENE (IFN-L4) FOR DIRECT-/ANTIVIRAL TREATMENT IN HEPATITIS C VIRUS INFECTED PATIENTS WITH GENOTYPES 1, 2, 3, AND 4 (2014) (0)
Presence of only wildtype virus is the strongest determinant of HBV DNA undetectability and HBsAg clearance in HBeAg-positive chronic hepatitis B patients treated with peginterferon (2012) (0)
O.127 Phase 2b interim (week 12) results of albumin interferon alpha-2b combined with ribavirin in IFN-naïve, genotype 1 chronic hepatitis C infection (2006) (0)
["Hepatitis C awareness, searching for it and referral for therapy"]. (2006) (0)
Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center. (2023) (0)
[The influence of autonomic diabetic neuropathy and human atrial natriuretic peptide on adrenal gland function in postural changes]. (1991) (0)
From the Editor's Desk…. (2021) (0)
4.4 Bartonellose (2013) (0)
O‐27: Early HCV RNA kinetics predict relapse to sofosbuvir/ribavirin dual therapy (2015) (0)
11.9 Pulmonalstenose (2013) (0)
488 Virodynamic predictors of treatment response to peginterferon and lamivudine combination treatment of HBeA-positive chronic hepatitis B (2006) (0)
Integrated Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Taking Concomitant Proton Pump Inhibitors: 2017 Presidential Poster Award: 970 (2017) (0)
A method for cleaning and, where appropriate, analysis of nucleic acids from biological samples (1997) (0)
Multicenter Performance Evaluation of a New TaqMan PCR Assay for Monitoring Human Immunodeﬁciency Virus RNA Load (cid:1) (2006) (0)
Editorial: HBsAg serum levels in HBeAg‐negative chronic HBV infection—is it a matter of genotype? Authors’ reply (2018) (0)
Supplemental Information Bidirectional Allosteric Communication between the ATP-Binding Site and the Regulatory PIF Pocket in PDK 1 Protein Kinase (2016) (0)
T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a (2010) (0)
Cost analysis of non-medical vs. treatment-related costs in patients with chemotherapy for colorectal cancer (2008) (0)
490 SERUM MICRORNA-122 LEVELS IN DIFFERENT GROUPS OF PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION (2012) (0)
[Individualised treatment of chronic hepatitis C]. (2006) (0)
T-26 Long-term FU of patients with CHC treated with telaprevir in combination with PEG-IFN alfa-2a and RBV: Interim analysis of the EXTEND study (2011) (0)
54 PRESENCE OF ONLY WILDTYPE VIRUS IS THE STRONGEST DETERMINANT OF HBVDNA UNDETECTABILITY AND HBSAG CLEARANCE IN HBEAG-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH PEGINTERFERON (2012) (0)
Progress in the diagnostic imaging and treatment of hepatocellular carcinoma (2007) (0)
Clinical and virological characteristics of DAA-experienced patients with chronic HCV infection treated with sofosbuvir/ velpatasvir/voxilaprevir: results from the Frankfurt Resistance Database (2018) (0)
4.3 Hyperventilation (2013) (0)
INCISIONAL HERNIAS FOLLOWING LIVER TRANSPLANTATION - IMPACT OF INCISION AND IMMUNOSUPPRESSION: 1839 (2010) (0)
IMO 1001 Lymph node detection by ultrasound within the hepatoduodenal ligament in patients with primary biliary cirrhosis (PBC) (1997) (0)
Title Page / Editorial Board / Contents / Imprint (2016) (0)
Disease progression is affected by pattern of serum alanine aminotransferase dynamics in a cohort of patients with hepatitis B e antigen-negative chronic infection: 4 years follow-up of a prospective longitudinal study (ALBATROS study) (2018) (0)
PE-056 : The Safety and Tolerability of SOF/VEL/VOX for 8/12 Weeks in >1,000 Patients Treated in the POLARIS Studies: An Integrated Analysis (2017) (0)
1325 CHARACTERISTICS OF ACUTE HEPATITIS C IN A HIV-COINFECTED COHORT: ANALYSIS OF IL28B AND VIRAL FACTORS ASSOCIATED WITH OUTCOME (2011) (0)
Severe 25-hydroxyvitamin D deficiency identifies HCC patients with a poor prognosis (2014) (0)
Virological response assessment by polymerase chain reaction and transcription mediated amplification in patients with chronic hepatitis C virus treated with peginterferon-alpha 2A (2001) (0)
Peroral cholangioscopy for diagnosis and therapy of biliary tract disease using an ultra-slim gastroscope (2011) (0)
11.5 Mitralstenose (2013) (0)
367 DETERMINATION OF APOPTOTIC ACTIVITY IN UNTREATED CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH DIFFERENT BASELINE VIRAL LOAD (2011) (0)
Anti-EGFR-based conversion chemotherapy in RAS wildtype colorectal cancer patients: Impact on survival and resection rates. (2017) (0)
SAT-068-Presence of liver cirrhosis is the strongest negative predictor of survival for patients admitted to intensive care unit (2019) (0)
885 INTRAHEPATIC MRNA LEVELS OF THE SUPPRESSORS OF CYTOKINE SIGNALLING 1 AND 3 ARE ASSOCIATED WITH CIRRHOSIS BUT NOT WITH TREATMENT RESPONSE IN CHRONIC HEPATITIS C (2012) (0)
High prevalence of hepatitis C virus (HCV) antibodies in patients visiting the accident and emergency department of the J. W. Goethe University Hospital, Frankfurt/Main (2010) (0)
THU-049-Impaired adaptive immunity is an early event in liver cirrhosis preceding acute-on-chronic liver failure (2019) (0)
10.5 Kyphoskoliose (2013) (0)
Combined percutaneous retrograde and peroral antegrade esophagoscopy for the treatment of complete upper esophageal obstruction (2015) (0)
FibroSURE TM and FibroScan ® in relation to treatment response in chronic hepatitis C virus (2011) (0)
In-hospital falls and fall-related injury in patients with liver-cirrhosis - malnutrition matters (2020) (0)
266 TAX1BP1 LIMITS TUMOR FORMATION IN EXPERIMENTAL LIVER CANCER (2011) (0)
Power-doppler sonographic appearance, autoimmune activity and clinical course of interferon-related thyroid disease during antiviral therapy of hepatitis C (2006) (0)
Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021 (2022) (0)
Activation kinetics of D-glucose transport in normal, obese and diabetic patients (1989) (0)
Management iatrogener Perforationen in der Endoskopie (2016) (0)
From the Editor's Desk... (2020) (0)
Liver Transplantation for Chronic HCV Infection in the United States 2002-2014: An Analysis of the UNOS/OPTN Database (2016) (0)
[Regulated exocytosis: Ca(2+)-sensor in exocrine cells?]. (1999) (0)
From the Editor's Desk…. (2022) (0)
7.2 Akute interstitielle Nephritis (AIN) (2013) (0)
Hepatitis B: Management of suboptimal response to oral antiviral therapy (2009) (0)
P.183 HCV NS5A protein and response to IFN α: mutational analysis in 3a genotype chronic hepatitis C patients from India (2006) (0)
Risk-guided strategy to prevent cytomegalovirus associated complications after liver transplantation (2018) (0)
From the Editor’s Desk… (2020) (0)
1118 DYNAMICS OF HEPATITIS B VIRUS QUASISPECIES HETEROGENEITY AND EARLY VIROLOGIC RESPONSE IN PATIENTS RECEIVING LOW TO MODERATE GENETIC BARRIER NUCLEOSIDE ANALOGS (2011) (0)
P1176 INCIDENCE AND RISK FACTORS FOR INFECTIONS DURING INTERFERON-BASED TREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH ADVANCED HEPATIC FIBROSIS (2014) (0)
All-trans retinoic acid co-administered with pegylated interferon and ribavirin does not influence viral kinetics in hepatitis C infected patients with previous non-response: Results of the ATRACTION study (2012) (0)
[Retrospective cohort study of lamivudine therapy in patients with chronic hepatitis B]. (2001) (0)
Health-Related Quality of Life (HRQL) and Health Utilities (HU) of Patients with Chronic Hepatitis C (CH-C) Treated with an Interferon (IFN)-Free Regimen Containing Ledipasvir (LDV) and Sofosbuvir (SOF): 568 (2014) (0)
Transarterial Chemoembolization before Liver Transplantation in Patients with Hepatocellular Carcinoma - a Single Center Experience: 2278 (2012) (0)
Two-dimensional real-time shear wave elastography and risk for de novo hepatocellular carcinoma in patients with advanced chronic liver disease (2020) (0)
Directly acting antiviral HCV therapy is safe and effective in patients with advanced cirrhosis: real world experience from the HCV-TARGET Cohort (2018) (0)
Mutations within the CD81-binding sites and hypervariable region (HVR) 2 of the envelope (E) 2 protein and correlation with treatment response in HCV infected patients (2002) (0)
From the Editor's Desk... (2023) (0)
2.5 Hiatushernie (2013) (0)
Non-invasive assessment of liver fibrosis in HIV infected adults with and without HCV / HBV co-infection and exposure to dideoxynucleosides (2010) (0)
Long-Term Follow-Up of European HBeAg-Negative Chronic Hepatitis B-Infected Patients on Antiviral Treatment (2016) (0)
269 DYNAMICS OF APOPTOTIC ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH ALBINTERFERON ALFA-2B OR PEGINTERFERON ALFA-2A (2010) (0)
Sofosbuvir/velpatasvir (SOF/VEL) for 12 weeks in genotype 1, 2, 4, 5, 6 HCV patients: ASTRAL-1 study (2016) (0)
Reply (2016) (0)
4.16 Listeriose (2013) (0)
483 IMPORTANCE OF HCV RNA ASSAY CHARACTERISTICS AND DIFFERENCES BETWEEN ASSAYS FOR RESPONSE GUIDED THERAPY OF CHRONIC HEPATITIS C (2011) (0)
Sa1029 An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, Bi 207127 and Ribavirin in the Sound-C2 Study (2013) (0)
Meetings and Conferences (2016) (0)
AGA AbstractEGF inhibits secretagogue-induced cAMP production and amylase secretion via pertussis toxin-sensitive G proteins in pancreatic acini (1995) (0)
Development and validation of the CLIF-AD score for the prognosis of patients with acute decompensation of cirrhosis not fulfilling criteria for acute-on-chronic liver failure (ACLF) (2014) (0)
Editorial Favourable and disappointing lessons from viral kinetics (2002) (0)
Colonization and infection with carbapenem-resistant non-fermenting gram-negative bacteria are associated with rapid deterioration and mortality in patients with decompensated liver disease (2016) (0)
THU-163-Efficacy and safety of direct-acting antivirals for hepatitis C in elderly patients: a systematic review and meta-analysis (2019) (0)
First 1-year follow up data from the German NAFLD prospective real-life cohort (FLAG study) show low frequencies of lifestyle changes (2020) (0)
Impact of a shorter replacement interval of plastic stents on premature stent exchange rate in benign and malignant biliary strictures (2022) (0)
NS5A resistance patterns and treatment outcomes in DAA-naive genotype 1a chronic hepatitis C patients with and without baseline resistance-associated substitutions (2018) (0)
Safety of add on Interferon-alpha-2a in hepatitis B patients receiving effective nucleos(t)de therapy: Interim results from the German multicenter PADD-ON trial (2014) (0)
[Generalized hyperpigmentation and malignant acanthosis nigricans. A case of a patient with hereditary hemochromatosis and gastric cancer]. (2005) (0)
Sofosbuvir and Velpatasvir for Patients with HCV Infection. (2016) (0)
From the Editor's Desk... (2022) (0)
1166 CLINICAL RELEVANCE OF MINIMAL RESIDUAL VIREMIA DETECTED WITH THE ABBOTT REALTIME HCV ASSAY FOR RESPONSE-GUIDED THERAPY WITH PEG-INTERFERON-a/RIBAVIRIN IN PATIENTS WITH HEPATITIS-C-VIRUS GENOTYPE 1 INFECTION (2012) (0)
Impact of Dynamic Viral and Biochemical Parameters on Progression of Liver Fibrosis in a Cohort of Inactive European Hepatitis B (HBV) Carriers: A Prospective Longitudinal Study (Albatros Study) (2016) (0)
In-hospital falls and impaired nutritional status are independently associated with in-hospital mortality in patients with liver cirrhosis (2022) (0)
HBV3 O‐29: A randomized comparative open label trial of tenofovir monotherapy versus tenofovir plus telbuvidine dual therapy in spontaneous reactivation of hepatitis B (NCT01732224) (2015) (0)
P0335 : Serum long chain ceramides, sphingosine and sphingosine-1-phosphate as novel diagnostic markers in patients with hepatocellular carcinoma (2015) (0)
Long-term Follow-up of a Hepatic Metastatic Acinus Cell Carcinoma of the Pancreas Using FDG-PET (1998) (0)
Reply: (2009) (0)
From the Editor's Desk... (2022) (0)
[The clinical relevance of the GB virus C/hepatitis G virus]. (1997) (0)
From the Editor's Desk…. (2020) (0)
2.1 Zyanose (2013) (0)
CYP24A1 haplotypes are associated with differentiated thyroid carcinoma (2010) (0)
CS4-01 Response-guided Therapy for Chronic Hepatitis C (2009) (0)
[Choose wisely - a critical assessment]. (2020) (0)
5.1 Akute Tracheobronchitis (2013) (0)
High SVR rates among patients with multiple negative predictive factors across genotypes treated with sofosbuvir-based regimens (2014) (0)
Impact of Soluble CD 26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection (2013) (0)
P0711 : Genome-wide association study of response to sofosbuvir-ribavirin treatment in GT2/3 HCV patients (2015) (0)
4.8 Adrenogenitales Syndrom (AGS) (2013) (0)
New Rat Model of Alcoholic Liver Cirrhosis Developing Acute-on-Chronic-Liver failure (2022) (0)
Treatment of hepatitis C in primary healthcare in the country of Georgia (2022) (0)
2.4 Cholestase (2013) (0)
The ef fi cacy and safety of direct acting antiviral treatment and clinical signi fi cance of drug – drug interactions in elderly patients with chronic hepatitis C virus infection (2016) (0)
809 DYSREGULATION OF MICRO-RNA EXPRESSION IN SPLENIC MARGINAL ZONE LYMPHOMA IN PATIENTS WITH AND WITHOUT CHRONIC HEPATITIS C VIRUS INFECTION (2011) (0)
T-28 Impact of insulin resistance on virologic response to a telaprevir-based regimen in patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: post-hoc analysis of the REALIZE Phase III study (2012) (0)
Human PDK1 Kinase Domain in Complex with Allosteric Activator PS171 Bound to the PIF-Pocket (2011) (0)
From the Editor's desk…. (2021) (0)
Su1414 On Treatment HCV RNA as a Predictor of SVR12 in Patients with Genotype 1-6 HCV Infection Treated With Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks: An Analysis of the ASTRAL-1, ASTRAL-2, and ASTRAL-3 Studies (2016) (0)
3.6 Zyanose (2013) (0)
Studies on insulin receptors of brush-border membranes isolated from human kidney proximal tubule. (1990) (0)
Future therapies in the management of hepatitis C virus infection (2010) (0)
Correction: Cyclic AMP induces transactivation of the receptors for epidermal growth factor and nerve growth factor, thereby modulating activation of MAP kinase, Akt, and neurite outgrowth in PC12 cells. (2020) (0)
1058 Multiple Plastic Stents (MPS) vs. Covered Self-Expandable Metal Stents (cSEMS) for Endoscopic Therapy in Stenosis of the Choledocho-Choledochal Anastomosis After Orthotopic Liver Transplantation: Data From a Randomised Multicentre Trial (2015) (0)
Molecular mechanisms of fitness compensation in drug resistance-associated NS3 protease variants in hepatitis C (2017) (0)
Su1729 A Randomized Trial of Guidewire Use for Biliary Stricture Cannulation in Endoscopic Retrograde Cholangiopancreatography (ERCP): Superior Success Rate of a New Single Use Guidewire (2014) (0)
From the Editor's Desk... (2021) (0)
5.6 Prognose (2013) (0)
5.3 Reizdarmsyndrom (RDS) (2013) (0)
1348 VIRAL HETEROGENEITY IN HCV NS5A GENOME IS LOW IN PATIENTS WITH FAVORABLE IL28B GENOTYPES (2011) (0)
[Glycyrrhizin for the treatment of allergic diseases and chronic hepatitis]. (1998) (0)
Effectiveness of sofosbuvir and ledipasvir/sofosbuvir based regimens in hepatitis C virus genotype 3 infection: real-world data from Georgian hepatitis C elimination program (2018) (0)
Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations (2015) (0)
Declining Numbers of Hepatitis C Virus-Associated Liver Transplantations in Germany. (2021) (0)
Treatment of Genotype 1 HCV Treatment-Naïve Patients: final results of phase III study ADVANCE (2011) (0)
Introducing the HCV miniseries. (2020) (0)
712 CELL DEATH DYNAMICS DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2010) (0)
310 MARKED SPIROMETRY DECLINE IN PATIENTS WITH CHRONIC HEPATITIS C DURING TREATMENT WITH ALBINTERFERON ALFA-2B IS SIMILAR TO PEGINTERFERON ALFA-2A (2010) (0)
1.1 Definition (2013) (0)
A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial (2014) (0)
426 Dynamics of CD81-expression on lymphocyte subsets during antiviral treatment of patients with chronic hepatitis C (2006) (0)
Sofosbuvir/Velpatasvir (SOF/VEL)-Based Regimens are Associated with Excellent Efficacy and a Significant Improvement of Patients-Reported Outcomes (PROs) across Patient Populations: From Non-Cirrhotics to Compensated Cirrhotics to Decompensated Cirrhotics (2018) (0)
DALYs in Chronic Hepatitis C : A Paneuropean Perspective (2010) (0)
Regulation of IL-22 in a rat model for acute-on-chronic liver failure (ACLF) (2020) (0)
Interferon-Free Strategies without a Nucleoside/Nucleotide Analogue (2014) (0)
P1134 DURATION OF UNDETECTABLE HCVRNA IN PATIENTS TREATED WITH FALDAPREVIR–DELEOBUVIR INTERFERON-FREE COMBINATION IS ASSOCIATED WITH SVR (2014) (0)
1055 SEQUENCE EVOLUTION OF THE HCV NS3/4A PROTEASE DURING ACUTE HEPATITIS C VIRUS (HCV) INFECTION (2010) (0)
Comparison of daily interferon alfacon-1 with standard regimens of thrice weekly interferon Alfacon-1 in patients with chronic hepatitis C â interim results from an ongoing international trial (2001) (0)
[Natural course and progression of liver cirhosis in patients with hepatitis C]. (1998) (0)
O‐28: Safety and efficacy of ledipasvir/sofosbuvir for the treatment of hepatitis c infection: interim analysis of a prospective, observational study (2015) (0)
P66 SVR with telaprevir, peginterferon alfa-2A and ribavirin in HCV patients with well-characterised prior null response, partial response, viral breakthrough or relapse after peginterferon+ ribavirin (2010) (0)
From the Editor’s Desk… (2001) (0)
292 Dynamics of apoptotic activity during antiviral treatment of patients with chronic hepatitis C (2006) (0)
From the Editor's Desk... (2020) (0)
2.7 Obstipation (2013) (0)
6.3 Thrombophlebitis (2013) (0)
[interferon-free treatment of hepatitis C: how and when will it become reality? [corrected]]. (2013) (0)
Contents (2020) (0)
Concurrent Session 4 – HCV Development and Strategies CS 401 Response-guided Therapy for Chronic Hepatitis C (2009) (0)
Su1051 Duration of Undetectable HCV RNA in Patients Treated With Faldaprevir-Deleobuvir Interferon-Free Combination Is Associated With SVR (2014) (0)
Efficacy and safety of Telaprevir in patients with hepatitis C genotype 1 infection: The German Telaprevir early access program (2014) (0)
[654] PREDICTION OF VIROLOGIC RESPONSE IN HCV GENOTYPE 1A-INFECTED PATIENTS ACCORDING TO AMINO ACID PATTERN IN NS5A USING STATISTICAL LEARNING ALGORITHMS FOR CLASSIFICATION (2007) (0)
Human PDK1 Kinase Domain in Complex with Adenosine Bound to the ATP-Binding Site (2016) (0)
1105 BASELINE CHARACTERISTICS CAN HELP TO PREDICT HEPATIC DECOMPENSATION DURING ANTIVIRAL THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C AND ADVANCED LIVER CIRRHOSIS (2012) (0)
IMO 1003 Perihepatic lymph nodes in patients with chronic hepatitis G and C (1997) (0)
Performing ERCP in elderly people – risk factors and indications (2014) (0)
Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability (2021) (0)
Su1398 Direct Retrograde Cholangioscopy (DRC) for Diagnosis of Indeterminate Biliary Lesions (2013) (0)
PNPLA3 and HSD17B13 gene variants exert opposite effects on fatty liver phenotypes: results from the FLAG cohort (2020) (0)
M1950 Prospective Evaluation of MYH Germline Variants in 352 Colonoscopy Patients (2009) (0)
Involvement of the epidermal growth factor receptor in SRC-dependent activation of extracellular-regulated kinases-1 and -2 in pancreatic AR42J cells (2000) (0)
Human PDK1-PKCiota Kinase Chimera in Complex with Allosteric Compound PS267 Bound to the PIF-Pocket (2014) (0)
25-hydroxyvitamin D deficiency is associated with infections and mortality in cirrhosis (2015) (0)
[Treatment of hepatitis C virus infection]. (2005) (0)
O111: Non‐invasive assessment of liver fibrosis (2014) (0)
Computer modeling of the 3D structure of human cytochrome P450c21 in a young woman with late-onset AGS and a new mutation within the steroid-21-hydroxylase gene (2005) (0)
Significance of HBsAg and HDVRNA levels in patients with delta hepatitis recruited in the Hep-Net/International HDV intervention trial (2006) (0)
Results of a ten year prospective observational study on acute hepatitis C in HCV-mono- and HIV/HCV-coinfected patients (2022) (0)
299 MIRNA EXPRESSION PROFILING OF LASER-MICRODISSECTED LIVER TISSUE FROM PATIENTS WITH HCV ASSOCIATED HCC REVEALS DISTINCT MIRNA-PATTERNS IN FOUR CHARACTERIZED SUB-COMPARTMENTS WITHIN THE TUMOR-INFILTRATED LIVER (2012) (0)
Steatosis does not affect the result of antiviral treatment in HCV genotype 3 infected patients (2005) (0)
Interleukin-12 (IL-12) therapy in patients with chronic hepatitis C (1998) (0)
From the Editor's Desk… (2020) (0)
4.4 Glutensensitive Enteropathie (2013) (0)
Real-world Effectiveness of Ledipasvir/Sofosbuvir (LDV/SOF) for 8 weeks in Patients Coinfected with HCV and HIV-1 (2017) (0)
1214 MECHANISMS FOR KETOAMIDE ESCAPE IN VAL55 VARIANTS OF THE HCV NS3/4A PROTEASE DOMAIN (2012) (0)
1350 HOST-SPECIFIC FACTORS INDEPENDENT OF IL28B GENOTYPE PREDICTING TREATMENT OUTCOME OF INDIVIDUALIZED THERAPY IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 INFECTION (2011) (0)
2.9 Invasive Methoden (2013) (0)
[Choosing wisely recommendations in gastroenterology]. (2017) (0)
Health-Economic Evaluation of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir for Treatment of Chronic Genotype 1 Hcv Infection in Germany (2016) (0)
O211: With Interferon (2014) (0)
THU-186-Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-August 2018 (2019) (0)
Qu antification of fecal carbohydrates near-infrared reflectance analysis by (0)
Association of common p53 and mdm2 variants with spontaneous and treatment induced viral clearance in patients with chronic hepatitis C infection (2010) (0)
[Treatment of hepatitis C infections in the era of direct-acting antivirals (DAAs)]. (2022) (0)
738 BONE MINERAL DENSITY AND METABOLISM IN NON-CIRRHOTIC PATIENTS WITH CHRONIC HEPATITIS C (2008) (0)
Ambulatory long-term immunoprophylaxis with intramuscular anti-HBS immunoglobulin to prevent hepatitis B reinfection after orthotopic liver transplantation (2000) (0)
Role of telaprevir plasma levels for predicting response to antiviral therapy in patients with hepatitis C virus genotype 1 infection (2014) (0)
Acute hepatitis C virus infection: a prospective ten-year observational study of HCV-mono and HCV/HIV-coinfected patients (2020) (0)
SAT-189-GCAC1809-1812TTCT a novel viral quadruple mutation is strongly associated with basal core promotor double mutation and viral load in Hepatitis B e antigen negative chronic hepatitis B virus infected patients (2019) (0)
From the Editor's Desk…. (2020) (0)
[Treatment of hepatitis C--update 2005]. (2005) (0)
response in chronic hepatitis C virus (2011) (0)
THU-211-Evaluation of point shearwave elastography using acoustic radiation force impulse imaging for non-invasive assessment of liver fibrosis in HBeAg-negative chronic HBV infection: A prospective longitudinal study (2019) (0)
2.2 Spondyloarthritiden (SpA) (2013) (0)
Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial (2020) (0)
Workshop report The American Association for the Study of Liver Diseases: new perspectives in the treatment of hepatitis C (2006) (0)
Interobserver agreement of thyroid imaging reporting and data system and realtime elastography for the assessment of thyroid nodules (2013) (0)
FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial (2019) (0)
287 EVALUATING VIROLOGIC RESPONSE WITHIN 2–4 WEEKS HAS HIGH POSITIVE/NEGATIVE PREDICTIVE VALUES FOR SUSTAINED VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C DURING TREATMENT (2010) (0)
Brown tumor of the mandible and osteitis fibrosa cystica in hyperparathyroidism: a rare disease mimicking an osseous metastasized malignancy (2008) (0)
NEMO catches the FOX. (2011) (0)
Reduced migration of MLH1 deficient colon cancer cells depends on SPTAN1 (2014) (0)
O.160 16 or 24 weeks of peginterferon alpha-2a (40KD) (PEGASYS®) plus ribavirin (RBV) (COPEGUS®) in patients with HCV genotype 2 or 3 and bridging fibrosis or cirrhosis: Results from a large, randomised multinational study (ACCELERATE) (2006) (0)
THU-050-Genetic variants of innate immunity receptors are associated with mortality but not with bacterial infections in liver cirrhosis (2019) (0)
799 EFFECTS OF RIBAVIRIN ON NK CELL PHENOTYPE AND FUNCTION IN HEPATITIS C VIRUS INFECTION (2012) (0)
Interactions with phospholipids and membrane remodeling by nonstructural protein 5A of hepatitis C virus (2021) (0)
P.241 Treatment outcomes in patients with hepatitis C virus genotype 1a and 1b and persistently ‘normal’ alanine aminotransferase (ALT) levels receiving peginterferon alpha-2a (40KD) plus ribavirin (2006) (0)
[Chronic hepatitis C virus infection: always treat!--Pro]. (2002) (0)
Final Results of a roll-over study (107) with Telaprevir, Peginterferon Alfa-2A and Ribavirin in Prior Null Response, Partial Response, Viral Breakthrough or Relapse HCV Genotype 1 Patients After PR (2011) (0)
[Chronic hepatitis C: new perspectives in therapy]. (2004) (0)
954 – Chronic Hepatitis C (CHC) Patients Who Do Not Achieve Sustained Virologic Response (SVR) Experience Worsening of Their Health-Related Quality of Life (HRQL) (2019) (0)
416 PREDICTION OF ACTIVE HBV-CARRIER STATUS IN A COHORT OF EUROPEAN UNTREATED HBeAg NEGATIVE PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (2013) (0)
4.5 Morbus Whipple (Lipodystrophia intestinalis) (2013) (0)
THU-143-High effectiveness of elbasvir/grazoprevir treatment in patients with HCV genotype 1a infection in German real-world: Results from the German hepatitis C registry (DHC-R) (2019) (0)
Variables associated with persistence of elevated ALT after SVR in patients with chronic hepatitis C: Data from the German Hepatitis C-Registry (DHC-R) (2018) (0)
Subcellular distribution and function of the low molecular mass GTPase Rab3A and Rab3B in AR42J cells (1998) (0)
From the Editor's Desk…. (2020) (0)
Screening for HNPCC-focussing on families (1999) (0)
P0721 : Viral and host parameters in association with outcome of acute hepatitis C in HIV-coinfected patients (2015) (0)
From the Editor's Desk... (2022) (0)
New Antiviral Therapies in the Management of Hepatitis C Virus Infection (2011) (0)
[Revolution in the treatment of hepatitis C -- how to adopt the guidelines afterwards?]. (2014) (0)
P1059 : Severity of coronary artery disease is associated with non-alcoholic fatty liver disease (2015) (0)
HBV2 O‐31: Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany and the major role of hepatitis B e antigen expression in disease severity and progression (2015) (0)
971 MOLECULAR MECHANISMS OF CROSS-RESISTANCE IN PEPTIDOMIMETIC PROTEASE INHIBITORS FOR STAT-C (2009) (0)
Prevalence and Clinical Impact of Sinusitis in Liver Graft Recipients (2019) (0)
The effect of peginterferon alfa-2a (40 KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (2003) (0)
4.8 Chlamydien-Infektionen (2010) (0)
3.1 Transplantation (2013) (0)
751 Patient-Reported Outcomes in Chronic Hepatitis C Patients With Cirrhosis Treated With Ribavirin-Containing Regimens: Sofosbuvir/Velpatasvir and Ribavirin or Sofosbuvir and Ribavirin (2016) (0)
Contents (2020) (0)
[In Process Citation]. (2014) (0)
616 EFFECT OF RIBAVIRIN ON THE FREQUENCY OF RNASE L CLEAVAGE SITES WITHIN THE HEPATITIS C VIRAL GENOME (2009) (0)
Comprehensive analysis of NK cell phenotype and function during the initial phase of antiviral therapy: distinct roles of Ribavirin and Interferon alpha (2013) (0)
Whole-genome sequencing of carbapenem-resistant gram-negative bacteria in patients with cirrhosis (2021) (0)
From the Editor’s Desk… (2022) (0)
5.2 Leitsymptom: Splenomegalie (2013) (0)
CKD / Human studies (2011) (0)
The predictive role of Week 8 (RVRw8) viral kinetics in prior PR null responders receiving telaprevir in the delayed-start arm of the REALIZE trial (2014) (0)
Su1608 No Distal Migration in Unfixed vs. Fixed Cell Structure Covered Self-Expanding Metal Stents for Treatment of Benign Biliary Disease (2015) (0)
751d SVR Results of Prove3, a Phase 2B Clinical Trial Assessing Safety and Efficacy of Telaprevir in Hepatitis C Genotype-1-Infected Patients with Prior Non-Response, Viral Breakthrough or Relapse to Peginterferon-Alfa-2a/B and Ribavirin Therapy (2009) (0)
Author response: Adaptation of hepatitis C virus to interferon lambda polymorphism across multiple viral genotypes (2019) (0)
9.1 Definition (2013) (0)
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection (2022) (0)
Contents (2020) (0)
Protein in Response to IFN-Expression and Release of IL-18 Binding (2001) (0)
Molecular characterization of the cancer-associated MLH1 mutation Asp132His (2006) (0)
[Joint Statement of the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) and the German Society for Internal Medicine (DGIM) to Ledipasvir / sofosbuvir-benefit assessment according to § 35a SGB V the G-BA]. (2015) (0)
Selective targeting of tumor-associated macrophages in hepatocellular carcinoma (2015) (0)
417 Subgenomic hepatitis C replicon deriving from a clinical isolate with virologic non-response to IFN-based therapy and IFN resistance in vitro (2006) (0)
From the Editor's Desk... (2020) (0)
From the Editor’s Desk… (2001) (0)
P.285 Differences in virus and host characteristics between patients with HCV genotype 2 or 3 participating in a large international study (2006) (0)
Management of hepatitis C in primary healthcare in the country of Georgia (2020) (0)
Structure and allosteric effects of activating compounds on protein kinase PDK1 (2010) (0)
Interleukin-12 (IL-12) treatment in chronic hepatitis C (1998) (0)
435 ANTI-HDV-IgM AS A MARKER OF DISEASE ACTIVITY IN HEPATITIS DELTA (2013) (0)
S1936 Health-Related Quality of Life (HRQOL) with Albinterferon Alfa-2b Plus Ribavirin in IFN Treatment-NaïVe Patients with Genotype 1 Chronic Hepatitis C (2008) (0)
7.3 Ileus (2013) (0)
439 Hepatitis C viraemia inhibits dendritic cell functions and their ability to induce adaptive immune response to HCV (2006) (0)
1006 Viral kinetics in chronically HCV infected patients with persistently normal or elevated ALT levels (2003) (0)
[Postexposure prevention after occupational exposure to HBV, HCV and HIV]. (2003) (0)
618 Prediction for treatment outcome in HCV type 1-infected patients: GAMMA-glutamyltranspepdidase (GGT) is the most reliable independent single parameter (2006) (0)
Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01 (2022) (0)
Escitalopram for the prevention of peginterferon alpha-2a- and ribavirin-associated depression in HCV-infected patients without prior psychiatric disease: A randomized controlled trial (2012) (0)
P0728 : Investigation of genetic recombination of hepatitis C virus in patients infected with genotypes 1, 2 and 4 (2015) (0)
5.3 Lungenemphysem (2013) (0)
Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry (2020) (0)
5.1 Definition (2007) (0)
Individualised Treatment of hepatitis C (2007) (0)
From the Editor's Desk (1957) (0)
The emerging role of Enterococcus spp. and multidrug-resistant bacteria causing pyogenic liver abscesses (2017) (0)
From the Editor's Desk... (2021) (0)
P699 PREDICTORS OF HEPATIC STEATOSIS IN A PROSPECTIVE STUDY OF EUROPEAN UNTREATED HEPATITIS B SURFACE ANTIGEN (HBsAg) CARRIERS: EVALUATION BY CONTROLLED ATTENUATION PARAMETER (CAP) (2014) (0)
PharmaNews (2016) (0)
A prospective multicenter pilot study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in HBsAg+/HCV-RNA+ patients: The HEP-NET B/C coinfection trial (2008) (0)
Computational Analysis of the Hepatitis C Virus Non-Structural Protein 4B and Functional Implications (2005) (0)
Human PDK1 Kinase Domain in Complex with Allosteric Compound PS182 Bound to the PIF-Pocket (2012) (0)
O112: HCV genome sequencing: what the clinician needs to know (2014) (0)
420 Dynamics of intra-individual HCV variants during antiviral treatment with peginterferon α and ribavirin (2006) (0)
P720 HEALTH-RELATED QUALITY OF LIFE (HRQL) AND PATIENT-REPORTED OUTCOMES (PROS) ASSESSMENT IN CHRONIC HEPATITIS C (CH-C) TREATED WITH SOFOSBUVIR (SOF) AND RIBAVIRIN (RBV): THE VALENCE STUDY (2014) (0)
From the Editor's Desk…. (2020) (0)
[596] GENOTYPE-SPECIFIC ASSESSMENT OF PREDICTIVE FACTORS FOR SUSTAINED VIROLOGIC RESPONSE AFTER STANDARD TREATMENT IN PATIENTS CHRONICALLY INFECTED WITH HCV (2007) (0)
P.09.14 FEASIBILITY AND REPRODUCIBILITY OF NON-INVASIVE LIVER AND PANCREATIC STIFFNESS ASSESSMENT IN A COHORT OF PATIENTS WITH ALCOHOL-RELATED LIVER DISEASE (2018) (0)
Comprehensive analysis of different phases of chronic Hepatitis B Infection (2022) (0)
Su1382 Endoscopic Treatment of Malignant Biliary Stricture by Intraductal Radio-Frequency Ablation (RFA) - Safety Concerns From a Pilot Study (2013) (0)
Angled-tip vs. straight-tip guidewire in ERCP: a randomized, multicenter study (2022) (0)
New aspects of treatment of chronic hepatitis C (2008) (0)
[230] META-ANALYSIS OF THE PERFORMANCE OF FIBROSCAN FOR THE STAGING OF LIVER FIBROSIS (2007) (0)
Mutations within the HCV Genotype 1b NS4B Protein and Correlation to Viral Replication and Initial Viral Kinetics During Interferon-alfa-Based Therapy (2005) (0)
Functional characterization of MLH1 missense variants unveils mechanisms of pathogenicity and clarifies role in cancer (2022) (0)
Identification of glycogen synthase kinase 3 beta as a novel host factor of hepatitis C virus replication (2017) (0)
2.2 Dyspnoe (2013) (0)
[Interferon-alpha plus ribavirin combination therapy in chronic hepatitis C]. (1999) (0)
Neopterin and ALT as markers of inflammation in chronic hepatitis C patients during administration of the HCV NS3•4A protease inhibitor telaprevir (VX-950) and/or peginterferon alfa 2a (2008) (0)
Transabdominal ultrasonography to reduce the burden of X‐ray imaging in prophylactic pancreatic stent localization after ERCP—A prospective trial (2021) (0)
23 The effect of peginterferon alfa-2a (40KD) on liver histology in chronic hepatitis C: A meta-analysis of individual patients data (MIPD) (2003) (0)
620 Presence of CD4-positive cells in the portal tract on pretreatment liver biopsy is associated with early viral reduction during antiviral treatment of HCV (2006) (0)
Prof. Dr. med. Peter Galle (2014) (0)
754 IMPACT OF RIBAVIRIN ON SUBGENOMIC HEPATITIS C VIRUS RNA DECAY DURING TREATMENT WITH INTERFERON ALFA AND THE PROTEASE INHIBITOR TELAPREVIR (2010) (0)
PS-086-Sustained virologic response in patients with cirrhosis from chronic hepatitis C leads to sustained and long-term improvement of health-related quality of life, fatigue, and work productivity (2019) (0)
Transmission of hepatitis C virus in patients undergoing chronic haemodialysis (1993) (0)
Reply to the letter to the editor "Interferon Lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in Hepatitis C Virus Genotype 3a". (2016) (0)
Novel experimental animal models for acute decompensation and acute-on-chronic liver failure (2020) (0)
Association of Alpha-1 Antitrypsin Pi*Z Allele Frequency and Progressive Liver Fibrosis in Two Chronic Hepatitis C Cohorts (2022) (0)
1364 DEEP SEQUENCING REVEALS ACCUMULATION OF VIRAL VARIANTS IN HCV GENOTYPE 1 INFECTED PATIENTS DURING RIBAVIRIN MONOTHERAPY (2011) (0)
[457] HCV INFECTION OF DENDRITIC CELLS AFFECTS THEIR FUNCTION LEADING TO AN IMPAIRED ADAPTIVE IMMUNE RESPONSE (2007) (0)
P725 IMPACT OF THE rs8099917 SNP ON SVR12 IN PATIENTS WITH HCV GT-1 INFECTION TREATED WITH FALDAPREVIR, DELEOBUVIR AND RIBAVIRIN (2014) (0)
4.15 Leptospirosen (2013) (0)
IMO 1002 Perihepatic lymph node volume is related to HCV-viremia but not to genotype (1997) (0)
Direct Antiviral Combination Treatment According to Presence of Baseline Ravs in NS3, NS5A and NS5B Leads to High SVR Rates in Non-Cirrhotic and Cirrhotic Genotype 1 Infected Patients (2016) (0)
27.5 Hypothyreose (2011) (0)
[Treatment of severe chronic constipation: differential roles of conventional laxatives and the prucalopride prokinetic]. (2011) (0)
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials. (2016) (0)
Safety and Efficacy of Interferon-free Regimens of ABT-450/r, ABT-267, ABT-333 ± Ribavirin in Patients with Chronic HCV GTI Infection: Results from the Aviator Study: 364 (2013) (0)
Comprehensive analysis of the different phases of chronic hepatitis B virus infection (2022) (0)
Impact of chronic liver disease on mortality and severity in community-acquired pneumonia (CAP) – Results from the German Competence Network CAPNETZ (2020) (0)
From the Editor's Desk... (2022) (0)
Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury (2022) (0)
N-terminus of hMLH 1 confers interaction of hMutL a and hMutL b with hMutS a (2003) (0)
23.3 Kollagenosen (2011) (0)
5.4 Enterokolitiden (2013) (0)
13.1 Akutes Abdomen (2007) (0)
4.6 Brucellosen (2013) (0)
HCV3 O‐30: The efficacy of antiviral therapy in HCV associated B‐cell non‐Hodgkin lymphomas: a meta‐analysis (2015) (0)
Colonization with multidrug‐resistant organisms is associated with impaired survival of patients with surgically resected cholangiocarcinoma (2022) (0)
Market uptake of pegylated interferons for the treatment of hepatitis C in Europe : meeting abstract (2008) (0)
O212: Simeprevir versus telaprevir in combination with pegylated interferon and ribavirin in HCV genotype 1‐infected patients: the Phase III ATTAIN study (2014) (0)
[66] MOLECULAR BASIS FOR VX-950 RESISTANCE (2007) (0)
1074 INFLUENCE OF NICOTINE ABUSE ON FIBROSIS PROGRESSION IN CHRONIC HEPATITIS C VIRUS (HCV) INFECTION (2010) (0)
Series : Host-pathogen interactions Emerging therapies for the treatment of hepatitis C (2013) (0)
776 GENETIC DIVERSITY IN THE LIGAND-BINDING SITE OF THE NS3.4A PROTEASE AND IMPACT ON PEPTIDOMIMETIC INHIBITORS IN HCV-1A (2010) (0)
Advanced chronic hepatitis C: How to handle if you cannot halt? (2009) (0)
Acoustic Radiation Force Impulse Imaging der Schilddrüse (2011) (0)
From the Editor's Desk... (2021) (0)
416 LONGITUDINAL PROSPECTIVE COMPARISON OF FIBROSURE AND TRANSIENT ELASTOGRAPHY IN RELATION TO VIROLOGIC RESPONSE: A SUBSTUDY OF THE PHASE 3 ALBINTERFERON ALFA-2B TRIALS (2010) (0)
5.3 Pathogenese (2013) (0)
Dicer Prevents Hypoxia-Induced Up-Regulation of HIF-1A, Hypoxic Response and Epithelial-Mesenchymal Transition in Hepatocellular Carcinoma (2016) (0)
820 CD81 EXPRESSION ON LYMPHOCYTE SUBTYPES FOR DISCRIMINATION BETWEEN SUSTAINED VIROLOGIC RESPONSE AND RELAPSE IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEG-INTERFERON-ALFA AND RIBAVIRIN (2011) (0)
CT-radiomics and clinical risk scores for response and overall survival prognostication in TACE HCC patients (2023) (0)
Prevalence of hepatitis C virus subtypes in Germany (1993) (0)
Human PDK1 Kinase Domain in Complex with Allosteric Activator PS114 Bound to the PIF-Pocket (2011) (0)
Safety and efficacy of twice daily versus every 8 hour telaprevir with Peginterfepon/Ribavirin (PR) in patients with cirrhosis (2013) (0)
819 THE BASIC LEUCINE ZIPPER MOTIF OF THE HEPATITIS C VIRUS NONSTRUCTURAL PROTEIN 4B IS ESSENTIAL FOR REPLICATION EFFICACY IN A GENOTYPE IB REPLICÓN MODEL (2011) (0)
DNA mismatch repair activity of MutLα is regulated by CK2-dependent phosphorylation of MLH1 (S477) Abbreviated title: Phosphorylation of MLH1 (2018) (0)
Predictors of virologic relapse in patients with chronic hepatitis C (CHC) treated with peginterferon alfa-2a (40KD) (pegasys) alone or in combination with ribavirin (copegus) (2003) (0)
T1971 Influence of Nicotine Abuse on Fibrosis Progression in Chronic Hepatitis C Virus (HCV) Infection (2010) (0)
PIN80 Multivariate Cox Analysis Regarding Treatment Switch on Chronic Hepatitis B (CHB) Disease Management Based on a 2-Year Prospective Study in 5 European (EU) Countries (2012) (0)
44 Was sind Interferone (2004) (0)
Intercellular crosstalk regulating ARRB2/RARRES1 is involved in transition from fibrosis to cancer (2021) (0)
Su1058 Early Stopping Rules for Faldaprevir Plus Pegylated Interferon α-2A and Ribavirin in Treatment-Naïve Patients: Exploratory Study of Pooled Data From Phase III Trials (2014) (0)
Pervasive Adaptation of Hepatitis C Virus to Interferon Lambda Polymorphism Across Multiple Genotypes (2018) (0)
FRI-207-Subgroup analysis of patients undergoing switch of nucleos (t)ide regimen for HBV treatment during the prospective BONIKA trial (2019) (0)
From the Editor's Desk…. (2020) (0)
Two year safety and tolerability of tenofovir disoproxil fumarate (TDF) treatment in HBeAg negative and HBEAG positive patients with chronic hepatitis B (CHB) (2009) (0)
P1309 HCV MUTANTS RESISTANT TO MACROCYCLIC NS3-4A PROTEASE INHIBITORS SUPPRESS INTERFERON-β INDUCTION BY EFFICIENT MAVS CLEAVAGE (2014) (0)
Letter: proton pump inhibitor treatment and increased mortality in cirrhotic patients – authors' reply (2015) (0)
320 TREATMENT RESPONSE TO SORAFENIB CORRELATES TO DISTINCT TUMOUR MICRO RNA CLUSTERS IN HEPATOCELLULAR CARCINOMA (2012) (0)
IMO 1004 Echopattern of the liver in patients with chronic hepatitis C (1997) (0)
P16 SOF/VEL/VOX for 8 or 12 weeks results in high SVR12 rates: an integrated analysis of the POLARIS-1, POLARIS-2, POLARIS-3 AND POLARIS-4 studies (2017) (0)
Mass Drug Administration for Scabies Control (2016) (0)
Clinical characteristics of patients with non-alcoholic fatty liver disease (NAFLD) in Germany – First data from the German NAFLD-Registry (2022) (0)
Usage of antiplatelet agents is inversely associated with liver fibrosis in patients with cardiovascular disease (2018) (0)
311 Final Results of a Rollover Study Assessing Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic HCV Patients With Well-Characterized Null Response, Partial Response, Viral Breakthrough, or Relapse After Prior PR Treatment (2010) (0)
The Role of Small Molecular Weight GTP-Binding Proteins in Stimulus Secretion Coupling of Pancreatic Acinar Cells (1993) (0)
[Gangliocytic paraganglioma--a rare differential diagnosis of a submucosal duodenal tumor]. (2011) (0)
376 SOLUBLE CD163 IS ASSOCIATED WITH LIVER INFLAMMATION AND FIBROSIS IN CHRONIC HEPATITIS B VIRUS INFECTION (2013) (0)
Human PDK1 Kinase Domain in Complex with Compound PS653 Bound to the ATP-Binding Site (2016) (0)
HBsAg transcomplementation of defective HBV genomes in HBeAg negative chronic HBV infected patients (2018) (0)
Intratumoral heterogeneity of intrahepatic cholangiocarcinoma. (2017) (0)
546 Early HCV-RNA decline in peripheral blood mononuclear cells predicts SVR versus relapse in chronic hepatitis C patients treated with pegylated interferon-α plus ribavirin (2006) (0)
Contrast-enhanced ultrasound of adrenal mass: differentiation between benign and malignant lesions (2008) (0)
1.3 Leitsymptome (2013) (0)
Contents (2020) (0)
Abstract B39: Inhibition of the oncoprotein FUBP1 by SN-38 represents a novel therapeutic option for the treatment of hepatocellular carcinoma (2016) (0)
Evaluation of 2D-shear wave elastography for characterisation of focal liver lesions running title: 2D-SWE and liver lesions (2016) (0)
O113: Association of the −515A>G CDC6 polymorphism with risk to develop hepatocellular carcinoma in patients with chronic hepatitis C (2014) (0)
6.2 Aspergillose (2013) (0)
848b TMC435 in Patients Infected with HCV Genotype 1 Who Have Failed Previous Pegylated Interferon/Ribavirin Treatment: Virologic Analyses of The ASPIRE Trial (2012) (0)
Glecaprevir/pibrentasvir in patients with hepatitis C and prior treatment experience: an integrated phase II/III analysis (2018) (0)
[Perspectives in hepatology in the next 2-3 years: what will be clinically relevant? Viral hepatitis]. (2005) (0)
Significance of elevated IL8 levels in patients with chronic hepatitis C in comparison with patients with liver diseases of different origin (2003) (0)
826 SAFETY AND EFFICACY OF TWICE DAILY VERSUS EVERY 8 HOUR TELAPREVIR WITH PEGINTERFERON/RIBAVIRIN (PR) IN PATIENTS WITH CIRRHOSIS (2013) (0)
Clinical and virological characteristics of patients with chronic hepatitis C virus (HVC) infection and failure to multiple direct acting antiviral (DAA) therapies (2017) (0)
719 A CROSS-SECTIONAL ANALYSIS OF CHRONIC HEPATITIS B PATIENT CHARACTERISTICS AND CLINICAL MANAGEMENT PATTERNS IN GERMANY, POLAND, ROMANIA AND TURKEY (2010) (0)
11.2 Nierentransplantation (NTX) (2013) (0)
694 HLA CLASS I ALLELES ASSOCIATED WITH HCV POLYMORPHISMS AND RESPONSE TO ANTIVIRAL THERAPY IN HCV GENOTYPE 1-INFECTED PATIENTS (2010) (0)
4.3 Myeloproliferative Neoplasien (MPN) (2013) (0)
[658] OPTIMAL PRE-TREATMENT HCV-RNA LEVEL FOR PREDICTION OF SVR WITH PEGINTERFERON a-2a (40 kD) PLUS RIBAVIRIN IN GENOTYPE 1 PATIENTS: GENERALISED ADDITIVE LOGISTIC REGRESSION MODEL (GAM) ANALYSIS (2007) (0)
S812 Hepatic Safety of Ozanimod in Ulcerative Colitis and Relapsing Multiple Sclerosis Phase 3 Trials (2022) (0)
Chronic hepatitis C virus infection: a general indication for treatment! - Pro (2002) (0)
Effectiveness of voxilaprevir/velpatasvir/sofosbuvir in hepatitis C patients previously treated with direct-acting antiviral agents (DAA) (2022) (0)
11.2 Aortenstenose (2013) (0)
6560 POSTER A Phase I Safety and Pharmacokinetic Study of Everolimus, an Oral mTOR Inhibitor, in Subjects With Impaired Hepatic Function (2011) (0)
From the Editor’s Desk… (2021) (0)
2.5 Ödeme (2013) (0)
46 Was sind pegylierte Interferone (2004) (0)
9.4 Pathogenese (2013) (0)
P483 CK 18 BASED SERUM APOPTOTIC CELL DEATH MARKER M30 PREDICTS SURVIVAL IN PATIENTS WITH LIVER CIRRHOSIS (2014) (0)
THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment (2019) (0)
From the Editor's Desk... (2021) (0)
High effectiveness of elbasvir/grazoprevir (EBR/GZR) treatment in patients with HCV genotype 1a (GT1a) infection in German real-world: results from the German Hepatitis C Registry (DHC-R) (2019) (0)
Hepatitis B Virus Precore-, Basal Core Promotor- and Pres-Gene Variants: Importance for Reactivation in a Large Cohort of HBS Antigen Carriers (2016) (0)
From the Editor's Desk... (2021) (0)
[Treatment of parenterally transmittable viral hepatitis]. (2022) (0)
P698 CLINICAL OUTCOME AFTER 2 YEARS FOLLOW-UP IN A COHORT OF EUROPEAN UNTREATED HEPATITIS B (HBV) INFECTED PATIENTS: A PROSPECTIVE LONGITUDINAL STUDY (ALBATROS STUDY) (2014) (0)
Enzymatic and antisense-effects of a specific anti Ki-ras ribozyme in vitro and in cell culture (1998) (0)
Reply to: "Real-world data on antiviral treatments for hepatitis C virus infections: Can we define intention to treat or per protocol analyses?" (2018) (0)
P1120 PREDICTION OF SUSTAINED VIROLOGIC RESPONSE IN TREATMENT-NAIVE CHRONIC HEPATITIS C GENOTYPE 1 PATIENTS TREATED WITH TELAPREVIR PLUS PEGYLATED INTERFERON AND RIBAVIRIN IN PHASE 3 TRIALS (2014) (0)
P0189 : Proton Pump Inhibitor treatment is associated with increased mortality in patients with cirrhosis (2015) (0)
Free Paper Session III (2006) (0)
[Use of Thrombopoetin-Receptor-Agonists (TPO-RA) in patients with liver cirrhosis before invasive procedures]. (2022) (0)
P683 INFLUENCE OF A NTCP RECEPTOR GENE POLYMORPHISM ON HEPATITIS B VIRUS (HBV) INFECTION (2014) (0)
Delayed activation of D-glucose transport in type II diabetes mellitus. (1992) (0)
[624] ALBUMIN INTERFERON ALFA-2b DOSED AT Q2W OR Q4W INTERVALS DEMONSTRATES COMPARABLE WEEK 12 EFFICACY RESPONSE IN IFN NAIVE, GENOTYPE-1 RAPID VIRAL RESPONDERS (2007) (0)
7.10 Kardiopulmonale Reanimation (2013) (0)
Inhibition of the oncoprotein FUBP1 by SN-38 represents a novel therapeutic option for the treatment of hepatocellular carcinoma (2016) (0)
Response to Braillon. (2013) (0)
Hepatic and portal vein flow in correlation with intrahepatic fat deposition and liver histology (1998) (0)
Diversity of amino acid sequences within the HCV E2 protein in serum and PBMC (2009) (0)
819 HEALTH-RELATED QUALITY OF LIFE (HRQOL) WITH ALBINTERFERON ALFA-2B PLUS RIBAVIRIN IN IFN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C (2008) (0)
6.2 Transfusionstherapie (2013) (0)
598 HOMOGENEOUS VIRAL DYNAMICS IN HETEROGENEOUS QUASISPECIES POPULATIONS IN HCV RESPONDERS TO STANDARD IFN THERAPY (2008) (0)
4.1 Definition (2013) (0)
[44-year-old patient with fulminant liver failure]. (2003) (0)
NS5A inhibitors to treat hepatitis C virus infection. (2012) (0)
298 ESCITALOPRAM FOR THE PREVENTION OF PEG-IFN-α AND RIBAVIRIN ASSOCIATED DEPRESSION IN HCV-INFECTED PATIENTS: FINAL RESULTS FROM THE CIPPAD-TRIAL (2010) (0)
Hepatitis C Virus Genotype 3: Hope for Nonresponders and Patients With Cirrhosis (2014) (0)
[430] RIBAVIRIN ACTS AS HEPATITIS C VIRUS MUTAGEN ON NONSTRUCTURAL 5B QUASISPECIES IN VITRO AND DURING ANTIVIRAL THERAPY (2007) (0)
Characterization of HBsAg decline by genotype in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumurate (TDF) for up to 4 years (2011) (0)
From the Editor's Desk…. (2021) (0)
Utility of Historical Data Compared to Lead-in Response in Predicting Sustained Virologic Response in Non-Responders and Relapsers to Peginterferon/Ribavirin When Re-Treated With Boceprevir+Peginterferon Alfa-2B/Ribavirin (PR) (2011) (0)
Dysfunctional adaptive immunity in liver cirrhosis and acute-on-chronic liver failure is characterized by aberrant immune checkpoint expression and diminished cytokine secretion in T cells (2020) (0)
813 TELAPREVIR SERUM LEVELS DURING TREATMENT FOR HCV GT1 INFECTION ARE ASSOCIATED WITH EXTENDED RAPID VIROLOGIC RESPONSE BUT DO NOT AFFECT HEMOGLOBIN DECLINE (2013) (0)
Reply: (2005) (0)
From the Editor's Desk... (2022) (0)
578 Comparison of RT-PCR and TMA-based assays for detection of HCV RNA in formalin fixed paraffin-embedded liver tissue samples (2003) (0)
Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01 (2022) (0)
P6: Prevalence of HCV, HBV and HIV infections among hemophiliac (2014) (0)
IMO 1205 Flow pattern in the right hepatic vein reflects fatty infiltration of the liver in patients with chronic hepatitis C (1997) (0)
13.3 Schock (2013) (0)
Acoustic radiation force impulse imaging of thyroid gland (2011) (0)
Hepatitis C Virus-Infektion und Lichen planus (1998) (0)
1.5 Geriatrische Rehabilitation (2013) (0)
1.11 Leberzirrhose (2013) (0)
4.9 Cholera (2013) (0)
Impact of small duct- and large duct type on survival in patients with intrahepatic cholangiocarcinoma: Results from a German tertiary center. (2022) (0)
1089 ASSOCIATION OF COMMON P53 AND MDM2 VARIANTS WITH SPONTANEOUS AND TREATMENT INDUCED VIRAL CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION (2010) (0)
OP12 Similar Svr Rates In Il28b Cc, Ct Or Tt prior relapser, partial- or null-responder patients treated with telaprevir/peginterferon/ribavirin: retrospective analysis of the Realize Study (2011) (0)
Su1064 Early Viral Kinetics Do Not Predict Treatment Outcome With Sofosbuvir + Ribavirin for 12 or 24 Weeks in HCV Genotype 2/3 Patients in the Valence Trial (2014) (0)
Gestörte Sekretions- und Resorptionsmechanismen bei Diarrhö (1994) (0)
Hepatitis C virus (HCV) genotypes 2 3 infection: A curable disease (2003) (0)
SAT-133-2D-Shear-Wave elastography predicts survival in advanced chronic liver disease (2019) (0)
The American Association for the Study of Liver Diseases: New Perspectives in the Treatment of Hepatitis C (2006) (0)
Decline In Pulmonary Physiology During Treatment Of Chronic Hepatitis C With Long-Acting Interferons And Ribavirin (2011) (0)
950 PK-PD MODELING OF VIRAL KINETICS WITH UPCOMING RESISTANCE SIMULATING COMBINATION THERAPY OF LONG-ACTING INTERFERONS AND STAT-C IN HCV PATIENTS (2009) (0)
From the Editor's Desk... (2022) (0)
893 VARIATIONS OF VITAMIN D LEVELS IN GENOTYPE 1HEPATITIS C PATIENTS UNDERGOING ANTIVIRAL THERAPY CORRELATE WITH STAGE OF FIBROSIS BUT NOT WITH TREATMENT OUTCOME (2012) (0)
STEROID-FREE IMMUNOSUPPRESSION FOLLOWING ORTHOTOPIC LIVER TRANSPLANTATION USING A ONCE-DAILY BASED FORMULATION OF TACROLIMUS: 2802 (2010) (0)
9.1 Pneumothorax (2013) (0)
Multiple HCV Amino Acid Variants Associate with Interferon Lambda Polymorphism in Genotype 1a, 1b and 3a Infections (2016) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Stefan S. Zeuzem?

Stefan S. Zeuzem is affiliated with the following schools:

Goethe University Frankfurt
Saarland University
Queen Mary University of London

Stefan S. Zeuzem's Academic­Influence.com Rankings

Why Is Stefan S. Zeuzem Influential?

Stefan S. Zeuzem's Published Works

Published Works

What Schools Are Affiliated With Stefan S. Zeuzem?

Stefan S. Zeuzem's AcademicInfluence.com Rankings